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Abstract 
In the UK, mortality from liver disease has increased by 400% between 1970 and 
2010 with death rates for those under 65 having risen by almost 500% (1). Up to 
75% of deaths related to chronic liver disease have an underlying aetiology of 
alcohol and are preventable (1, 2). Advanced chronic liver disease leads to 
multi-system clinical manifestations, many of which will require critical care. 
Evidence supporting this claim is seen in the increase in admissions to critical 
care for those patients with cirrhosis (3). These patients have higher rates of 
readmission to ICU (Intensive Care Unit), longer length of ICU stay and have an 
increased requirement for organ support (4). Despite this, both ICU and hospital 
mortality in those with cirrhosis have improved since the 1980s where mortality 
was reported to be up to 100% (5-7). 
With fewer beds compared to the USA or other European countries the existing 
demand on critical care capacity in the UK is increasing. There remains a need 
for a greater number of centres offering both critical care and hepatology input, 
with a significant number of hospitals nationwide lacking any hepatology input 
(8). Assessment of critically ill patients with cirrhosis is challenging, with many 
prognostic scoring systems in use. To date, no scoring system has been 
demonstrated to be superior in stratifying which patients would benefit from ICU 
admission. With the existing pressure on limited critical care beds within the UK 
and the increased demand to support critically ill patients, identifying those 
patients who merit admission to critical care will become an increasingly 
important challenge. 
This thesis focuses on the factors used in the decision to admit a patient with 
advanced chronic liver disease or cirrhosis to critical care, their long-term 
survival and quality of life. Attention is given to the utility of the Child-Pugh 
score and when it should be assessed. As the majority of deaths due to chronic 
liver disease have an underlying aetiology of alcohol, this thesis will also address 
how an alcohol use disorder can be assessed in the critically ill.  
The first investigation of this thesis explores the criteria used in the decision to 
escalate a patient to intensive care. This is explored through 2 Scottish surveys 
of consultant gastroenterologists and intensivists. Results highlighted agreement 
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by both specialities on the importance of Child-Pugh score measured when a 
patient was clinically stable. Inconsistencies were evident in the escalation of 
therapy with intensivists more likely to offer intensive care and multi-organ 
support as compared to gastroenterologists.  
In response to these findings, the timing and utility of Child-Pugh score was 
investigated. This observational cohort study compared Child-Pugh score 
measured on ICU admission with the score when a patient was clinically stable 
and short-term mortality. Only Child-Pugh score measured at time of ICU 
admission was associated with hospital mortality, which contradicted the 
findings of the previous chapter. The degree of change in Child-Pugh score 
between these time points was associated with mortality.  
Given that the majority of deaths due to chronic liver disease in the UK are 
primarily caused by alcohol, challenges exist in identifying alcohol use disorders 
in the critically ill. A prospective study examined the use of a proxy to report an 
alcohol use disorder in critically ill patients and suggested that a proxy could be 
used as a reliable historian.  
Whilst short-term survival of critically ill cirrhotics has improved, there is a 
paucity of studies reporting long-term outcomes. An observational cohort study 
investigated survival at 12 months for cirrhotic patients admitted to a general 
ICU in the UK. Long-term survival following an ICU stay has improved, in keeping 
with other studies. When measured on admission to ICU, Child-Pugh class was 
demonstrated to stratify patients into 3 distinct groups for long-term survival. 
With the improvement in survival, the sequelae of an ICU stay were investigated. 
A prospective observational cohort study explored the long-term quality of life 
and prevalence of sleep disturbance. A number of survivors reported that their 
quality of life was worse than, or equal to death. Quality of life and sleep 
disturbance were influenced by pre-existing comorbidity and events during their 
ICU. In this study, there was no association found between QOL and insomnia in 
those with liver cirrhosis. 
This thesis addresses the decision to admit a patient with advanced chronic liver 
disease or cirrhosis to critical care, reports their long-term survival and quality 
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of life and explores how one preventable cause of chronic liver disease can be 
assessed in the critically ill by use of a proxy.  
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Chapter 1 Literature Review 
1.1 Literature review search strategy 
A literature search was performed to establish background knowledge and 
identify current evidence in this area of research. Electronic databases explored 
included: Medline; EMBASE; Cochrane Library; Web of Science and Google 
Scholar. The search was conducted using combinations of keywords, which 
included: cirrhosis, liver, chronic liver disease, alcohol, intensive care, critical 
care, critical illness, outcome, survival and scoring system. A search was 
performed to identify relevant books, Government and professional association 
websites and policies. Any references of articles related to the search were 
reviewed. The literature search was updated during the research period to 
ensure new evidence was incorporated into the thesis.  
1.2 The Liver 
1.2.1 Anatomy of the liver  
Located in the right upper quadrant of the abdomen, the liver weighs 
approximately 1.5kg and accounts for 2% of total body mass (9). Anatomically 
the liver is described with 4 lobes; left, right, quadrate and caudate or by 9 
segments identified by individual anatomical, portal venous, lymphatic and 
bilious connections. The liver receives its arterial blood supply from the left and 
right hepatic arteries and venous blood from the hepatic portal vein. Venous 
drainage occurs through the hepatic veins to the inferior vena cava. The liver 
produces bile which drains into left and right hepatic ducts which join to form 
the common bile duct.  
The liver mainly consists of individual cells called hepatocytes which are 
arranged in plates, separated from vascular sinusoids by endothelial and Kupffer 
cells (10). The vascular sinusoids consist of both hepatic arterial and portal 
venous blood and drain into the hepatic veins through central veins (10). 
Hepatocytes form bile, which is secreted into canaliculi and subsequently drains 
into bile ducts (10). Cells are surrounded by portal tracts which each contain a 
branch of the hepatic artery, portal vein and bile duct.  
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The microanatomical arrangement of hepatocytes is in ‘functional units’ which 
can be explained by ‘acinar’ or ‘lobular’ concepts (10). In the ‘acinar’ concept, 
hepatocytes are centred on the portal tracts and arranged into 3 zones (10). 
Zone 1 is most proximal to the portal tracts whilst zone 3 is located proximal to 
the central vein. Cells within zone 3 are most distal to the hepatic blood supply 
and as such are most at risk of vascular insufficiency (10). The ‘lobular’ concept 
describes hepatocytes arranged around central veins, with portal tracts on the 
periphery of the lobule. Hepatocytes exhibit heterogeneity, with cells in 
different zones of the liver performing different physiological functions (11). 
1.2.2 Function of the liver  
The liver performs multiple physiological roles in synthesis and degradation 
within the body. The physiological roles of the liver can be divided between 
those located in the hepatic sinusoids and those within the hepatocytes (11).  
Hepatic sinusoidal cells secrete prostaglandin E2, prostacyclin, cytokines and 
nitric oxide (11). Kupffer cells, located within the sinusoids, are macrophages 
and perform endocytosis. Kupffer cells fulfil an important role in immunity and 
inflammation; secreting lipids such as leukotrienes and peptides including 
interleukin and tumour necrosis factor (11). These specialised cells degrade 
haemoglobin and remove erythrocytes (11). Pit cells within the sinusoids are 
natural killer cells performing a role in immunity (11). The sinusoids also contain 
stellate cells which synthesise collagen and growth factor, aiding hepatic 
regeneration (11). They regulate hepatic vascular tone and store vitamin A (11).  
Hepatocytes display functional heterogeneity; controlling nutrient metabolism 
and energy production (11). They manage the uptake and release of glucose and 
amino acids, glycogen synthesis and storage, urea and ketone body production 
(11). As such, the liver regulates acid-base balance within the body. Hepatocytes 
synthesise and degrade plasma proteins including albumin; determining plasma 
oncotic pressure and in addition acting as carrier proteins, protease inhibitors 
and intercellular messengers (11). Hepatocytes synthesise vitamin K dependent 
clotting factors, activation factors and fibrinolytic factors regulating haemostasis 
(11). Cytochrome P450 is located within the hepatocytes and is responsible for 
drug detoxification, whilst the liver also fulfils a significant role in phase 2 
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metabolism. In addition, hepatocytes are involved in bile formation and 
excretion. 
1.2.3 Pathophysiology of liver disease 
1.2.3.1 Liver injury 
Damage to liver cells can result from insults such as hypoxia, ischaemia, drug 
exposure and infection, with initiation of a number of different 
pathophysiological processes. Inflammation results from liver injury causing a 
cellular immune response and cell death (9). Insults to the liver can lead to 
hepatocyte ballooning, with swelling of the cells and necrosis (9). Furthermore 
liver injury can result in steatosis, with the development of fat droplets within 
hepatocytes. Whilst all cells in the liver are able to regenerate in response to 
injury, repeated insult can impair this process and lead to irreversible damage. 
Fibrosis results from an inability of the liver to regenerate pre-existing cellular 
arrangement with deposition of excess collagen and nodular formation altering 
the liver architecture (9). With continued liver insult vascular remodelling occurs 
and there is endothelial dysfunction with loss of sinusoidal porosity, vascular 
thrombosis and increased vascular resistance (9). Fibrous tissue obstructs blood 
flow leading to shunting of blood and angiogenesis. Until the 1970s the processes 
of fibrosis and cirrhosis were considered irreversible, however studies now 
illustrate variable resolution of both fibrosis and cirrhosis with cessation of liver 
injury (12). Furthermore, the rate of regression or deterioration in liver disease 
is multifactorial and encompasses the aetiology of liver disease, genetic and 
environmental factors (9). 
1.2.3.2 Cirrhosis 
The term ‘cirrhosis’ was first noted in the literature in 1819 by Laennec in the 
‘Traité de l’Auscultation’ in which the neoformations within the liver were 
described by their colour (13). ‘Cirrhosis’ originates from the Greek word kirrhós 
which translates as ‘tawny’, reflecting the tan colour of the liver and osis 
meaning condition (12).  
Liver cirrhosis occurs as a result of chronic liver injury with the development of 
inflammation, fibrogenesis and angiogenesis (14). The World Health Organisation 
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(WHO) defined cirrhosis in 1978 as “a diffuse process characterised by fibrosis 
and the conversion of normal liver architecture into structurally abnormal 
nodules”(15). A loss of normal architecture leads to increased resistance to liver 
blood flow and the development of intrahepatic vascular shunts as anastomoses 
develop between the hepatic artery and portal vein and efferent centrolobular 
vessels (12). Whilst the histological diagnosis of cirrhosis is definitive, there is a 
lack of distinction in the literature in the clinical diagnosis of chronic liver 
disease and cirrhosis, with both terms often used interchangeably to describe 
advanced liver disease (16).  
This thesis will focus upon advanced liver disease and will refer to both chronic 
liver disease and cirrhosis. For the remainder of this thesis the term ‘cirrhosis’ 
will only be applied if patients had knowingly met the diagnostic criteria for 
cirrhosis described below or when referring to existing research using that 
terminology.  
The diagnostic criteria used for cirrhosis in this thesis were a histological 
diagnosis on biopsy or clinical evidence of portal hypertension, encephalopathy 
or oesophageal varices. These criteria have been used in previous research 
published by the University of Glasgow Anaesthetic Department (17, 18). 
1.2.4 Aetiology of chronic liver disease 
There are many causes of chronic liver disease and underlying aetiologies 
include infection, metabolic, vascular, autoimmune, cholestasis or exposure to 
toxins. Morbidity and mortality from liver disease is often preventable with 
modification of risk factors or treatment of the underlying aetiology. The 2012 
Annual Report of the Chief Medical Officer noted excess alcohol consumption, 
obesity and undiagnosed hepatitis infection were all preventable causes of 
chronic liver disease in England and Wales (2). Alcoholic liver disease and 
Hepatitis C infection are the most common causes of chronic liver disease in the 
Western world, whilst chronic liver disease secondary to Hepatitis B infection 
predominates in Asia and sub-Saharan Africa (19). The most common 
preventable causes of chronic liver disease are discussed in greater detail below.  
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1.2.4.1 Alcohol 
Analysis of United Kingdom (UK) death certification in 2006 demonstrated that 
over 80% of deaths due to liver disease were due to an underlying aetiology of 
alcohol (20). Worldwide, the relationship between alcohol consumption and liver 
mortality is well recognised (21). Excess alcohol consumption leads to 
accumulation of fat within hepatocytes and collagen production (10). 
Furthermore, acetaldehyde – the breakdown product of alcohol - causes 
inflammation of hepatocytes (10). Risk factors for alcoholic liver disease include 
female gender, ongoing alcohol use and underlying genetic predisposition, whilst 
progression of liver disease is accelerated by the presence of other liver insults 
such as viral infection, obesity or drug exposure (22). With cessation of alcohol 
consumption, the majority of individuals display improvement in symptoms of 
chronic disease and the histological changes in the liver can reverse (22). 
1.2.4.2 Hepatitis B 
Whilst it is estimated that there are 180,000 people with Hepatitis B infection in 
the UK, it remains the most common cause of chronic liver disease in Asia and 
sub-Saharan Africa (19, 23). In the UK it is mainly transmitted by unprotected 
sex, whilst transmission in developing countries is more often from mother to 
child (24). Infection with Hepatitis B virus leads to the formation of antigens on 
the cell surface of hepatocytes (10). The resulting host immune response 
destroys native hepatocytes. Chronic liver disease secondary to Hepatitis B 
infection may progress to cirrhosis in 10-20% of individuals within 5 years, with 
15% of those with cirrhosis dying within 5 years (22). Of the individuals with 
chronic Hepatitis B infection, 5-10% develop hepatocellular carcinoma (22). 
Vaccination aims to prevent Hepatitis B infection whilst antiviral medications 
aim to reduce viral DNA load and can lead to antigen loss or seroconversion of 
individuals (22). 
1.2.4.3 Hepatitis C 
There are an estimated 200,000 individuals with Hepatitis C in the UK (25). 
Approximately 34,500 of those individuals live in Scotland, with transmission 
primarily through use of infected needles in intravenous drug users (26). It can 
also be transmitted via blood products, unprotected sex, skin piercings and 
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tattoo equipment or vertical transmission from mother to child (24). The 
prevalence of Hepatitis C is higher in other areas of the world, including Africa 
where 5.3% of the general population are estimated to be infected (24). The risk 
of progression to cirrhosis in those infected with the virus is increased by excess 
alcohol consumption, male gender, immunosuppression and advanced age (19). 
Additionally, progression to cirrhosis is increased in those individuals with 
concurrent insulin resistance secondary to diabetes or obesity (22). Following 
the development of cirrhosis, survival with Hepatitis C infection remains high, 
with up to 91% of those with cirrhosis alive at 5 years and up to 79% alive at 10 
years (22). However, once an episode of decompensated liver failure occurs, 
survival reduces to 50% at 5 years (22). Liver damage is believed to result from 
three different mechanisms. The virus may directly attack hepatocytes, an 
autoimmune reaction occurs, or similar to Hepatitis B, a host immune response 
may occur (22). Antiviral medications exist, which aim to decrease Hepatitis C 
RNA activity and the introduction of new direct acting antiviral agents appear to 
show promising improvements in survival for those with end-stage liver disease 
(22, 27). 
1.2.4.4 Non-alcoholic fatty liver disease 
Non-alcoholic fatty liver disease (NAFLD) is the term used to describe both 
steatosis and non-alcoholic steatohepatitis (NASH) (22). Steatosis is defined as 
excess triglyceride droplets within hepatocytes, with minimal alcohol 
consumption (22). When steatohepatitis is associated with necroinflammation 
the term NASH is applied (22). NASH results from the metabolism of free fatty 
acids to nontriglyceride metabolites, which cause liver injury (22). With 
increased rates of obesity worldwide, the incidence of NAFLD continues to rise. 
Approximately 20% of the UK population are estimated to have NAFLD and it is 
associated with concurrent diabetes, hypertension, dyslipidaemia and advanced 
age (24). Up to 50% of individuals with NASH progress to fibrosis or cirrhosis (22). 
To date there are no recognised pharmacological interventions and treatment 
for NAFLD consists of weight loss and exercise (28). 
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1.2.5 Epidemiology of liver disease 
1.2.5.1 Worldwide 
As many individuals are asymptomatic the exact prevalence of liver disease 
worldwide remains unknown; however, cirrhosis is estimated to be the 14th most 
common cause of death and is known to account for 1.03 million deaths per year 
(29). Mortality from cirrhosis increased between 2005 to 2015 worldwide, 
however global differences exist (30). Mortality from cirrhosis reduced in east 
Asia and Europe whilst an increase was noted in central Asia, north Africa and 
the Middle East (30). These trends are attributed to Hepatitis B vaccination and 
improvements in treatment of Hepatitis C in developed countries, with increased 
alcohol consumption and prevalence of Hepatitis C in those countries with 
increased mortality (30). In 2008 it was estimated up to 1% of the population 
have histological cirrhosis based on the population prevalence in the United 
States of America (USA) and Europe (19). 
1.2.5.2  United Kingdom 
Between 1970 and 2010, mortality rates from liver disease in the UK have 
increased by 400%; higher than other countries in western Europe (Figure 1-1) 
(1). Between 2015 and 2017, UK mortality due to liver disease in men was 
reported as 24.3 deaths per 100,000 and in women the mortality rate was 13 
deaths per 100,000 (31). In the UK, liver disease is the third highest cause of 
premature mortality, with the majority of patients dying within working age (18-
65 years) (1). As emphasised in the 2012 Annual Report of the Chief Medical 
Officer, liver disease was the only cause of premature mortality which had 
increased in England in contrast to other European countries where premature 
mortality from liver disease had decreased (2). Death rates in those under 65 
have risen by almost 500% (1). Up to 75% of deaths due to liver disease have an 
underlying aetiology of alcohol (1). In England and Wales 600,000 people are 
diagnosed with liver disease and 60,000 of these individuals are known to have 
cirrhosis (1).  
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Figure 1-1 Graph to show percentage change in standardised UK mortality 
rates for those aged 0-64 years (1) 
Reproduced with permission from Elsevier, (license no. 4544711432707) 
 
In Scotland, the 2017 death rate for chronic liver disease was 16.6 per 100,000, 
similar to the 2016 death rate (32). Mortality from chronic liver disease 
appeared to peak in 2003 at 25.4 per 100,000 people (32). Male mortality (22.5 
per 100,000) is twice as high as female mortality (10.7 per 100,000) (Figure 1-2) 
(32). Reflecting the rest of the UK, alcohol remains the most common underlying 
aetiology of chronic liver disease causing mortality (32). Mortality secondary to 
chronic liver disease was highest in NHS Greater Glasgow and Clyde (32). The 
burden of alcohol in Scotland is discussed in greater detail in Chapter 5. 
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Figure 1-2 Graph of chronic liver disease mortality by gender in Scotland (32) 
Reproduced from the Scottish Public Health Observatory 
 
In 2018 the Lancet Commission on Liver Disease in the UK stated that alcoholic 
liver disease would soon become the most common cause of working years lost, 
thus having a significant economic impact upon individuals with chronic liver 
disease, their dependents and society as a whole (27). Mortality from liver 
disease is associated with increased socioeconomic deprivation, with both 
incidence and mortality from liver disease being higher in the north of England 
compared to the south (27). Furthermore, the impact of chronic liver disease is 
reflected in the number of hospital admissions in Scotland with a dramatic 
increase from 47.1 per 100,000 in 1982/3 to 208 per 100,000 in 2016/7 (Figure 1-
3) (32).  
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Figure 1-3 Graph of chronic liver disease morbidity in Scotland, as measured 
by number of admissions (32) 
Reproduced from the Scottish Public Health Observatory 
 
1.2.5.3 Deprivation 
The association between socioeconomic deprivation and poor health is long 
established in the literature (33). Carstairs and Morris examined UK deprivation 
and mortality in the 1980s, concluding that the higher rates of mortality in 
Scotland, compared to England and Wales was in part related to deprivation and 
most evident in younger adults (34). This replaced previous acceptance that 
mortality was related to social class (34). Townsend defined deprivation in 1987 
as “observable and demonstrable disadvantage relative to the local community 
or wider society or nation to which an individual, family or group belongs” (35). 
Deprivation was classified into material deprivation which included diet, 
housing, health and work and subjective deprivation encompassing social support 
and education (35). 
Deprivation has been measured using a number of tools including the 
Underprivileged Area Score to assess primary care need (36), the Carstairs index 
(37) developed for Scotland and the Townsend index designed for Northern 
England (38). The Index of Multiple Deprivation was published in 2000 and widely 
used in current studies in England (39). It measures deprivation over 7 domains; 
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income, employment, health, education and training, housing, access to services 
and crime.  
In Scotland deprivation is measured by the Scottish Index of Multiple Deprivation 
(SIMD), which was first published in 2004 using the same 7 domains as the Index 
of Multiple Deprivation (40). The SIMD divides areas of Scotland into 6976 small 
data zones of approximately 760 people. Each data zone is ranked in order of 
deprivation from most deprived (ranked 1) to least deprived (ranked 6976) (40).  
1.2.5.4 The Glasgow effect 
Whilst inequalities in health can be explained in part due to deprivation, 
epidemiological studies highlight higher mortality in Scotland when 
socioeconomic differences have been accounted for (41). Between 1981 and 
2001 Scotland’s excess mortality had increased to 8% when compared with 
England and Wales (41). This ‘excess’ mortality was particularly evident in 
Glasgow and the term ‘Glasgow effect’ has been used extensively in the 
literature (42). In 2000 mortality was examined in 3 post-industrial UK cities – 
Glasgow, Manchester and Liverpool with similar levels of deprivation and it was 
reported excess mortality between Glasgow and the 2 other cities had risen 
since the 1970s (Figure 1-4) (42). The excess mortality was particularly evident 
in those of working age and mortality in areas with low socioeconomic 
deprivation remained higher in Glasgow compared to Liverpool or Manchester 
(42).  
Whilst no single cause has been identified for the difference in mortality, a 
recent study concluded that excess mortality in Glasgow may result from high 
levels of deprivation, town planning and government policies whilst Liverpool 
and Manchester benefitted from migration and social capital (43). However, 
another suggested hypothesis to explain the variation in mortality is a difference 
in the culture of substance misuse. The underlying causes of premature 
mortality in Glasgow are reported to result from alcohol, suicide, drug use and 
violence (43). Alcohol sales are reported to be higher in Scotland compared to 
England and Wales, with a higher proportion of individuals consuming alcohol 
within the home (43). Furthermore, there is believed to be a greater incidence 
of binge drinking, with increased use of concentrated spirits.  
  37 
 
Figure 1-4 Excess mortality in Glasgow compared to Liverpool and 
Manchester (42) 
Reproduced with permission from Elsevier, (license no 4544720154401) 
 
1.3 Classification of liver disease 
Terminology describing the classification of liver failure has evolved over time, 
differing between centres (44). Variations in the time course between the onset 
of the symptoms of disease and deterioration in liver function have been used to 
differentiate between acute and chronic liver failure. The concept of acute-on-
chronic liver failure (ACLF) has been introduced in recent decades and it was 
proposed that acute liver failure, ACLF and decompensated chronic liver disease 
were 3 separate clinical entities at the World Congress of Gastroenterology in 
2014 (45).  
1.3.1 Acute liver failure 
Lucké and Mallory described 2 forms of acute hepatitis in US Army personnel in 
1946 (46). The first type described by the authors was fatal within 10 days and 
they termed this ‘fulminant’ hepatitis. The other form of hepatitis was noted to 
have a slower deterioration over 4 to 6 weeks and was labelled ‘subacute’ (46).  
In 1970 in response to the recognition of halothane induced hepatic injury, the 
term ‘fulminant hepatic failure’ was introduced and defined as a “potentially 
reversible condition, the consequence of a severe liver injury, with an onset of 
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encephalopathy within 8 weeks of the appearance of the first symptoms and in 
the absence of pre-existing liver disease”(47). In 1985 the term ‘late-onset 
hepatic failure’ was introduced to define the development of encephalopathy 
between 8 and 24 weeks after initial symptoms of disease (48). 
An alternative classification was proposed in France in 1986 which reflected the 
time between the specific development of jaundice and the onset of 
encephalopathy (49). Fulminant liver failure was used in cases with an interval 
of less than 2 weeks between the onset of jaundice and development of 
encephalopathy and subfulminant liver failure was applied to a time interval of 
between 2 and 12 weeks and the authors argued that this classification indicated 
prognosis (49). This classification is still used in centres outwith the UK, 
including the USA (50). 
Current nomenclature used within the UK classifies acute liver failure based 
upon the time between the onset of jaundice and development of 
encephalopathy proposed by O’Grady (44). The onset of jaundice was used in 
preference to other symptoms of liver disease as this was demonstrated to 
predict outcome (44). Acute liver failure was divided into 3 groups; hyperacute, 
acute and subacute with the time from jaundice to encephalopathy 0-1 week in 
hyperacute liver failure, 1-4 weeks in acute liver failure and 4-12 weeks in 
subacute liver failure (44). Furthermore, each group within this classification of 
acute liver failure has been demonstrated to exhibit differences in the severity 
of clinical features and prognosis. Different time intervals between the 
development of jaundice and encephalopathy can indicate specific aetiologies of 
acute liver failure (51).    
The O’Grady classification has been criticised as it introduced ambiguity with 
acute liver failure divided into 3 classes with one named acute liver failure (52). 
In addition, it has been noted that encephalopathy may not reflect deterioration 
as it is not specific to liver function (52). 
1.3.2 Chronic liver failure and cirrhosis 
Chronic liver disease describes a wide range of diseases encompassing fatty 
liver, steatohepatitis, chronic hepatitis, and cirrhosis (10). As explored earlier, 
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cirrhosis describes a histological change in the architecture of the liver (section 
1.2.3) but within the literature the term ‘cirrhosis’ is often used to describe 
end-stage chronic liver disease. Liver cirrhosis is classified into asymptomatic or 
‘compensated’ cirrhosis and ‘decompensated’ cirrhosis based upon the presence 
of portal hypertension or liver dysfunction (53). Deterioration in liver function in 
those with chronic liver failure can progress to chronic decompensation which is 
often irreversible (54). Alternatively, individuals with compensated chronic liver 
disease can experience a potentially reversible acute decompensation known as 
ACLF explored in section 1.3.3 (54).   
Definitions of compensated cirrhosis vary but reflect a clinical state whereby 
there are no clinical complications of cirrhosis and portal pressure is normal or 
not elevated sufficiently to cause ascites (53). Transition from compensated to 
decompensated cirrhosis results from increased portal pressure and 
deterioration in liver function, marked by the development of ascites, portal 
hypertensive gastrointestinal bleeding, encephalopathy and jaundice (53). 
Deterioration is accelerated by variceal bleeding, renal impairment, 
hepatopulmonary syndrome (HPS), sepsis and hepatocellular carcinoma (53). 
Liver cirrhosis was classified into 4 stages of increasing severity at the Baveno IV 
consensus conference in 2005 (55). This was based upon combined data of 1649 
patients from two Italian studies of cirrhotic patients admitted between 1974-
1980 and 1981-1984 (56, 57). Each stage was defined by the presence or absence 
of oesophageal varices and ascites (55). Stages 1 and 2 reflect individuals in 
compensated cirrhosis whilst stages 3 and 4 describe those with decompensated 
cirrhosis (Figure 1-5) (53). 
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Figure 1-5 Clinical stages of cirrhosis with outcomes at 1 year (53) 
Reproduced with permission from Elsevier, (license no. 4563780850150) 
 
 
Most studies investigating survival in liver cirrhosis are based only on individuals 
admitted to hospital. A 2012 cohort study based on 4537 individuals with 
cirrhosis listed on the UK General Practice Research Database found 1 year 
survival for compensated and decompensated cirrhosis to be 87.3% and 75% 
respectively, with survival at 5 years 66.5% and 45.4% (58). A 2006 systematic 
review of 118 studies described median survival for compensated cirrhosis to be 
over 12 years, exceeding that of decompensated cirrhosis, which is 
approximately 2 years (53). The majority of deaths in those with cirrhosis result 
from complications of cirrhosis rather than concurrent comorbidities (59). 
Annual mortality in the stages of cirrhosis classified at Baveno IV is 1% in Stage 1, 
3.4% in Stage 2, 20% in Stage 3 and 57% in Stage 4, with almost 50% of deaths 
occurring within the first 6 weeks following an initial variceal bleed (Figure 1-5) 
(53). 
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1.3.3 Acute-on-Chronic liver failure 
ACLF first appeared in the literature in 1995 and described a state whereby both 
acute and chronic disease processes were evident (60). Unlike the chronic 
decompensation of chronic liver disease it is postulated that ACLF is potentially 
reversible if precipitants of liver insult are controlled and organ support 
provided during the acute deterioration (54). Whilst the underlying 
pathophysiology is not yet fully understood, ACLF encompasses an altered host 
response to liver injury in a patient with existing liver disease (61). It is 
recognised that this involves pro-inflammatory cytokine production, neutrophil 
dysfunction and subsequent immune system dysregulation (61). The literature 
suggests that ACLF may be considered in a similar manner to the systemic 
inflammatory response syndrome and multi-organ failure evident in those with 
sepsis (62).   
A 2013 systematic review identified 13 different definitions of ACLF (63). Until 
2014 there was a global divide in its definition with the Asian Pacific Association 
for the study of the liver (APASL) defining ACLF as an “acute hepatic insult 
manifesting as jaundice and coagulopathy, complicated within 4 weeks by 
ascites and/or encephalopathy in a patient with previously diagnosed or 
undiagnosed chronic liver disease” (64). The European Association for the Study 
of the Liver (EASL) and the American Association for the Study of Liver Diseases 
(AASLD), however, proposed ACLF to be “an acute deterioration of pre-existing 
chronic liver disease, usually related to a precipitating event and associated 
with increased mortality at 3 months due to multisystem organ failure” (65). 
These definitions lacked consensus in the recognised precipitants of ACLF, prior 
decompensated cirrhosis and the timeline of acute illness (45).  
In 2013 the European Association for the Study of the Liver-Chronic Liver Failure 
(EASL-CLIF) Consortium published the Acute-on-Chronic Liver Failure in Cirrhosis 
(CANONIC) study and proposed 3 diagnostic criteria for ACLF (66). The diagnosis 
of ACLF required an acute decompensation of liver disease, organ failure and a 
28 day mortality rate of 15% (66). ACLF was noted to be a significant cause of 
death in cirrhotics and those without prior episodes of acute decompensation 
appeared to develop a more severe form of ACLF with higher levels of 
inflammatory mediators and increased short-term mortality (66).  
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A united definition was proposed at the World Congress of Gastroenterology in 
2014 and is based on the findings of 2 prospective observational studies; the 
CANONIC study and North American Consortium for the study of End-Stage Liver 
Disease (NACSELD) (45). It was defined as “a syndrome in patients with chronic 
liver disease with or without previously diagnosed cirrhosis which is 
characterised by acute hepatic decompensation resulting in liver failure 
(jaundice and prolongation of the INR) and one or more extrahepatic organ 
failures that is associated with increased mortality within a period of 28 days 
and up to 3 months from onset” (45). ACLF can be precipitated by a 
physiological insult such as sepsis, gastrointestinal bleed or surgery or by liver 
injury due to viral infection, alcohol ingestion or drug exposure (54). 
As the diagnostic criteria for ACLF have only recently been agreed upon, there is 
a lack of awareness and confidence in determining which critically ill patients 
have ACLF rather than chronic decompensation of liver function. Given this 
clinical challenge it was the MD student’s experience that few patients are 
documented to have this diagnosis, in particular in retrospective clinical notes. 
As such, the body of work in this thesis concentrates upon patients diagnosed 
with chronic liver disease and those with identified cirrhosis.  
1.4 Clinical manifestations of chronic liver disease 
Whilst chronic liver disease is often asymptomatic for many years it can lead to 
complications within most systems in the body. There are a number of clinical 
manifestations of chronic liver disease which are discussed in further detail 
below. 
1.4.1 Ascites 
Ascites is defined as the excess free fluid within the peritoneal cavity (67). 
Ascites is the most common complication of cirrhosis, occurring in more than 
50% of patients within 10 years of a diagnosis of cirrhosis (68). Whilst ascites can 
develop secondary to non-cirrhotic causes such as cardiac failure or malignancy, 
75% of patients presenting with ascites have an underlying diagnosis of cirrhosis 
(68). Once ascites is present in those with cirrhosis, 2-year mortality is up to 40% 
(68). Uncomplicated ascites is defined as not infected nor accompanied by 
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hepatorenal syndrome (HRS) and is classified into grades 1-3 (68).  Without 
immediate access to ultrasound the scoring of ascites is subjective (Table 1-1). 
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Table 1-1 Grading of Ascites (68) 
Grade of 
Ascites 
Definition 
1 Mild ascites evident only on ultrasound examination 
2 Moderate ascites which is easily palpable on physical examination 
and associated with symmetrical abdominal distension 
3 Large or gross ascites with marked abdominal distension 
 
Ascites is defined as refractory when it remains present despite use of medical 
treatment including diuretic therapy or dietary salt restriction or in the presence 
of diuretic-induced complications including hepatic encephalopathy, renal 
impairment or electrolyte abnormalities preventing their use (68). Refractory 
ascites is also defined by a recurrence of grade 2 or 3 ascites following 
paracentesis (68). Refractory ascites occurs in up to 10% of cases of ascites (69).  
The development of ascites in those with cirrhosis has been explained by a 
number of different theories. The ‘overfill’ hypothesis describes increased renal 
sodium retention due to a signal from the liver resulting in larger plasma volume 
(22). The ‘underfill’ hypothesis describes increased renal sodium retention as a 
compensatory mechanism following the development of ascites secondary to 
portal hypertension (70). This occurs in response to the increased plasma oncotic 
pressure and decreased venous portal pressure which result from the 
development of ascites and loss of intravascular volume (22). Finally there is a 
peripheral arterial vasodilatation hypothesis (70). The increased resistance to 
hepatic blood flow with the development of cirrhosis (section 1.2.3) leads to 
portal hypertension, collateral vein formation and shunting of blood into the 
systemic circulation (69). Local vasodilators such as nitric oxide increase 
vascular capacitance through splanchnic arterial dilatation and decreasing 
effective arterial blood volume and reducing arterial blood pressure (69). In an 
effort to expand plasma volume and maintain blood pressure, sodium and water 
are retained (69). Fluid accumulates in the abdominal cavity as a result of 
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altered intestinal capillary pressures and permeability secondary to 
vasodilatation and portal hypertension (69).  
The initial management of uncomplicated ascites introduces dietary sodium 
restriction, which is successful in approximately 10% of patients (22). Those with 
dilutional hyponatraemia are treated with fluid restriction (69). To achieve both 
a negative sodium balance and loss of ascitic fluid, diuretics can be introduced 
(69). If ascites is refractory, large volume or has not improved with 
pharmacological therapy, therapeutic paracentesis and albumin replacement can 
be instigated (69). This has proven to be more effective with shorter hospital 
duration than diuretic therapy (69). Placement of a transjugular intrahepatic 
portosystemic shunt (TIPS) is an alternative to repeat paracentesis, however, 2 
randomised controlled trials did not show a survival benefit, nor improvement in 
patient quality of life (QOL) when TIPS was undertaken (71, 72). 
 
1.4.2 Portal hypertension and variceal bleeding  
Portal hypertension is defined as an increased portal venous pressure, reflecting 
a raised hepatic venous pressure gradient, predicting the development of varices 
and decompensation (55). Approximately 60% of individuals with decompensated 
cirrhosis and 30% of those with compensated cirrhosis have endoscopic findings 
of varices at diagnosis (73). Analysis of a national American endoscopic database 
demonstrated increased incidence of varices in Child-Pugh class B or C, 
reflecting the correlation between deteriorating liver function and increased 
hepatic venous pressure gradient (74). The incidence of new varices in cirrhotics 
reported by Italian group is 5% at 1 year, 17% at 2 years and 28% at 3 years (75). 
There remains significant mortality associated with variceal bleeding with 6-
week mortality reported to be between 10-20% (55).  
 
Portal hypertension results from an increased resistance to portal blood flow and 
increased portal venous inflow (76). Increased resistance results from both 
structural change in the liver (section 1.2.3) and raised vascular tone due to 
endothelial cell dysfunction and altered vasoactive substance availability (76, 
77). In the sinusoidal microcirculation, nitric oxide has been demonstrated to be 
an important regulator of vasodilatation (77). Increased portal venous inflow 
results from splanchnic vasodilatation and raised cardiac output (78).  
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Therapeutic management of portal hypertension and variceal bleeding comprises 
pharmacological and non-pharmacological intervention. At diagnosis, it is 
recommended that all cirrhotic patients should be screened for evidence of 
varices (55). The Baveno V consensus workshop recommended that in those with 
small varices and Child C class cirrhosis, non-selective beta-blockers should be 
considered to prevent variceal haemorrhage (55). Individuals with medium or 
large varices, irrespective of Child-Pugh score, should be considered for 
prophylactic band ligation of varices and treatment with non-selective beta-
blockers (55). Beta-blockers reduce portal venous inflow by decreasing both 
cardiac output and splanchnic blood flow (79). In acute variceal bleeding, 
volume resuscitation, antibiotic prophylaxis and vasoactive drug administration 
should be followed by prompt upper gastrointestinal endoscopy (55). Vasopressin 
promotes splanchnic vasoconstriction, reducing portal venous inflow (73). In 
those individuals with Child-Pugh Class C or Child-Pugh Class B with bleeding 
these treatments are more likely to fail (55). As such, TIPS should be considered 
and can be used as a bridge to liver transplantation (55). Balloon tamponade can 
be considered in massive uncontrolled haemorrhage as a temporary solution to 
reduce bleeding (55).  
 
1.4.3 Hepatic encephalopathy 
Hepatic encephalopathy is a diagnosis of exclusion and defined as 
neuropsychiatric abnormalities in those with liver disease which cannot be 
attributed to other causes (80). It is estimated that 20-80% of those with 
cirrhosis may develop hepatic encephalopathy (81). The clinical symptoms of 
hepatic encephalopathy can fluctuate in severity, are often reversible and can 
be caused by multiple factors (81). There are a number of different hypotheses 
surrounding the development of hepatic encephalopathy. The first attributes 
encephalopathy to a rise in the ammonia concentration within the blood due to 
portosystemic shunting, or a decrease in metabolism due to liver dysfunction 
(22). Ammonia crosses the blood brain barrier causing astrocyte swelling, 
oedema and increasing oxidative stress (81). Interestingly, the severity of 
symptoms are not linked to the level of ammonia within the blood (81). Unlike 
the cerebral oedema and raised intracranial pressure which can occur in 
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cirrhosis this does not occur in hepatic encephalopathy (81). An alternative 
hypothesis concerns inflammation, which may result in increased blood-brain 
barrier permeability and altered binding site activity for benzodiazepines (22). 
Other hypotheses include an increase in benzodiazepine-like compounds in the 
brain, manganese accumulation in the basal ganglia or altered tryptophan 
metabolites (22). 
 
Disagreement concerning the definition of hepatic encephalopathy exists. In 
1998 at the World Congress of Gastroenterology a standard nomenclature for 
hepatic encephalopathy was proposed based upon the underlying diagnosis, 
clinical course and severity (Table 1-2) (80). It has since been suggested that the 
term minimal encephalopathy be replaced by covert encephalopathy to 
emphasise the clinical significance of this diagnosis (82). The diagnosis of 
hepatic encephalopathy is based on a clinical or neuropsychiatric assessment 
examining factors such as attentiveness, cognitive impairment, behaviour and 
consciousness (80). Recognised precipitants include gastrointestinal bleed, 
sepsis, uraemia, medication, constipation, dehydration or electrolyte 
disturbances (80). The West Haven criteria have been used to describe the 
severity of symptoms demonstrated by individuals with hepatic encephalopathy 
(Table 1-3) (83).  
  
  48 
 
Table 1-2 Classification of Hepatic Encephalopathy (80) 
Type of Hepatic 
Encephalopathy 
Definition Subcategory Subdivision 
A Encephalopathy 
associated with acute 
liver failure 
  
B Encephalopathy 
associated with portal-
systemic bypass in the 
absence of intrinsic 
hepatocellular disease 
  
C Encephalopathy 
associated with cirrhosis 
and portal hypertension 
or portal-systemic shunts 
Episodic Hepatic 
Encephalopathy 
 
 
Persistent 
Hepatic 
Encephalopathy 
 
 
Minimal Hepatic 
Encephalopathy 
Precipitated 
Spontaneous 
Recurrent 
 
Mild 
Severe 
Treatment-
dependent 
 
Table 1-3 West Haven Criteria (83)  
Stage Features 
0 No abnormality detected 
1 Trivial lack of awareness, euphoria, anxiety, shortened attention span, 
inability to perform addition or subtraction  
2 Lethargy, disorientation, personality change, inappropriate behaviour 
3 Somnolence or semi-stupor, responsive to stimuli, confusion, gross 
disorientation, bizarre behaviour 
4 Coma 
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Management of hepatic encephalopathy depends on the severity of clinical 
symptoms. Individuals with decreased conscious level may require airway 
protection and any potential precipitants such as sepsis, dehydration following 
diuretic use and gastrointestinal bleeding must be addressed (22).  
 
Treatments for hepatic encephalopathy are limited and at present include 
lactulose and Rifaximin (84). The mechanism of action for lactulose is unknown 
and it is hypothesised that it acidifies colonic contents and evacuates bacteria 
from the bowel (84). Rifaximin is a non-absorbable antibiotic which has been 
shown to improve outcomes in hepatic encephalopathy (84). With treatment 
symptoms of encephalopathy should improve within 72 hours, however, second 
line pharmacological interventions include Metronidazole, Neomycin or 
Vancomycin to promote gut motility.  
 
1.4.4 Hepatorenal syndrome 
HRS is defined as impaired renal function in the presence of intrarenal arteriolar 
vasoconstriction and extra-renal vasodilatation (85, 86). Individuals develop 
circulatory dysfunction with insufficient cardiac output and their renal function 
does not respond to fluid therapy (85, 86). HRS develops in those with overt liver 
failure and includes individuals with acute or chronic liver disease (85). A study 
of 234 cirrhotics with ascites demonstrated an incidence of HRS of 39% within 5 
years, with median survival of less than 2 weeks (87). 
 
HRS can develop spontaneously or secondary to infection – in particular 
spontaneous bacterial peritonitis (SBP), bleeding or insufficient albumin 
administration following paracentesis (85). HRS is classified into Type-1 and 
Type-2. Type-1 HRS is recognised by a deterioration in renal function within 2 
weeks with serum creatinine doubling to over 226 µmol/l (85). It is associated 
with a poor prognosis and is commonly attributed to SBP (85). Type-1 HRS may 
present with hypotension and vasoconstriction accompanied by cardiac, liver 
dysfunction and hepatic encephalopathy (85). The deterioration in renal function 
in Type-2 HRS is slower with a serum creatinine between 133-226 µmol/l and 
often occurs in the presence of refractory ascites (85). 
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It is understood that whilst the splanchnic circulation is vasodilated in HRS, 
other body systems such as the brain undergo vasoconstriction (85). 
Furthermore, the reduction in cardiac output can lead to renal hypoperfusion 
(85). 
 
HRS is potentially reversible and the mainstay of HRS treatment is volume 
replacement with albumin and vasopressor use (85). TIPS can also be used to 
improve survival and individuals can be considered for liver transplantation (85). 
 
1.4.5 Hepatopulmonary syndrome 
Cirrhosis is associated with a number of different respiratory complications, with 
up to 70% of individuals exhibiting arterial hypoxaemia (16). This is due to 
ventilation-perfusion mismatch, impaired diffusion, intrapulmonary shunting and 
decreased hypoxic pulmonary vasoconstriction (16, 88). It may result from 
comorbidities such as chronic obstructive pulmonary disease (COPD) or 
complications of liver disease such as ascites (89). 
Hepatopulmonary syndrome (HPS) describes decreased oxygenation and 
intravascular pulmonary vasodilatation in those with liver disease (90). It is 
graded from mild to very severe depending upon the alveolar-arterial oxygen 
gradient and partial pressure of oxygen (89). Individuals present with dyspnoea, 
although this is non-specific and can be secondary to other diagnoses such as 
portopulmonary hypertension (89).  
Portopulmonary hypertension is an increased pulmonary vascular resistance due 
to vasoconstriction and thrombosis which ultimately causes right heart failure 
(89). The incidence of HPS is reported to be up to 32% in those considered for 
liver transplantation, although this figure excluded the majority of cirrhotics 
who are not assessed for transplantation (91). In those with HPS who did not 
receive a liver transplant 5 year survival was 23%, much lower than the survival 
rate of 63% in the control group of matched patients of similar liver disease 
severity (92). 
At present, treatment for HPS is limited to liver transplantation, with individuals 
offered symptom control with long-term oxygen therapy (89).  
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In those with chronic liver disease the incidence of adult respiratory distress 
syndrome (ARDS) is higher (16). It is understood that this is due to greater 
numbers of inflammatory mediators due to impaired liver function and impaired 
immune function (16). Additionally those with alcoholic liver disease are more 
likely to have reduced glutathione, which is required to prevent oxygen free 
radical damage (16). The current mortality rate for those with ARDS and 
cirrhosis is between 35-70% (16). 
1.4.6 Cirrhotic cardiomyopathy 
Cirrhotic cardiomyopathy describes “cardiac dysfunction in patients with 
cirrhosis characterised by impaired contractile responsiveness to stress, 
diastolic dysfunction and electrophysiological abnormalities” (93). The 
splanchnic vasodilatation and decreased vascular resistance evident in cirrhosis 
causes a functional hypovolaemia and a ‘hyperdynamic circulation’ develops 
(78). Cardiac dysfunction may only be evident when there are extra demands on 
cardiac output, during exercise or illness (16). It is therefore difficult to 
ascertain the prevalence of cirrhotic cardiomyopathy, however it has been 
reported that cardiac dysfunction is present in up to 50% of those offered liver 
transplantation (94). Furthermore, heart failure is a common cause of death 
following liver transplantation (95). 
Cirrhotic cardiomyopathy occurring in chronic liver disease is due a number of 
different mechanisms including impaired adrenergic receptor function, changes 
in the cardiac cell membrane and increased levels of nitric oxide which is a 
negative inotrope (94). To date, there are no medical interventions proven to be 
of benefit in cirrhotic cardiomyopathy, however, liver transplantation may 
improve cardiac function (94). 
1.4.7 Coagulopathy  
Historically, it has been accepted that those with chronic liver disease are 
‘autoanticoagulated’ and are at high risk of bleeding (96). Cirrhosis is associated 
with altered haemostasis and in the presence of portal hypertension individuals 
develop thrombocytopenia due to platelet sequestration in the spleen (16). This 
is associated with platelet function defects, decreased pro- and anti-coagulant 
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proteins and a reduction in the proteins required for fibrinolysis (96). However, 
despite such changes and in the presence of abnormal haemostatic tests such as 
prothrombin time (PT) and platelet count, it is now believed that this specific 
group of patients may have ‘re-balanced haemostasis’(97). Compensatory 
mechanisms exist to promote coagulation (96). These include increased levels of 
von Willebrand factor and factor VIII with decreased levels of plasminogen, 
proteins C and S and antithrombin (97). It is accepted that this haemostatic 
balance can tilt towards a bleeding tendency in the presence of portal 
hypertension, bacterial infection and renal impairment (97). One study 
demonstrated a 0.5% incidence of venous thromboembolism in patients with 
cirrhosis admitted to hospital (98). 
Whilst the treatment of active bleeding involving transfusion of blood products is 
established, little is agreed regarding prevention of bleeding or thrombosis (96). 
Patients undergoing liver transplant are at high risk of bleeding, however, 
evidence now suggests a restrictive approach to transfusion rather than 
prophylactic administration of blood products achieves better outcomes (99). 
Evidence exists to suggest those with cirrhosis should be anticoagulated to 
prevent thrombosis, however, there is no universal agreement on how this is 
approached (16). 
1.4.8 Bacterial Infection 
Bacterial infections are the most common cause of decompensation in patients 
with chronic liver disease, with up to 50% of deaths attributable to bacterial 
infection (100). The incidence of bacterial infection is higher than the general 
population of hospitalised patients (100). Up to 45% of individuals presenting 
with gastrointestinal haemorrhage have been demonstrated to have an 
underlying bacterial infection (100). Chronic liver disease is specifically 
associated with the development of SBP, although the incidence of respiratory, 
urinary and skin infections is significant (16). When compared to other critically 
ill patients, those with cirrhosis are more likely to have bacterial infection with 
a higher rate of Methicillin-resistant Staphylococcus aureus (101).  
The high incidence and mortality of bacterial infections in those with chronic 
liver disease is due to impaired immune function (section 1.2.2). With an 
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existing ‘hyperdynamic state’ (section 1.4.6) the body is unable to meet the 
demands of increased cardiac output required in sepsis and cardiovascular 
collapse occurs (16).  
SBP is a bacterial infection of ascitic fluid in the absence of any other source of 
intra-abdominal sepsis (102). The incidence of SBP is between 10-30% (103). 
One-year mortality following the development of ascites is approximately 30% 
(103). SBP is often asymptomatic and there must be a high suspicion of SBP in 
those with hypothermia, ascites, sepsis, hepatic encephalopathy and renal 
failure (16). Risk factors for SBP include hyponatraemia and upper 
gastrointestinal haemorrhage (104). Treatment of SBP includes antibiotics and 
albumin, to prevent the development of HRS (16). 
1.5 Critical illness and liver disease 
1.5.1 Definition of critical care 
Levels of care required by patients admitted to hospital have been categorised 
by the Department of Health in the 2000 report ‘Comprehensive Critical Care’ 
which reviewed adult critical care services in the UK (Table 1-4) (105). 
Table 1-4 Levels of patient care as classified by the Department of Health 
(105) 
Level 0 Patients whose needs can be met through normal ward care in an 
acute hospital 
Level 1 Patients at risk of their condition deteriorating, or those recently 
relocated from higher levels of care, whose needs can be met on an 
acute ward with additional advice and support from the critical care 
team 
Level 2 Patients requiring more detailed observation or intervention including 
support for a single failing organ system or post-operative care and 
those ‘stepping down’ from higher levels of care 
Level 3 Patients requiring advanced respiratory support of at least 2 organ 
systems. This level includes all complex patients requiring support for 
multi-organ failure 
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Level 2 care is typically provided in a High Dependency Unit (HDU) whilst Level 3 
care is provided only in an Intensive Care Unit (ICU). However, many hospitals in 
the UK now have critical care units providing both Level 2 and 3 care.  
1.5.2 Organisation of critical care in the UK 
There are 24 ICUs in Scotland with 15,072 admissions to ICU and 31,859 
admissions to HDU in 2017 (106). In 2017-2018 there were 148,817 admissions to 
critical care units in England, Wales and Northern Ireland where there are 196 
general Critical Care Units (107). 
1.5.3 Organisation of liver services in UK 
Whilst intensive care is offered to critically ill patients with liver disease in ICUs 
throughout the UK, the 2009 National Plan for Liver Services UK highlighted that 
the development of specialist care for those with liver disease was focussed in 
only 3 centres: Queen Elizabeth Hospital, Birmingham, King’s College Hospital, 
London and Royal Free Hospital, London (8). All 3 sites have specific Level 3 
units for the management of critically ill patients with liver disease and offer 
liver transplantation. Whilst these 3 units specialise solely in managing patients 
with liver disease, the vast majority of such individuals will not be admitted to 
one of these units. There are four additional transplant centres in the UK 
situated in Cambridge, Edinburgh, Newcastle and Leeds (108). A further 8 
centres within the UK have a “critical mass” of hepatologists (8). None of these 
centres are based in Scotland. 
There were 990 consultant gastroenterologists in the 2009 National Plan for Liver 
Services Report, with an estimated 10% specialising in liver disease (8). Forty-
three percent of consultant gastroenterologists had no specialist training in 
Hepatology and in the 2013 NCEPOD report, only 3% of those admitted with 
complications of liver disease were reviewed on admission by a consultant in 
hepatology (8, 109). Despite acknowledgement of the lack of specialists within 
this field, a recent report by the Lancet noted that less than 50% of 
gastroenterology trainees had experience of working in units offering specialist 
liver services such as out of hours endoscopy, TIPS or even liver clinics (27). 
Nationally, hepatologists are based in transplant or specialist referral centres, 
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with the majority of district general hospitals lacking a specialist hepatology 
service (1). 
The dearth of hepatologists is mirrored in Scotland with 103 gastroenterologists 
listed in the 2013 Survey of Liver Services in Scotland. Thirty-four clinicians 
(33%) had a liver interest, defined as more than 50% of clinical commitment to 
liver or biliary disease (110). Eleven individuals (10.7%) exclusively practiced 
hepatology, 6 of whom were academics in the Royal Infirmary of Edinburgh 
(110). Eleven hospitals (45.8%) had no clinician with a specific hepatology 
interest (110). 
1.5.4 Precipitants for admission to critical care 
Critically ill patients with chronic liver disease may require admission to critical 
care with organ failure as a direct consequence of their chronic liver disease or 
for another reason, complicated by their comorbidity. In addition to organ 
support, critical care aims to reverse causative factors and avert deterioration in 
liver function (111). There are multiple precipitants recognised to cause a 
decline in liver function and they include infection, alcohol ingestion, 
gastrointestinal bleeding, viral hepatitis, surgery, ischaemia or iatrogenic causes 
such as drugs (111). In a study of patients with alcoholic liver disease admitted 
to ICU in Scotland between 2005 and 2010, the most common underlying reasons 
for admissions were reported to be variceal haemorrhage, pneumonia and septic 
shock (4). 
Cardiovascular support offered in critical care encompasses invasive arterial and 
central venous monitoring, echocardiography and pulmonary artery 
catheterisation to assess blood pressure, fluid status and cardiac function. 
Vasopressors and inotropes can be commenced to treat hypotension, maintain 
tissue perfusion and cardiac contractility, which can be required in patients with 
complications of chronic liver disease such as sepsis or cardiomyopathies 
(sections 1.4.6, 1.4.8).  
Respiratory support may be required in the form of invasive or non-invasive 
ventilation for those individuals with hypoxia secondary to severe respiratory 
tract infection, HPS or increased intra-abdominal pressure due to ascites 
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(sections 1.4.5, 1.4.8). Renal replacement therapy or vigilant management of an 
acute kidney injury may be required for complications of chronic liver failure 
such as HRS or ascites (section 1.4.4).  
Those with complications of chronic liver disease such as portal hypertension 
who present with gastrointestinal haemorrhage may warrant admission to critical 
care (section 1.4.2). They may require resuscitation with blood products, 
sedation or respiratory support to facilitate investigation and treatment of 
haemorrhage. Coagulation abnormalities may predispose these patients to 
haemorrhage or thrombosis and can require input to correct abnormalities 
(section 1.4.7). 
Neurological support can encompass management of seizures or decreased 
conscious level secondary to hepatic encephalopathy. Individuals may require 
airway protection with intubation and invasive ventilation for a reduced Glasgow 
Coma Scale (GCS) or additional nursing support for agitation (section 1.4.3). 
1.5.5 Liver transplantation 
Whilst the focus of this thesis is on critically ill patients with chronic liver 
disease outwith the transplant setting, it would be remiss not to mention 
individuals undergoing liver transplantation. Most patients will be admitted to 
intensive care postoperatively following a liver transplant due to the mortality 
and morbidity associated with the procedure (112). Postoperatively, individuals 
may require an extended period of mechanical ventilation and they are at 
increased risk of infection and renal failure (112). Additionally, intensive care 
provides an environment for enhanced monitoring, enabling early identification 
of any issues with organ graft function (112). Outwith the immediate 
postoperative period, with immunosuppression, patients are at increased risk of 
infection in the first year following transplant and may require critical care 
admission (113). Liver transplantation is more extensively offered to those with 
decompensated liver disease, comorbidities and poor functional status, with 
these factors having an increased risk of postoperative complications (112).  
There are 7 centres in the UK offering liver transplant, with 8428 transplants 
performed between 2008 and 2018 (114). Edinburgh Royal Infirmary is the only 
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liver transplant centre in Scotland and performed 92 transplants between April 
2017 and March 2018 (114). Thirty-one percent of those listed for elective liver 
transplants in Edinburgh had liver failure secondary to alcoholic liver disease 
(114).  
1.5.6 Survival of patients admitted to critical care 
The Scottish Intensive Care Society Audit Group (SICSAG) produces an annual 
audit of patients admitted to critical care in Scotland (106). In 2017 the annual 
SICSAG audit reported that 81% of patients admitted to ICU in Scotland survived 
to hospital discharge (106). At present, annual published data does not facilitate 
analysis of mortality by underlying aetiology of admission or chronic disease, 
such as chronic liver disease. 
1.5.7 Survival of patients with cirrhosis admitted to critical care 
Existing studies in the literature have reported short-term mortality for critically 
ill cirrhotic patients since the early 1980s. In 1983 Goldfarb et al. examined 
survival in 100 French cirrhotic patients requiring mechanical ventilation (5). 
Hospital mortality was reported at 89% and rose to 100% in those with septic 
shock, severe cirrhosis or acute hepatitis (5). ICU mortality was described at 
100% in a small group of cirrhotic patients with septic shock admitted to a 
general ICU in 1992 (6). Similarly, Shellman et al. reported a 2% survival within 
72 hours of admission to ICU for those individuals with Child-Pugh Class C 
requiring mechanical ventilation and renal failure (7).  
Mortality decreased over the following 2 decades with studies reporting ICU 
mortality in cirrhotics to be between 36.6% and 60% (115-119). The most recent 
study of ICU outcome for cirrhotic patients in the UK was published in 2018 and 
demonstrated an improvement in survival with ICU mortality reported to be 31% 
(120). The mortality reported by McPhail et al. is mirrored in results published 
by Majumdar et al. who report 32.4% mortality in non-elective ICU admissions in 
Australia and New Zealand (121). Both studies report on large national cohorts of 
patients admitted over a number of years. In addition to the figures reported for 
cirrhosis each study highlights the improvement in survival for other cohorts of 
patients admitted to ICU with multi-organ failure over this time period (120, 
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121). The reason for this is most likely multifactorial; encompassing reductions 
in the incidence of ventilator associated pneumonia and catheter-related 
infections and improvements in staff training (120). In the UK study it is noted 
that organ failure scores on admission to ICU have declined over the last decade, 
suggesting that the severity of illness in those admitted to ICU has reduced 
(120). Thus improved survival may also reflect a change in admission policy to 
include patients with less severe critical illness, exclusion of those unlikely to 
survive or identification and admission of critically unwell patients at an earlier 
point in their illness with greater potential for reversibility (120). 
Mortality is recognised to be lower in those requiring critical care secondary to 
upper gastrointestinal haemorrhage, with ICU mortality reported at 24% in a 
study of 243 cirrhotics (118). A 2012 systematic review demonstrated an ICU 
mortality of 40-50% in those with cirrhosis secondary to alcoholic liver disease 
(122). Mortality remains unchanged with a contemporary study of 2463 
individuals admitted to Scottish ICUs with alcohol-related liver disease reported 
an ICU mortality of 44.1% (4). 
Worldwide hospital mortality in those with critical illness and cirrhosis is 
reported to be between 32%-89% (117, 123-127). Higher mortality is reported in 
subgroups of critically ill cirrhotics with renal failure and those who have 
required mechanical ventilation during their hospital admission (125, 127, 128). 
Mortality at 6 weeks following ICU admission was reported as 65% in a UK cohort 
of critically ill cirrhotics, however, in those with multi-organ failure affecting 3 
or more systems mortality rose to 90% (129). 
Locally, the short-term outcome of the critically ill patients with cirrhosis 
admitted to Glasgow Royal Infirmary (GRI) was explored, with ICU mortality 
reported to be 30% and hospital mortality 46% (18). These figures are similar to 
other recent studies of cirrhotic patients and demonstrate that overall trend is 
an improvement in mortality (120). 
1.5.8 The demand on critical care resources 
Critical care beds are in high demand in UK hospitals, with a 2018 survey by The 
Faculty of Intensive Care Medicine reporting the majority of critical care units 
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had pressure on limited bed numbers (130). Coupled with a shortage of critical 
care nurses, this has led to patients being transferred to different hospitals for 
critical care, use of theatre recovery to increase bed capacity and cancellation 
of elective operations (130). A 2015 UK study of unwell ward patients 
demonstrated that ICUs at capacity prevented prompt admission of patients, 
leading to deterioration and increased mortality (131). To maintain patient 
safety and quality of care it is recommended that critical care units run at 85% 
of capacity, however this survey concluded that the fill rate was 87% in England, 
95% in Northern Ireland, 100% in Wales and 84% in Scotland (130).  
In comparison to other European countries of similar wealth the UK has fewer 
ICU beds per head of population (132). A 2012 study found the UK had 6.6 ICU 
beds per 100,000 of the population, compared to 29.2 beds per 100,000 in 
Germany and 11.6 per 100,000 in France (132). The USA has a reported 28 ICU 
beds per 100,000 population (133). Furthermore, it is predicted that the demand 
on critical care beds will continue to rise worldwide, in the UK this is predicted 
to be an increase of 5% per year with a 100% rise in demand by 2033 (134). 
A 2012 study found that 2.6% admissions to ICU in England, Wales and Northern 
Ireland had liver cirrhosis between 1995 and 2008 (3). Of those admissions, 1.8% 
had cirrhosis named as the primary or secondary reason for ICU admission whilst 
for 0.8%, cirrhosis was a listed co-morbidity (3). Further analysis of data 
revealed that the numbers of those admitted to ICU with cirrhosis has increased 
from 2.8% between 2003-2005 to 5.4% between 2006 and 2008 (3). A recent 
study investigating ICU admissions for those with alcoholic liver disease reported 
5.2% of admissions to ICU in Scotland between 2005 and 2010 had alcoholic liver 
disease (4). When compared to other groups of patients admitted to ICU, 
including those with severe comorbidities such as cardiovascular disease causing 
angina at rest, those with alcoholic liver disease had higher rates of readmission 
to ICU and a longer ICU length of stay (4). In contrast to the other ICU 
admissions those with alcoholic liver disease required more organ support (4).  
These trends reflect the increased incidence of chronic liver disease and 
cirrhosis, highlighting the particular problem of alcoholic liver disease, which is 
preventable (section 1.2.5). With the existing pressure on limited critical care 
beds within the UK and the increased demand to support critically ill patients, 
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deciding which patients merit admission to critical care will become a greater 
challenge. 
1.6 Assessment of scoring systems 
Assessment of critically ill patients with cirrhosis is challenging, with many 
different prognostic models and scoring systems in use. Scoring systems are used 
for a variety of reasons. They are used within diagnosis and prognosis of disease 
and to guide clinical decision-making (135). Further, scores can be used in 
prediction of an event. Predicting patient prognosis is imperative in effective 
utilisation of resources for both surgical and medical management. Scoring 
systems may facilitate standardisation of clinical practice and ultimately 
improve quality of care (135). To interpret the result of a scoring system, it is 
important to know the probability that result gained is correct using positive and 
negative predictive values (136). The positive predictive value of a test is the 
ability to identify those with positive results who have a disease whilst the 
negative predictive value identifies those who do not have a disease with a 
negative result (136). Each scoring system must be evaluated on different 
populations to ensure validity. When considering the utility of scoring systems 
there must be a balance between the ‘rule in’ and ‘rule out’ capabilities. The 
more sensitive the system the more likely it is to correctly ‘rule out’ disease or 
the likelihood of an event and the more specific a system the more likely it is to 
‘rule in’ a disease or event (137).  
 
Prognostic models for patients admitted to critical care are broadly categorised 
into evaluation of severity of illness, such as the Acute Physiology and Chronic 
Health Evaluation (APACHE) (138) and models quantifying organ dysfunction and 
failure, such as the Sequential Organ Failure Assessment (SOFA) (139). The type 
of organ failure is significant with evidence suggesting that renal failure in 
particular has an impact on mortality (66). Specific scoring systems for 
individuals with liver disease exist, although to date, prognostic models designed 
for the overall critically ill population have been found to have better predictive 
ability for predicting prognosis in critically ill cirrhotics (140).  
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1.6.1 Chronic liver disease scoring systems 
1.6.1.1 Child-Pugh score 
In 1973, Pugh et al. modified an existing scoring system used for the assessment 
of mortality in those who had oesophageal transection for the treatment of 
oesophageal varices, which had been designed by Child and Turcotte (141). 
Initially developed to assess risk in those treated with porto-caval shunting in 
1964, the Child and Turcotte’s score graded encephalopathy, ascites, bilirubin, 
albumin and body nutrition (141). Pugh modified this score, adding prothrombin 
time and omitting body nutrition (141). The 5 factors in the Child-Pugh score are 
graded from 1 to 3, with 3 denoting increased abnormality and each factor given 
equal weighting Table 1-5) (141). A healthy individual will score 5 points, whilst 
an individual with end stage liver disease will score a maximum of 15 points 
(141). Individuals were graded into groups A, B and C based upon good, 
moderate and poor operative risks respectively (141).  
The variables in the Child-Pugh score and their measurement do introduce error. 
Measurement of ascites and encephalopathy are subjective (142). Assessment 
and detection of ascites and encephalopathy have changed since 1973 with the 
widespread introduction of ultrasound in ascites and the use of psychometric 
analysis and use of electroencephalography. PT varies between different 
laboratories and the sensitivities of the reagents used for measurement (142). 
Furthermore, the variables measured in Child-Pugh score can be altered by 
medical intervention such as use of albumin, diuretics, paracentesis or use of 
blood products, with no guidance on timing of the score (142). 
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Table 1-5 The Child-Pugh score (141) 
Clinical and biochemical 
measurements 
 
1 
 
2 
 
3 
Encephalopathy None Grade 1 and 
2 
Grade 3 and 4 
Ascites None Mild Moderate-
Severe 
Total Bilirubin (mg/dL) <34 34-50 >50 
Serum Albumin (mg/dL) >35 28-35 <28 
Prothrombin time (seconds prolonged) <4 4-6 >6 
 
Child-Pugh Class Score 
A 5-6 
B 7-9 
C 10-15 
 
Existing work by the MD student’s research group investigated the addition of 
lactate to the Child-Pugh score. This score was demonstrated to outperform 
existing scoring tools in the prediction of ICU mortality in critically ill cirrhotic 
patients (17). The addition of lactate to the model for end stage liver disease 
(MELD) and the UK model for end stage liver disease (UKELD) was shown to 
improve their predictive abilities in a cohort of patients admitted to a tertiary 
liver referral centre in London (143).  
Validation and utility of the Child-Pugh score is discussed in further detail in 
Chapter 4. 
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1.6.1.2 Model for End-stage Liver Disease 
Malinchoc et al. described a scoring system used to predict short-term survival 
of patients undergoing elective TIPS which was termed the MELD (144). The 
score comprised the variables creatinine, bilirubin, International Normalised 
Ratio (INR) and aetiology of cirrhosis (144). This scoring system has been 
subsequently adapted for use in individuals awaiting liver transplantation (145). 
The aetiology of liver disease was excluded from the MELD score as it was not 
found to predict survival (145). In addition to those undergoing TIPS, MELD has 
been validated in other groups with cirrhosis including those hospitalised with 
complications of chronic liver disease and clinically stable patients with chronic 
liver disease who do not require hospital admission (145). The validation of the 
MELD in the inpatient group was limited as it excluded individuals with sepsis, 
renal disease, hepatocellular carcinoma, cardiopulmonary comorbidity and those 
who used alcohol within one month prior to admission (145).  
 
One advantage of the MELD score is that it is a continuous scale, with no ceiling, 
which claims to rank patients based on severity of liver disease (146). Unlike 
Child-Pugh scoring which uses subjective measurement of ascites and hepatic 
encephalopathy, MELD is based upon only objective factors. A limitation of the 
MELD score is the use of INR as a marker for liver disease which may be altered 
by medical intervention (59). MELD excludes assessment of ascites and hepatic 
encephalopathy and therefore patients without deranged liver function may 
have a low MELD score but may have severe liver disease (59).     
 
The MELD score measures short-term mortality in end-stage liver disease with a 
score of 30 or over indicating an individual is more likely to die if not 
transplanted within a short time frame (147). For those with a MELD score of 
under 9, 3-month mortality is 1.9%, 6% for a score of 10-19, 19.6% for a score of 
20-29, 52.6% for 30-39 and 71.3% for a MELD score of over 40 (146). For each unit 
increase in the MELD score there is a 4-9% rise in predicted increased mortality 
(148).  
 
Scoring systems for liver disease continue to evolve with studies suggesting the 
addition of hyponatraemia to the MELD score may improve predictive value for 
disease severity and mortality, in particular for those awaiting liver 
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transplantation (149). Evidence suggests that both renal function and nutritional 
state are significant prognostic factors in cirrhotic patients and should be 
considered in scoring tools (150).  
 
1.6.1.3 Chronic Liver Failure-Sequential Organ Failure 
Assessment 
The chronic liver failure-sequential organ failure assessment (CLIF-SOFA) score is 
a modified SOFA score, developed specifically for a study which aimed to further 
develop diagnostic criteria for ACLF and identify those at most risk of short-term 
mortality (66). The CLIF-SOFA score grades organ systems from 0 to 4 based on 
increasing dysfunction (66). The variables measured include bilirubin, creatinine, 
grade of hepatic encephalopathy, INR, mean arterial pressure (MAP) and 
Pa02/Fi02 ratio or Sp02/Fi02 ratio (66). If MAP is below 70mmHg, the use and 
volume of vasopressor is incorporated within the score (66). The initial study 
examined all patients admitted with cirrhosis to 29 European hospitals, all of 
which had specialised liver units, intensive care facilities and offered liver 
transplantation. In this population, the CLIF-SOFA score measured on study 
enrolment, was demonstrated to correlate with development of ACLF and 
mortality (66). In those with ACLF, the CLIF-SOFA score was shown to be as 
accurate as MELD and more accurate than Child-Pugh in predicting 28-day 
mortality (66). The CLIF-SOFA score has been demonstrated to have good 
predictive power for short-term mortality in those with an acute 
decompensation of alcoholic liver disease (151). It has also performed well in 
prediction of 6-month mortality in a group of critically ill cirrhotics (152). 
 
1.6.1.4 Royal Free Hospital score 
The Royal Free Hospital (RFH) score was designed as a prognostic model for 
critically ill cirrhotic patients (129). Based upon the factors found to 
independently predict mortality in a group of critically ill patients admitted to 
the Royal Free Hospital in London, the RFH score includes measurements of 
bilirubin, urea, lactate and inspired oxygen concentration (129). The RFH score 
is only one of 3 prognostic scoring tools designed using data from critically ill 
patients with cirrhosis, the others being the Intensive Care Cirrhosis Outcome 
(ICCO) score and the Mean Arterial Pressure, Bilirubin, Acute Respiratory Failure 
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and Sepsis (MBRS) score (153-155). The RFH score was validated on a cohort of 
patients with cirrhosis admitted to the Royal Free Hospital, demonstrating 
similar prognostic accuracy to SOFA whilst it was found to be superior to MELD, 
Child-Pugh and CLIF-SOFA (153). The score has been further validated in an 
external cohort of UK critically ill cirrhotic patients, outperforming existing 
established scoring systems (156). 
 
1.6.1.5 United Kingdom Model for End-stage Liver Disease 
The UKELD model was designed to predict transplant waiting list mortality in the 
UK (157). Whilst the MELD scoring system has been adopted to prioritise organ 
allocation in the USA it was not developed for use in transplantation (145, 157). 
In addition the MELD score may be low in those with high risk of mortality such 
as individuals with ascites or hyponatraemia (158). 
 
UKELD was developed using data from 1103 patients on the transplant list in the 
UK (157). The most common underlying aetiology of liver disease in this 
population was alcoholic liver disease and Hepatitis C (157). INR, bilirubin and 
sodium were all found to predict mortality in those on the waiting list. At the 
author’s discretion, creatinine was added to the score as its inclusion was 
believed to add value to the score (157). The score was subsequently validated 
with a prospective cohort of 452 patients (157). Whilst a higher UKELD score was 
associated with death on the transplant list, there was no association between 
UKELD and survival following transplant in the initial paper (157). A UKELD score 
of 60 has been demonstrated to predict 50% survival at 1 year, enabling 
identification of those at high risk of short-term mortality without 
transplantation (159). The UKELD model is limited in that it excludes those with 
hepatocellular carcinoma and scoring occurs when individuals are placed on the 
list and thus changing clinical picture during waiting time is not taken into 
account (157).  
 
The UKELD score has been examined outwith the transplant setting in critically 
ill cirrhotic patients in the UK and was found to have a similar predictive value 
to the both the MELD and Child-Pugh scores (17, 156).  
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1.6.1.6 Intensive Care Cirrhosis Outcome  
The ICCO score consists of variables found to predict ICU and hospital mortality 
in a cohort of cirrhotic patients admitted to Austrian critical care unit (154). The 
score incorporates bilirubin, cholesterol, lactate and creatinine measured on ICU 
admission (154). The ICCO was subsequently prospectively validated on 70 
patients admitted to the same unit (154). ICCO outperformed APACHE III in 
mortality prediction in this cohort, with the authors reporting that no patient 
with an ICCO score of above +2.6 survived (154). This score has not been utilised 
widely in studies, as such there is little evidence to its validity in an external 
cohort. The ICCO score was excluded from analysis within this thesis as serum 
cholesterol measurements are not routinely measured on ICU admission. In the 
acute phase response to critical illness, cholesterol levels are known to decrease 
in certain individuals and may be affected by multiple different factors (160). 
 
1.6.1.7 Mean arterial pressure, Bilirubin, Acute respiratory 
failure and Sepsis  
Whilst a number of scoring systems include assessment of renal dysfunction in 
critically ill cirrhotics, the MBRS score was designed specifically to predict 
mortality in this population (155). This scoring tool was designed using data from 
patients admitted to a Taiwanese ICU with a high mortality of over 80%, as such 
the application may be limited in a UK cohort due to differences in the 
underlying aetiologies of chronic liver disease (155). The MBRS score reflects 
organ dysfunction by including MAP and liver impairment with the inclusion of 
bilirubin (155). The MBRS was measured following admission to ICU and therefore 
would be affected by medical intervention. It is therefore of limited value in 
helping decide whether or not to offer intensive care (155). The use of MBRS in 
other populations of critically ill cirrhotics is limited, with a paucity of evidence 
to support its wider use (153). 
 
1.6.1.8 Glasgow Alcoholic Hepatitis Score 
The Glasgow Alcoholic Hepatitis Score (GAHS) was designed to predict mortality 
in individuals with alcoholic hepatitis (161). The score was derived using clinical 
data of patients with alcoholic liver disease admitted to Glasgow Royal Infirmary 
and the Victoria Infirmary, Glasgow (161). The GAHS incorporates 5 variables; 
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age, serum bilirubin, blood urea, PT and peripheral white blood cell count – all 
scored on day 1 of hospital admission (161). Individuals receive a score from 5-
12, with a score greater than 8 associated with poor prognosis (161). Day 1 and 7 
GAHS scores were more accurate in predicting the 28 and 84 day outcomes than 
the MELD score (161). Whilst this score has been validated in 8 centres in the 
UK, it has not been validated outwith the UK (161, 162). The GAHS has been 
examined in cohorts of critically ill cirrhotic patients and has been demonstrated 
to have good predictive value for mortality when compared to the established 
scores of Child-Pugh and MELD (17, 156). This may be explained by the 
predominance of underlying aetiology of alcoholic liver disease in critically ill 
cirrhotic patients in the UK (156). 
 
1.6.2 General critical illness scoring systems   
1.6.2.1 Acute Physiology and Chronic Health Evaluation score 
The APACHE score was designed in 1981 to enable assessment of the severity of 
illness of critically ill patients (138). The authors note that the APACHE score 
should apply to groups of patients rather than be used as a tool to inform 
medical care on an individual basis (138). The APACHE classification is based 
upon age, pre-admission health evaluation and an objective score of 34 
physiological variables reflecting acute illness (138). In 1985 the original authors 
revised APACHE, creating APACHE II and reducing the 34 measured variables to 
12 (163). The revised score gave greater weighting to GCS and renal dysfunction 
whilst the significance placed on arterial oxygen concentration and inspired 
oxygen requirement was refined (163). Individuals can have a maximum APACHE 
II score of 71, with physiological variables measured within the first 24 hours of 
ICU admission (163). A score of 0-4 predicts a mortality of 1.9%, whilst a score 
over 35 indicates a 84% chance of mortality (163). Further refinements to the 
APACHE score have been made, with the APACHE III prognostic system published 
in 1991 (164). APACHE III incorporated 5 new variables; blood urea nitrogen, 
urine output, serum albumin, bilirubin and glucose (164). Furthermore, the 
authors designed an equation to predict death incorporating underlying disease 
and location of patient prior to ICU admission (164). Patients admitted from 
hospital wards, transfers and readmissions to ICU were noted to have higher 
death rates than those admitted directly from the emergency department (ED), 
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although this study was based on an American healthcare model (164). APACHE 
IV incorporated new variables including requirement for mechanical ventilation 
and adjustment of GCS when sedation or paralysis was used (165). 
 
All versions of the APACHE scoring system have been extensively validated, with 
APACHE II reported to be the most commonly used tool worldwide for 
assessment of severity of illness (166). APACHE II has been found to predict 
mortality in populations of critically ill cirrhotic patients (119, 129, 167). 
 
1.6.2.2 Simplified Acute Physiology Score 
The SAPS was proposed as an outcome predictor which incorporated commonly 
measured variables in the critically ill (168). Whilst the authors acknowledged 
the value of the first version of the APACHE score it was thought that error was 
introduced by the likelihood of missing measurements (168). The SAPS utilises 13 
variables plus age, which are all measured in the initial 24 hours following ICU 
admission (168). In 1993, the SAPS II was published and aimed to use statistical 
modelling to predict outcome using data from 13,152 patients admitted to 137 
ICUs in Europe and North America (169). SAPS II incorporated 12 physiological 
variables, plus age, type of admission and adjustment for three comorbidities; 
acquired immunodeficiency syndrome, metastatic cancer and haematological 
malignancy (169). The SAPS II score has been demonstrated to accurately predict 
mortality in populations of cirrhotic patients (170, 171). A subsequent study has 
created the SAPS 3 score, which utilised data from 16,784 critically ill patients 
admitted to ICUs in 35 countries worldwide (172). As with the SAPS II, the SAPS 3 
incorporates information regarding the type of admission, patient age and 
comorbidities, however, it assesses physiological variables within 1 hour of ICU 
admission (166, 172). To date, validation of the SAPS 3 model in the critically ill 
cirrhotic population is lacking within the literature.  
 
1.6.2.3 Mortality Prediction Model 
The mortality prediction model (MPM) aims to predict ICU outcome using 7 
variables, with one model utilising values measured on admission to ICU and 
another using values recorded during the first 24 hours of admission (173). Both 
models were updated in the publication of the MPM II model (174). The MPM II 
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utilises a greater number of variables, with 15 variables included in the 
admission model MPM0 and 13 variables in the MPM24 (166, 174). The admission 
MPM (MPM0-III) was revised to more accurately predict mortality assessing 16 
variables within 1 hour of ICU admission (175). No studies were identified within 
the literature assessing the prognostic ability of the MPM in the cirrhotic 
population. 
 
1.6.2.4 Sequential Organ Failure Assessment 
The SOFA score was developed at a consensus meeting by the European Society 
of Intensive Care and Emergency Medicine to describe the severity and 
complications of organ dysfunction in the critically ill and was not designed to 
predict mortality (139). The SOFA combines scores from 6 different organ 
systems: cardiovascular, respiratory, hepatic, renal, coagulation and 
neurological over the first 24 hours of admission (139). The cardiovascular 
system is assessed using MAP or inotropic requirement, the respiratory system is 
assessed using the Pa02/Fi02 ratio, the hepatic system is assessed by serum 
bilirubin concentration, renal using creatinine or urine output, coagulation by 
platelet count and neurological using GCS (176). Each system is graded from 0 to 
4, with a score of 4 indicating greatest dysfunction and a maximum score of 24 
(139).  
 
Despite not being developed to predict outcome, the SOFA has been 
demonstrated to predict prognosis in individuals with cirrhosis and compares 
favourably with APACHE II or Child-Pugh (129, 177). Unsurprisingly, it was 
reported that length of ICU stay increased with greater organ dysfunction as 
reflected in the SOFA score (177).  
 
1.6.2.5 Multiple Organ Dysfunction Score  
The Multiple Organ Dysfunction Score (MODS) was designed to measure severity 
of organ dysfunction in critically ill patients (178). Similar to the SOFA score, 
organ failure is measured in 6 physiological systems: respiratory, renal, hepatic, 
cardiovascular, haematological and neurological (178). Each system is scored 
from 0 to 4, with a score of 4 given to the most severe organ impairment and a 
maximum score of 24 (178). MODS and SOFA are very similar in the variables 
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included to ascertain the level of organ dysfunction with the exception of the 
cardiovascular system (176). MODS uses the pressure-adjusted heart rate and 
does not make allowance for inotrope use (176). In a study of 949 patients 
admitted to a Belgian ICU, assessment of cardiovascular dysfunction as measured 
by the SOFA score had greater correlation with mortality than the pressure-
adjusted heart rate measured in MODS (176). 
 
1.7 Summary and research questions 
This literature review has described the importance of the liver, explored the 
pathophysiological deterioration in liver function and the development of 
cirrhosis in chronic liver disease. There has been a focus upon preventable 
aetiologies of chronic liver disease in particular excess alcohol consumption. The 
MD student has outlined the increased prevalence and mortality of chronic liver 
disease and the lack of specialist liver services in the UK to meet demand. There 
has been exploration of the reasons why patients with advanced chronic liver 
disease require intensive care, the improvement in short-term survival in those 
admitted and the limitations in scoring systems used to predict mortality. With 
limited critical care provision and increased demand, deciding which patients to 
admit to the ICU can be challenging.  
This thesis focuses on the decision to admit a patient with advanced chronic 
liver disease or cirrhosis to critical care, their long-term survival and quality of 
life and addresses how one preventable cause of chronic liver disease can be 
assessed in the critically ill.  
1.7.1 What criteria are used in the decision to offer intensive 
care to a patient with chronic liver disease? 
Individual factors involved in the decision to offer patients intensive care have 
been investigated extensively. However, there is a lack of evidence examining 
whether differences exist in the degree of influence each factor has on the 
referring gastroenterologist and receiving intensivist.  
  71 
 
1.7.2 When should the established prognostic scoring tool Child-
Pugh be measured to inform the decision to admit a 
patient? 
Child-Pugh score was the first scoring tool used to predict mortality in liver 
disease. The score is used worldwide to inform the decision regarding whether 
to admit a patient to intensive care. Debate exists as to whether its value in 
prognostication lies in measurement when a patient is stable, to reflect chronic 
liver dysfunction, or at the time of admission to ICU, where it may reflect acute 
illness and organ dysfunction. 
1.7.3 Can a proxy be used to measure alcohol intake in a patient 
admitted to intensive care? 
Alcoholic liver disease is one of the preventable causes of chronic liver disease 
and cirrhosis. Prompt recognition and treatment of patients who consume excess 
alcohol would inform acute medical management and facilitate targeted health 
intervention. Gaining an accurate alcohol history is challenging, particularly if 
the patient is critically ill. If a proxy is found to provide a precise alcohol history 
this would provide valuable information in the intensive care setting. 
1.7.4 What is the long-term survival of patients admitted to 
intensive care with cirrhosis? 
Multiple studies demonstrate that the short-term survival of patients with 
cirrhosis admitted to intensive care is improving. However, there are few studies 
reporting the long-term survivorship of patients with cirrhosis admitted to 
intensive care outwith tertiary referral centres or beyond 6 months. Information 
on the long-term outcomes could inform the clinical decision whether to admit 
patients to ICU and give valuable information to patients who have capacity to 
make the decision to undertake intensive treatment.   
1.7.5 What is the long-term quality of life of patients who 
survive intensive care? 
QOL following intensive care stay is considered to be one of the most important 
outcomes for survivors. Sleep is known to contribute to QOL and is disturbed 
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whilst patients are admitted to hospital. Moreover, little is known about the QOL 
and sleep in the subgroup of critical illness survivors with cirrhosis. Determining 
the prevalence of insomnia and the long-term QOL in survivors of critical illness 
could inform patients about recovery following discharge and facilitate targeted 
interventions if QOL or sleep were found to be impaired. 
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Chapter 2 Methodology 
This chapter aims to introduce the research methods utilised in this thesis and 
explores the concepts involved in research design. It incorporates the 
approaches to statistical analysis used throughout the thesis.   
2.1 Research design 
Research can be quantitative or qualitative. Some studies combine aspects of 
both and are described as mixed methods research. The majority of the studies 
in this thesis use quantitative methods, however, Chapter 3 involves qualitative 
research and as such both methodologies are discussed in further detail.  
2.1.1 Quantitative research 
Quantitative research is the collection of numerical data (179). Data are 
measured using defined research instruments and analysed using statistical 
techniques (179). This thesis involved a number of different techniques to 
answer study questions. Chapter 3 entailed the creation of 2 surveys and 
incorporated different techniques including likert scales and vignettes to answer 
questions. Chapters 4 and 6 comprised the analysis of existing data whilst 
Chapters 5 and 7 utilised established measuring tools to answer study questions.  
2.1.1.1 Likert scale 
A Likert scale consists of a statement and a scale consisting of different 
categories to indicate respondent agreement with the statement (180). The 
scale includes a range of responses enabling the respondent to rank whether 
they ‘agree’ or ‘disagree’ with the statement and usually includes a middle 
response of ‘neither agree nor disagree’(179). The statements in the Likert scale 
must relate to the same topic.  
A Likert scale is an example of a multiple-indicator measure, which facilitates 
assessment of different aspects of a concept and gives a broader range of 
information from the respondent (179).   
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2.1.1.2 Vignettes 
Vignette questions supply a hypothetical scenario and the respondent must 
decide on their response based upon the scenario (181). It is argued that 
because a vignette includes a scenario it encourages the respondent to reflect 
on their answer, rather than using an open question enquiring about their beliefs 
or attitude on a topic (181). In order to be successful a vignette must be realistic 
to the respondent. 
2.1.2 Issues of rigour  
In research it is important that a number of concepts are understood when 
designing a study. To ensure the credibility and quality of the research 
performed in this thesis, it was considered important to explore the concepts of 
reliability and validity. Both criteria are essential in determining whether 
findings can be incorporated into clinical practice. 
2.1.2.1 Reliability 
Reliability is defined as “the degree to which a measure of a concept is stable” 
and the consistency of measurement (179). It determines whether the study can 
be accurately replicated and if a measurement can be interpreted the same way 
in different situations (179, 182).  
When a measurement tool is used within a study the reliability of that tool must 
be questioned (179). There are a number of different indices of reliability such 
as internal consistency, test-retest and inter-rater reliability (183). Assessment 
of the internal consistency reliability of a psychological tool is the most 
commonly reported measure of reliability (183). To ensure the internal 
reliability of a measurement tool, the indicators used must be related and assess 
the same concept if the answers are combined to create a total score (179). 
Literature suggests that a reliability of 0.80 is required for tests used solely in 
research and a reliability of 0.90 is necessary for a test to be used to determine 
important clinical decisions (184). To maintain internal reliability the 
measurement tools used within this thesis were chosen as they had been widely 
tested for internal reliability. 
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Where more than one person was involved in data collection the inter-observer 
consistency had to be maintained (179). To ensure consistency, objective 
measurements were used where possible within each study.  
2.1.2.2 Validity 
Validity is defined as the “integrity of conclusions that are generated from a 
piece of research” (179). In order to ensure a study draws sound conclusions, 
different aspects of validity must be appreciated. Measurement or construct 
validity concerns the ability of a measurement tool to appropriately assess the 
variable in question and assumes that the tool is reliable (179). Concurrent 
validity is a type of measurement validity. It describes a comparison of how well 
a tool performs in the measurement of a variable compared to an existing tool 
which has been validated (179). Face validity is an alternative form of 
measurement validity and concerns whether a question truly reflects the 
concept in question (179).  
Conclusion validity concerns the ability of data to support the conclusions made 
in a study (185). Internal validity concerns the ability of data to support an 
outcome within a study, whilst external validity is whether the data and 
conclusions made in a study can be applied outwith the study to other 
populations (185). 
2.1.3 Study sites 
Data collection and patient recruitment was undertaken at 2 hospitals in 
Glasgow, with the exception of the national Scottish survey discussed in Chapter 
3.  
GRI ICU consists of 12 Level 3 beds and 8 Level 2 beds and is a tertiary referral 
unit for burns, pancreatic disease and oesophageal surgery. It is located to the 
North-east of Glasgow city centre. As highlighted in Chapter 1, Glasgow has one 
of the highest rates of alcohol use in Western Europe. Many patients admitted to 
the hospital have problems related to alcohol, either as the primary cause of 
their admission or indirectly complicating their health. GRI was chosen as the 
primary site for each of the studies in this thesis for a number of reasons. 
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Firstly, this site has recently undertaken research within the ICU and the 
University of Glasgow into the assessment and management of alcohol-related 
admissions to the ICU and attendance at the ED (186, 187). Secondly, the MD 
student had worked in the ICU as a core Anaesthetic trainee and as such was 
familiar with the hospital, staff and electronic patient record systems. GRI 
utilises the NHS Greater Glasgow and Clyde electronic patient record (Clinical 
Portal, Orion Health, Auckland, New Zealand) to record inpatient and outpatient 
hospital attendances, correspondence and the results of any investigations. Case 
notes in the ICU are computerised and use Philips IntelliVue Clinical Information 
Portfolio or CareVue Revision D.03, which is used in other ICUs but is not 
universal across NHS Greater Glasgow and Clyde (188). 
 
The QEUH in Glasgow houses a critical care unit for both ICU and HDU patients 
comprising 20 ICU beds and 39 HDU beds. The hospital is located in the South-
west of Glasgow and receives approximately 850 admissions to critical care per 
year. It is a regional unit for trauma and vascular surgery and houses the 
regional infectious diseases and renal units. The QEUH was chosen as a research 
site as it is the largest hospital in Glasgow and uses the same electronic patient 
record systems as GRI.  
The MD student did not work in a clinical capacity at either hospital during 
patient recruitment. This prevented any confusion regarding role when 
recruiting patients in the study described in Chapter 5.  
2.1.4 Participants 
Participants are described in each separate chapter of this thesis as they differ 
between studies. Participants included critically ill patients, their close contacts 
and consultants in gastroenterology and intensive care. Ethical approval was 
sought for each study when required and is documented within each chapter. It 
was appreciated that this group of patients and their contacts are a vulnerable 
group within the population. Survivors of critical illness experience physical, 
social and psychological problems following an ICU stay whilst contacts of 
critically ill individuals experience significant psychological strain (189).  
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2.1.5 Informed consent  
All participants were asked to give consent to their involvement in the research 
in this thesis. For those who could not give consent, such as patients who were 
admitted to ICU, consent was sought once the individual had improved clinically. 
Information sheets were provided prior to consent, with participants informed of 
their right to decline involvement in the research.   
2.1.6 Confidentiality and data management 
Patient confidentiality was maintained at all times with completed 
documentation relating to each study kept anonymous. This was performed in 
accordance with the Data Protection Act 1998. All information recorded was 
kept on an encrypted memory stick and raw data remained locked within 
University of Glasgow Anaesthetic department. 
2.2 Statistical software 
Two different statistical software programmes were used in this thesis. R was 
used for all data analysis with the exception of Chapter 6. In Chapter 6, the MD 
student supervised an undergraduate BSc student who performed data analysis 
as part of an intercalated degree. The student was given statistical lectures 
using SPSS and as such was required to use this software for data analysis. 
2.2.1 R  
R is a statistical software package which enables the user to write programming 
language and perform statistical tests (190, 191). It is based on the statistical 
software S-plus and uses descriptive code to perform functions (191).  
There are a number of reasons why R software was utilised. It is used worldwide 
by many researchers as it is considered to be superior to other statistical 
software in its abilities to manipulate data and draw high-quality plots (191). R 
software is free, open source and can be used on multiple computer platforms 
(191). Furthermore, there is expertise in using R software within the University 
of Glasgow Anaesthetic department facilitating assistance with data analysis 
when required. 
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In all data analysis, coded data were initially entered into a Microsoft Excel 
spreadsheet (2011). Data were then imported from the spreadsheet to the 
statistical package RStudio version 1.0.136 © 2009-2016 RStudio, Inc. 
2.2.2 SPSS 
SPSS is a statistical program which was the original abbreviation for the 
Statistical Package for the Social Sciences (179). It is a commercial software 
product owned by IBM and as such a license and payment is required to use the 
software. The statistical packages offered by SPSS are limited to the version of 
SPSS, unlike R in which packages are frequently added. However, SPSS has the 
advantage of not requiring the user to learn a programming language and as such 
may be regarded as easier to operate. As a commercial product there is official 
user support available for SPSS, which is not available for R. 
As with R, coded data were entered into a Microsoft Excel spreadsheet (2011) 
and then imported to the SPSS Data View Sheet.  
2.3 Data analysis 
Identification of the type and spread of data are essential in determining that 
the correct statistical tests are chosen to analyse data. Assistance in data 
analysis was provided by a clinical physicist in the University of Glasgow 
Anaesthetic department. 
2.3.1 Scales of measurement  
To interpret data it is important to determine the type of variable measured. 
Data can be continuous, whereby a score is given on a measurement scale, such 
as height or number of days.  
Categorical data are separated into distinct entities and is described as binary, 
nominal and ordinal (182). Binary variables are those with only 2 choices such as 
‘yes or no’. If there are more than 2 categories, the data are described as 
nominal such as admission speciality. Ordinal data describes ranked categories, 
such as a Likert scale. 
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2.3.2 Measures of central tendency 
Once data are collected it is vital to ascertain the frequency of distribution of 
the values. To do this it is customary to identify a central value to represent the 
dataset (192). Measurement of central tendency can be reported as the mode, 
median and mean. The mode is the most commonly occurring number. The 
median is identified by ranking the values in ascending order and identifying the 
middle number. The mean is obtained by adding all the values together and 
dividing the total by the number of values.   
2.3.3 Measures of variability  
In this thesis, data were initially analysed to determine the spread around a 
central tendency using histograms. This established whether each variable 
examined displayed parametric (normally distributed data) or non-parametric 
data (lack of a normal distribution). The central value in parametric data were 
described as a mean, whilst the central value in non-parametric data were given 
as a median. 
To describe the spread of data around a central value different terms are used. 
The range describes the spread of all scores from highest to lowest. Parametric 
data are described using the variance and the square root of variance - standard 
deviation. Non-parametric are described using the interquartile range (IQR). 
Data are split into 4 quartiles and an IQR describes the middle 50% of values.  
2.3.4 Statistical significance  
Statistical significance is the confidence that the results provided by data 
analysis are true and have not occurred at random. It is the ability of results to 
accurately reject a null hypothesis. Statistical significance is set as a probability 
level. Medical research commonly uses a 5% (0.05) probability level, which 
indicated that there is up to a 5% chance that the difference found by a 
statistical test occurred at random (192). The threshold for statistical 
significance set in this thesis was p<0.05, as per comparable studies in the 
literature. 
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In research there are often multiple statistical tests performed on datasets 
rather than using multivariate analysis or creating a single model. Such tests will 
provide a number of p-values, which can increase the likelihood of a Type I error 
where results are incorrectly identified as significant. To reduce the error 
resulting from multiple testing the p-values are adjusted using a Bonferroni 
correction (193). 
2.3.5 Univariate analysis 
Univariate analysis concerns analysis of one variable. Data can be described 
using frequency, measures of central tendency and variability (179). 
2.3.6 Bivariate analysis 
Bivariate analysis concerns the analysis of two variables to determine if there is 
a relationship between them. The choice of statistical test depends upon the 
type of variables analysed and a variety of bivariate tests were used within this 
thesis.  
In the analysis of 2 independent groups and a numerical or ordinal variable the 
tests used depend on the distribution of data. In the presence of a parametric 
distribution the independent t-test is used to determine the presence of a 
relationship between the mean of each of the variables (182). If the data display 
a non-parametric distribution the Mann-Whitney or Wilcoxon rank sum test are 
utilised instead, both of these tests are equivalent and use ranking rather than 
actual values (182).   
If 2 non-parametric categorical variables are measured a Pearson’s Chi-square 
test is used to determine if there was a relationship present (182). A Fisher’s 
exact test is used with smaller sample sizes of under 5. 
2.3.7 Multivariate analysis 
Multivariate analysis concerns the analysis of multiple variables. Using 
multivariate analysis is preferable when comparing a number of independent 
groups with a single nominal or ordinal variable (193). The alternative is to use 
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multiple tests comparing each individual group with the variable. This would 
increase the likelihood of a high Type I error (section 2.3.4). 
One-way analysis of variance (ANOVA) is used to compare the means of different 
variables (194). In these populations it must be assumed that the data are 
normally distributed with the same variance within each group (193). Whilst a 
one-way ANOVA can be used for 2 variables, it is convention to use a t-test for 2 
variables and ANOVA for 3 or more variables (182).  
The Kruskall-Wallis is used for non-parametric data to determine if there is a 
relationship between 3 or more variables (182). 
2.3.8 Confidence intervals 
A confidence interval (CI) is a range of values around a statistic in which there is 
a set certainty that the true value is found (182). When a 95% CI is used there is 
a 95% probability that the true value lies within the range of values given. The 
width of a CI determines the precision of a result (193). A narrow CI suggests 
that the result is precise, however, studies with a smaller sample size or greater 
variability in results will have wider CI. To reflect similar studies a 95% CI was 
used within this thesis. 
2.3.9 Odds Ratios  
Odds are the ratio of the probability of an event occurring compared to the 
event not occurring (195). 
The Odds ratio (OR) represents the ratios of the probability of an event 
occurring or not occurring in 2 different groups (179). An OR of 1 indicates that 
the probability of an event occurring in 2 different groups are the same and that 
there is no relationship between the variables (179).  
2.3.10 Linear regression 
A linear regression model is used to analyse and quantify relationships between 2 
continuous variables (194). Regression analysis predicts an outcome variable 
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from a predictor variable (182). Simple regression describes 1 predictor variable, 
whilst multiple regression involves more than 1 predictor variable (182).  
To perform linear regression a graph is drawn with a dependent variable on each 
axis and a straight line drawn through the data. A linear regression line is 
represented by the equation Y = a + bx (Figure 2-1) (193). a and b are the 
regression coefficients (Table 2-1). A linear regression model calculates an 
equation that minimises the distance between the fitted line and the data (194).  
  
  83 
 
Figure 2-1 Estimated linear regression line (193) 
Reproduced with permission from Wiley Books, (license no.4544720793557) 
 
Table 2-1 Elements of the simple linear regression equation (193) 
Elements of 
equation 
Represent 
x Predictor variable 
y Dependent or response variable  
Y  
Value of y which lies on the estimated straight line for a 
given value of x   
a Intercept of the line; value of Y when x = 0 
b 
Gradient of the line; amount by which Y increases if x is 
increased by 1 unit 
 
R2 is the coefficient of determination and indicates the goodness of fit of the 
data points to the straight line produced by the model (193). R2 indicates the 
proportion of the variability in the model which is explained by the regression 
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(193). R2 is usually expressed as a percentage and has a value of between 0 and 
100%. If the R2 is 100% then the model explains all of the variability of the 
response data around its mean, whilst if R2 is 0% the model will explain none of 
the variability.  
An adjusted R2 is performed to determine the goodness to fit on a multiple 
linear regression model (193). It is a modification of R2 to adjust for the number 
of different predictor variables in the model. It describes the proportion of the 
variability of y which is explained by its relationship with each of the x’s (193).  
The variables included within predictive models can be selected using different 
types of selection processes. A backward selection process begins by including 
all variables judged to be predictive in the model. Variables are removed in 
turn, with those least likely to influence the model removed first until removing 
any further variables from the model significantly affects the fit of the model 
(193). A forward selection model adds variables considered to add to the 
predictive ability of the model in succession until no further variable 
significantly improves the model (193). A stepwise selection uses both forward 
and backward selection of variables. It initially uses a forward selection process 
of variables but ensures that all variables included to that point significantly add 
to the model (193).  
2.3.11 Logistic regression 
Logistic regression is similar to linear regression but it is used when one of the 
outcome variables measured is binary, such as the presence or absence of a 
disease (193). A logistic regression model can determine which of the predictor 
variables predict the outcome variable and gauge the probability of a particular 
outcome occurring (193). The probability of an event occurring is described using 
the OR and CI. 
A Wald statistic is reported with a logistic regression model. This indicates 
whether the coefficient for a predictor variable differs significantly from zero 
(182). If a Wald statistic is reported as zero then the variable is not significant 
and should be removed from the model. 
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2.3.12 Survival analysis  
Survival analysis is a collection of statistical methods exploring the concept of 
‘time to an event’ (196). In many cases the event will be death, however, it may 
refer to hospital discharge or time to readmission. Due to the constraints of 
research there will be individuals who have not experienced the ‘event’ by the 
end of the data collection period. In survival analysis it is possible that there will 
be individuals who have not died by the end of the study. The term given to the 
survival time for such patients is ‘censored’, whereby it is unknown when the 
patient will die but they have not died by the end of the data collection period 
(196). Censoring will also apply to those lost to follow up as their survival will be 
unknown (196). To appropriately interpret survival analysis a specific time point 
must be chosen from which to measure survival (196). Survival time could be 
measured from an event such as ICU admission or discharge.  
The Kaplan-Meier method is used within survival analysis (197). It allows for 
censoring and enables estimation of the probability of survival at each time 
point measured (197). A survival curve is plotted with survival probability 
measured on the y-axis and time on the x-axis (197).  
The log-rank test is used to determine if there is a statistically significant 
difference between survival times of each group as measured on a survival 
curve. It assesses the hypothesis that there is no difference in the survival times 
of each group (193).   
2.3.13 Receiver-operating characteristic curves 
Receiver-operating characteristic (ROC) analysis is used within medical research 
to determine the accuracy of diagnostic tests and statistical models which divide 
individuals into 2 categories (198). A ROC curve can also be used to determine 
the discriminative ability of a scoring system (199). A graph is plotted of a true 
positive rate, or the sensitivity, against the false positive rate (1-specificity) 
(200).  
To ascertain the performance of a scoring system the area under the ROC curve 
(AUC) is calculated (200). An AUC of 1 denotes a perfectly accurate scoring 
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system, whilst an AUC of 0.5 indicates that the performance of a scoring system 
is random (198). In comparative clinical studies an AUC of 0.8 has been 
determined as the threshold for clinical use (201). 
 
  87 
 
Chapter 3 Admission and referral to critical care 
of patients with liver disease 
3.1 Introduction 
The literature review explored the clinical manifestations of advanced liver 
disease and the precipitants for critical care admission in this population. It 
highlighted the current demand on critical care in the UK and the challenges 
clinicians face in determining which patients to admit to intensive care when 
capacity is limited.   
This chapter further investigates the decision to admit or refer a patient with 
chronic liver disease to critical care. 
3.2 Ethical dilemmas in critical care and liver disease 
Introduced in response to the polio epidemic in the early 1950s, the concept of 
intensive care has developed from the provision of positive pressure ventilation 
through the use of ‘iron lungs’ to the delivery of multi-organ support for patients 
at high risk of death (202). Such medical advances coupled with increased 
incidence and survival of those with chronic disease has raised demand and 
pressure on finite resources, with challenges arising in the allocation of critical 
care beds (203, 204). Critical care utilisation varies worldwide, with differing 
attitudes and thresholds for admission, reflecting both healthcare organisation 
and funding. ICU capacity is difficult to define with no standard definition of an 
ICU bed (205). For example there are 6.6 beds per 100,000 of the population in 
the UK, which rises to 29.2 beds per 100,000 in Germany, introducing variation 
in bed capacity (132). 
There are many ethical aspects to consider in deciding which individuals should 
be offered critical care, in particular individuals perceived to have self-inflicted 
illness, including specific aetiologies of liver disease (204). Beauchamp and 
Childress describe a 4 principle approach to medical ethics encompassing 
autonomy, beneficence, non-maleficence and justice which apply when deciding 
if critical care admission is appropriate (206).  The importance of decision-
making is reflected in guidelines with the General Medical Council (GMC) 
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recommending a joint partnership between doctor and patient, with the onus on 
the clinician to outline options for patients using clinical knowledge and 
judgement (207). Individuals should be informed of both non-survivorship and the 
potential risks and burden of an ICU stay. Guidelines for ICU admission have 
been published by the American Society of Critical Care Medicine which suggests 
models based on prioritisation, diagnosis and objective parameters (208). A 
prioritisation model stratifies individuals at risk, with those at highest priority 
requiring invasive treatment only available within the ICU and those at lowest 
priority at low risk of requiring intervention or individuals with irreversible 
disease facing imminent death (208). The diagnosis model suggests diseases 
which commonly require ICU admission whilst the objective model encompasses 
vital signs, laboratory values, radiological findings, electrocardiogram record and 
physical findings on examination (208). Whilst these guidelines suggest the 
proposed models are used to inform site and population specific policies, they 
also highlight the value of scoring tools and emphasise the overriding value of 
clinician judgement to assess every individual case (208).   
The capacity to understand disease processes, what intensive treatment 
strategies involve or potential outcomes may be impaired by critical illness with 
an ICU candidate unable make an informed decision regarding care (209, 210). 
The Adults with Incapacity (Scotland) Act 2000 provides a framework to aid in 
decision-making with regular review of capacity and clinicians acting in the best 
interest of the patient (211). The presence of an advanced directive can provide 
a useful insight into the patient’s wishes, however challenges will remain for 
those who express a wish for intensive care but for whom clinicians’ perceive no 
potential benefit (212).  
Decision-making involved in ICU admission is complex, with the aim to admit 
critically unwell individuals, whilst excluding those ‘too sick or well to benefit’ 
(208, 213). Results of a European survey in 1990 suggested that bed availability 
and likely survivorship were the 2 most influential factors in a clinician’s 
decision to admit to ICU (209). A subsequent survey of critical care practitioners 
showed that QOL, probability of survival, reversibility of acute disease and any 
chronic illness were important factors in offering individuals ICU management 
(214). Social standing, psychiatric history, societal cost and cost-benefit of ICU 
care were not deemed significant (214). Sprung et al. further examined factors 
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associated with ICU triage decision-making and described the influence of 
patient age, admission diagnosis, severity of disease, operative status and bed 
capacity (215). Seniority of the admitting clinician, ability to examine patient, 
presence of comorbidities and level of functional ability are known to influence 
the decision (216). Physiological reserve, prognosis of disease and quality of life, 
treatment availability and response to therapy already initiated, require 
consideration (212). Admission to ICU can be influenced by the referring 
consultant; with difference in seniority and the relationship between intensivist 
and referring clinician playing important roles (217). 
Whilst individual factors involved in ICU triage decisions have been evaluated 
extensively within the literature, there is a paucity of evidence examining 
whether any differences exist in the degree of influence each factor has in 
decision between the referring specialty and intensivist. This study intends to 
identify whether differences exist between gastroenterologists and intensivists 
in the decision-making surrounding ICU triage, level of care offered and 
prognosis of patients with chronic liver disease.  
3.3 Study question and aims 
3.3.1 What criteria are used in the decision to offer intensive 
care to a patient with chronic liver disease? 
With the increased burden of chronic liver disease in the population and 
improved ICU survival, the pressure to admit individuals with advanced liver 
disease to ICU will increase. Historically, the survival of critically ill patients 
with cirrhosis has been poor and has acted as a barrier to ICU admission. Whilst 
there is a good working relationship between the gastroenterologists and 
intensivists within GRI there was an increasing interest by both specialties in 
exploring the characteristics of patients who warrant ICU admission. This would 
attempt to reduce barriers and ensure those who may benefit from an ICU stay 
were admitted.   
Individual factors involved in the decision to offer patients intensive care have 
been investigated extensively within the literature. However, there is a lack of 
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evidence examining whether differences exist in the degree of influence each 
factor has on the referring gastroenterologist and receiving intensivist.  
3.3.2 Aims of Survey 1 
• Identify criteria used in decision-making for ICU admission for patients 
with liver disease, the weighting given to each and determine any 
differences in opinion between gastroenterologists and intensivists in non-
transplant units  
• Establish whether there are differences between specialties in the 
management of each grade of Child-Pugh liver disease and presentation of 
gastrointestinal bleed or sepsis 
3.3.3 Aims of Survey 2 
• Explore the level of organ support offered to individuals with different 
aetiologies and severity of liver disease and whether management differs 
between gastroenterologists and intensivists 
• Determine opinion on readmission following ICU discharge  
• Establish clinicians’ estimated 1 year mortality of each grade of Child-
Pugh if stable and ICU mortality  
3.4 Methodology 
3.4.1 Design 
3.4.1.1 Use of a survey for data collection 
There are a number of research instruments which can be used to collect data 
on clinical practice and opinions. They include surveys, focus groups and 
structured interviews. A questionnaire-based survey was used in this chapter in 
favour of focus groups or structured interviews as the individuals targeted were 
spread throughout Scotland with time constraints due to clinical commitments.  
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An electronic survey was chosen as it was considered to have a number of 
advantages. This enabled individuals to complete questions at a convenient 
time, avoided geographical barriers and accelerated response rates with minimal 
financial cost (179). Online based surveys have the advantage that individuals 
are required to answer each question to progress and are thus unable to leave 
questions unanswered, with the ability to determine how many questions 
respondents can view and in what order. Using a web-based survey enabled 
distribution to respondents using a link embedded in an email facilitating 
distribution through a national organisation – the Scottish Society of 
Gastroenterologists (SSG), ICU secretarial staff and to individual email 
addresses. 
A postal survey was considered, however this would have involved difficulties in 
distribution as individual consultant names would be required. Furthermore, 
each respondent would incur inconvenience as they would be required to post 
back a response, incurring financial cost (179).  
It was acknowledged that web-based surveys have reduced response rates 
compared to postal surveys and whilst it could be expected that NHS consultants 
are computer literate, they may have more than one email address (218). 
Features which impact upon a doctor’s decision to complete a survey are the 
perceived time required to complete a survey, relevance of the subject matter, 
understanding that the results will be used appropriately and confidentiality 
maintained (218). To improve the response rate a cover email provided details 
of the MD student and supervisors, the intended use of the survey and an 
assurance of anonymity of answers. Respondents were given the option to email 
the MD student directly to be informed of the results.  
A combination of open and closed questions were utilised within each survey. 
The closed questions concerned factors used in a clinician’s decision to admit or 
refer a patient and enabled direct comparison of each specialty. An open 
question added a qualitative element to the research and was included to allow 
clinicians to add additional comments on their practice, potentially introducing 
other aspects overlooked in the survey design. 
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3.4.1.2 Validity and reliability 
In order to ensure both validity and reliability the MD student designed a draft of 
both surveys. Both surveys were reviewed by 2 consultant intensivists (Professor 
John Kinsella and Dr Tara Quasim) and a consultant gastroenterologist (Dr 
Stephen Barclay). This review by those with expertise in admitting and referring 
patients to ICU provided face validity confirming that each question within the 
survey appropriately reflected the research question. The amended survey was 
subsequently piloted to trainee doctors working within intensive care and 
gastroenterology. Respondents were asked to comment on readability, clarity of 
questions, layout and time taken to complete the questionnaire. In addition, 
respondents were encouraged to annotate the survey noting readability and 
clarity of questions to ensure that any ambiguity in the questions was addressed. 
Concurrent validity was addressed by asking both specialties identical questions, 
with certain answers predicted not to differ between the groups asking the 
questions (179). It would be expected that there should be no difference 
between specialities in the influence of certain factors such as sex and 
employment, which have been demonstrated not to influence decision-making in 
this setting. 
Following an initial pilot, the survey was transferred into an online format using 
the ‘surveymonkey’ web-based software for self-completion. The survey was 
tested for usability prior to distribution to identify technical problems in 
question completion and eliminate any grammatical errors.  
3.4.1.3 Design of Survey 1 
In response to the findings of the literature review, physiological and social 
criteria were identified which were purported to impact on decision-making in 
ICU admission. Criteria included demographic factors, chronic health status, 
current clinical status and aetiology of liver disease and underlying cause of 
admission. Respondents were questioned as to whether they would refer 
(gastroenterologists) or admit (intensivists) patients to ICU (Appendix 1). 
Eighteen criteria were subsequently chosen and a likert scale designed to rate 
the influence of each factor on the decision to admit or refer an individual to 
ICU. The scale ranged from 1 (no influence on decision) to 5 (significant factor in 
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decision). A free text box was included, enabling respondents to list any 
additional factors used within their clinical practice. Respondents were asked a 
closed question on whether intensive care was indicated in individuals with 
Child-Pugh A, B or C liver disease presenting with gastrointestinal bleeding or 
sepsis (Appendix 1). These scenarios aimed to determine if aetiology of 
presentation altered management. 
To measure the influence of each factor on each clinician’s decision to admit or 
refer a patient to intensive care, a multiple-indicator measure was required 
(section 2.1.1.1) (179).  A likert scale was chosen as it would measure the 
intensity of influence each factor had on offering ICU care to an individual on a 5 
point scale (179). In order to utilise the likert scale effectively, every 
respondents was given a statement and asked how each factor influenced their 
decision. All factors making up the scale were identified within the literature to 
impact upon ICU triage. 
3.4.1.4 Design of Survey 2 
The MD student designed a second survey to further examine findings of the 
initial survey. This survey was reviewed prior to distribution using the same 
method and individuals as Survey 1 (section 3.4.1.2). The aim was to explore ICU 
admission and level of organ support offered to patients, re-referral/readmission 
to ICU, mortality of liver disease and the role of underlying aetiology of chronic 
liver disease. This second survey comprised 3 parts; 3 vignettes, a closed 
question estimating percentage mortalities and open question exploring the role 
of aetiology. 
3.4.1.5 Vignettes 
The use of vignettes was chosen to explore whether differences existed in 
consultant behaviour when presented with scenarios based on common 
presentations of critically ill cirrhotic patients (section 2.1.1.2) (Appendix 2). In 
this survey, the vignettes were designed to enable the respondent to consider a 
range of factors in making the decision to offer intensive care and the level of 
organ support offered. These factors included the severity of liver disease (using 
Child-Pugh grading), nature of presenting complaint, underlying aetiology of 
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chronic liver disease and clinical progression during hospital admission. These 
themes were included in the vignettes to examine conflicting results from the 
first survey. The role of clinical progression during hospital stay was included as 
the concept of reversibility had been introduced by 1 respondent in the first 
survey. The level of organ support offered to an individual was examined in the 
second survey in response to both discussion between the survey reviewers and 
comments received by the MD student from respondents to the first survey.   
Each case study provided a summary of history and examination, laboratory and 
radiology results, Child-Pugh grade when stable and clinical progression since 
hospital admission (Appendix 2). The objective was to provide clinicians with 
realistic scenarios to explore decision-making without giving confounding factors 
to complicate their choice. The advantage of vignettes was that each 
respondent had to reflect on a case scenario and consider a number of different 
factors which mirrored routine practice rather than answering a closed question 
on a specific issue such as grade of liver disease (179, 181).  
Three vignettes were composed. To improve credibility they were based on case 
presentations of patients admitted to the ICU at GRI. Three cases were chosen 
as both the MD student and survey reviewers considered that this would provide 
sufficient differences in case scenarios whilst ensuring that the survey could be 
completed within a reasonable time-frame. The presentations of haematemesis 
and sepsis were chosen as both had been identified to have differing prognoses. 
Higher survival rates being achieved by patients admitted to ICU with 
haematemesis as compared to sepsis (section 1.5.7).  
Each respondent was asked whether they would opt for ICU management and if 
the answer was ‘yes’ they were asked to determine whether the patient would 
be offered single organ or multi-organ support. This question was included to 
enable the respondent to reflect on a ceiling of care for each patient.  
To explore the responses received in the first survey on the topic of readmission, 
each vignette asked the respondent whether the patient would be readmitted to 
ICU if they survived to ward or hospital discharge. Following the introduction of 
the concept of ‘reversibility’ in the responses to the initial survey, 2 cases asked 
respondents to determine if they would continue to offer ICU care if the initial 
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presenting complaint (haematemesis or sepsis) resolved but the patient 
developed a new problem requiring ICU care (sepsis or renal failure).  
An abbreviated version of each case scenario is given below, with a full version 
in Appendix 2. 
Case 1 
A 55 year old woman presented to the ED (Emergency Department) with 
abdominal pain, diarrhoea and vomiting. She had a past medical history of Type 
2 diabetes, obesity and a 10 year history of alcohol excess. She was drinking a 
litre of vodka each day. She had been graded Child-Pugh B at a liver outpatient 
clinic.  
Following admission under general medicine she was commenced on intravenous 
fluids and Tazocin. Blood cultures revealed a gram negative bacteraemia. Over 
the following 2 days she deteriorated with increasing oxygen demands. She was 
diagnosed with a pleural effusion and ascites and was graded Child Pugh C at 
consideration for ICU admission. 
 
Case 2 
A 35 year old man presented to the ED following multiple episodes of 
haematemesis within the previous 24 hours. He has evidence of hypovolaemic 
shock and has a further episode of haematemesis in the ED. He is graded Child-
Pugh C. He requires an emergency upper gastrointestinal endoscopy and 
placement of a sengstaken tube for a variceal bleed. 
He had a past medical history of alcohol excess and had a previous admission 6 
months earlier with jaundice and ascites. During that admission he was graded 
Child-Pugh C and was noted to have oesophageal varices. 
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Case 3 
A 64 year old man presented to the ED with a 6 day history of shortness of 
breath and malaise. He had clinical findings suggestive of respiratory tract 
infection and severe sepsis. He was graded Child-Pugh B. He required 
vasopressor support for hypotension and was hypoxic despite 15 litres of oxygen. 
He had a past medical history of Type 2 diabetes, obesity, peripheral vascular 
disease and a previous stroke. He had been diagnosed with non-alcoholic fatty 
liver disease and graded Child-Pugh A at an outpatient clinic. 
 
3.4.1.6 Mortality estimation 
Respondents were asked to estimate 1-year mortality for individuals with stable 
Child-Pugh A, B and C liver disease and ICU mortality for each grade of liver 
disease should they be admitted to ICU. This question was included as there is a 
paucity of literature providing figures for survival of individuals with stable and 
unstable liver disease. The results would ascertain if there was agreement 
between gastroenterologists and intensivists on perspective of survival. To 
investigate the conflict which arose between specialties in survey 1, each 
respondent was asked whether aetiology of liver disease influenced their 
decision to admit a patient to ICU and to describe the impact on their decision-
making. The aim of this was to determine if the difference between specialties 
was reproducible and further investigate the underlying reasons for this 
difference.   
3.4.2 Participants 
The goal of both surveys was to reach every consultant gastroenterologist and 
intensivist in Scotland. Consultants working within the liver transplant centre in 
Edinburgh Royal Infirmary were excluded as the survey was designed to examine 
practice of management of liver disease in non-transplant units. The first survey 
invitation was distributed in October 2014. Every ICU secretary in Scotland was 
emailed and requested to distribute an online link to the survey to consultant 
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intensivists within their department. Access to gastroenterologists within 
Scotland proved challenging as there is no national database of all consultant 
gastroenterologists. Consultants involved in the management of individuals with 
liver disease in Scotland can encompass gastroenterologists, hepatologists and 
those with interests in other medicine areas, particularly out of hours. All 
consultant gastroenterologists based in Scotland listed on the online directory of 
UK consultants SpecialistInfo were contacted with an email invitation and online 
survey link by their NHS email addresses (219). As there was no guarantee that 
this internet directory was comprehensive all consultant members of the SSG 
were emailed a survey link. The 2013 Scottish Survey of Liver Services found 103 
gastroenterologists working within Scotland, which is the number used as a 
denominator within this survey to determine a response rate (110). To maximise 
the response rate a reminder for survey completion was distributed 1 month 
after the initial invitation.  
3.4.3 Ethics 
As respondents were recruited as research participants due to their professional 
role, formal ethical approval was not deemed necessary, as per the guidance 
issued by the NHS Health Research Authority (220). Respondents were made 
aware that their electronic survey responses were anonymous. This would 
encourage individuals to answer honestly, without fear of consequences and 
improve response rates (179, 221).  
3.4.4 Data analysis 
The surveys described in this chapter involved mixed methods research. Both the 
qualitative and quantitative results are presented together for each topic 
explored in the surveys.  
The quantitative research was analysed using percentages to represent 
proportions. The average responses to the Likert scale were expressed as a 
median score.  
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Thematic analysis was used to assess qualitative data and identify recurrent 
themes given by respondents to the survey. Key quotes were selected and 
included within the results.      
3.5 Results 
3.5.1 Results of Survey 1  
3.5.1.1 Responses 
35 of 103 consultant gastroenterologists and 65 of 143 consultant intensivists 
replied, representing a response rate of 34% and 45% respectively.  
3.5.1.2 Weighting of factors involved in the decision to admit or 
refer patients with liver disease to ICU 
Survey participants were asked to rate the significance of different factors on 
their decision to refer (gastroenterologists) or admit (intensivists) a patient with 
liver disease to ICU from 1 (no influence on decision) to 5 (significant factor in 
decision). 
The only factor given a median rating of 5 by both gastroenterologists and 
intensivists was Child-Pugh score when stable (Figure 3-1). ICU admission 
secondary to bleeding varices was given a median rating of 5 by 
gastroenterologists and 4 by intensivists, likewise presence on the liver 
transplant list was rated 5 by gastroenterologists and 4 by intensivists. 
Individuals with more than one additional organ failure, nutritional status and 
body mass index (BMI) of below 18.5, age under 30 and ICU stay during the same 
hospital admission were given a median rating of 4 by both groups of clinicians. 
ICU admission within the previous year was given a rating of 4 by intensivists and 
3 by gastroenterologists, whilst 6-month abstinence from alcohol was given a 
median weighting of 4 by intensivists and 3.5 by gastroenterologists. Lactate of 
over 2mmol/L, age over 65 and Child-Pugh score at time of referral to ICU were 
all given a rating of 3 by both groups of clinicians. Aetiology of liver disease was 
given a median rating of 1 by gastroenterologists and 3 by intensivists. No 
significance was placed on deprivation, virology status, sex, smoking or drug use 
or employment by either group of respondents.  
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Figure 3-1 Results of Survey 1 – Criteria used in the decision to admit or refer 
a patient with liver disease to ICU 
 
 
3.5.1.3 Additional factors involved in decision-making  
Participants were asked to list any additional factors judged to be influential in 
deciding whether ICU management was appropriate using free text. 
Gastroenterologists and intensivists both listed pre-morbid functional state, 
physiological reserve, comorbidities and engagement or compliance with therapy 
as factors which influenced their decision. The presenting diagnosis, an 
identified precipitant factor for deterioration, perceived reversibility of illness 
and survival were listed by both groups as important. One intensivist answered 
that their decision to admit a patient would depend on “whether I think they 
are going to survive” and a gastroenterologist added that the “likelihood of a 
positive outcome” would influence their decision. Patient and family wishes 
were sought by both specialties. The opinion of colleagues was deemed to be 
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important with intensivists utilising the views of a consultant involved in the 
patients’ long-term care, with one noting “consensus can be useful”. Intensivists 
took into account white cell count and both groups noted the importance of 
complications such as hepatic encephalopathy and renal failure. Intensivists 
listed MELD-Na score, demand for critical care beds, levels of organ support 
required and potential for tertiary level care as significant factors, whilst 
gastroenterologists placed importance on the patient’s psychological status. If 
the admission was the patient’s first presentation of disease gastroenterologists 
listed this to be influential on their decision. One intensivist commented “if this 
is the first presentation I would admit whereas with progressive presentations I 
would be less likely to admit”.   
3.5.1.4 Child-Pugh grade and reason for admission 
Each specialty was asked whether they would refer or admit individuals with 
different grades of Child-Pugh cirrhosis with gastrointestinal bleeding for ICU 
management (Table 3-1).  
Table 3-1 Percentage of specialist who would refer or admit each Child-Pugh 
grade with gastrointestinal bleeding to ICU 
 Child-Pugh A Child-Pugh B Child-Pugh C 
Gastroenterologists 79.4% 85.7% 80.0% 
Intensivists 98.5% 100% 81.0% 
 
Each specialty was asked whether they would refer or admit different grades of 
Child-Pugh cirrhosis with sepsis for ICU management (Table 3-2).  
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Table 3-2 Percentage of specialist who would refer or admit each Child-Pugh 
grade with sepsis to ICU 
 Child-Pugh A Child-Pugh B Child-Pugh C 
Gastroenterologists 82.9% 94.3% 76.4% 
Intensivists 96.9% 92.2% 33.3% 
 
3.5.2 Results of Survey 2 
3.5.2.1 Responses 
31 of 103 consultant gastroenterologists and 42 of 143 consultant intensivists 
replied, representing response rates of 30.1% and 29.4% respectively. 
3.5.2.2 Levels of organ support  
For Case study 1, a patient with Child-Pugh C cirrhosis with sepsis secondary to 
respiratory tract infection, 48.4% of consultant gastroenterologists would refer 
the patient to ICU, whilst 57.1% of consultant intensivists would admit the 
patient. Of those who would refer or admit the patient 57.1% of 
gastroenterologists and 69.6% of intensivists would offer multi-organ support. 
For Case study 2, a patient with Child-Pugh C cirrhosis with haematemesis, 93.3% 
of consultant gastroenterologists and 95.2% of consultant intensivists felt ICU 
admission was appropriate. Of those, 38.5% of gastroenterologists and 57.5% of 
intensivists would offer multi-organ support.  
For Case study 3, a patient with Child-Pugh B cirrhosis with sepsis secondary to 
respiratory tract infection, 93.1% of gastroenterologists would refer the patient 
to ICU and 94.7% of intensivists would admit the patient to ICU. Of those 77.8% 
of gastroenterologists and 94.4% of intensivists would offer multi-organ support. 
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3.5.2.3 Continuation of intensive care 
In Case study 2 following resolution of haematemesis, the patient deteriorated 
whilst in the ICU developing a new problem of sepsis. Consultants were asked 
whether they would continue care. 90.0% of gastroenterologists and 78.6% of 
intensivists supported continuation of care.  
In Case study 3 following resolution of sepsis secondary to respiratory infection 
the patient develops renal failure whilst in ICU. 85.7% of gastroenterologists and 
81.6% of intensivists would support continuation of ICU care.  
3.5.2.4 Readmission to intensive care 
In Case study 1, respondents were asked if they would readmit the patient 
following ICU discharge, but prior to hospital discharge. 33.3% of 
gastroenterologists and 28.6% of intensivists would readmit the patient to ICU. 
Respondents were asked would they admit the patient to ICU if they re-
presented following home discharge with reduced functional ability and 
continued alcohol intake. 10.0% of gastroenterologists and 9.5% of intensivists 
would consider readmission. 
In Case study 2 respondents were asked if they would readmit a patient 
discharged to the ward following the development of recurrent sepsis. 60.0% of 
gastroenterologists would re-refer the patient, whilst 28.6% of intensivists would 
readmit. If the same patient survived to hospital discharge 90.0% of 
gastroenterologists and 76.2% of intensivists would readmit the patient if they 
later presented with gastrointestinal bleeding, whilst 53.3% and 31.0% 
respectively would readmit if the patient presented with sepsis. 
In Case study 3 respondents were asked whether they would readmit the patient 
following ICU discharge following the development of hospital acquired 
pneumonia. 75.0% of gastroenterologists would refer the patient to ICU, whilst 
71.1% of intensivists would readmit the patient. If the same patient survived to 
hospital discharge and represented with sepsis six months later, 75.0% of 
gastroenterologists would refer the patient and 83.8% of intensivists would 
readmit.  
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3.5.2.5 Mortality of chronic liver disease 
Respondents were asked to estimate the percentage 1-year mortality in a stable 
patient with Child-Pugh A, Child-Pugh B and Child-Pugh C liver disease.  
For those with stable Child-Pugh A disease, intensivists estimated a mean 1-year 
mortality of 14% and gastroenterologists 33%. For those with Child-Pugh B, 
intensivists estimated mortality at 26% and gastroenterologists 38%. Individuals 
with stable Child-Pugh C had an estimated annual mortality of 48% by both 
intensivists and gastroenterologists.  
Respondents were asked to estimate the percentage mortality in each grade of 
Child-Pugh if the patient was admitted to ICU. For those with Child-Pugh A 
admitted to ICU, intensivists estimated a mean ICU mortality of 30% and 
gastroenterologists 32%. For those with Child-Pugh B, intensivists estimated 
mean ICU mortality of 47% and gastroenterologists 48%. Individuals with Child-
Pugh C had an estimated ICU mortality of 74% by intensivists and 65% mortality 
by gastroenterologists.  
3.5.2.6 Aetiology of chronic liver disease 
Respondents were asked whether aetiology of liver disease impacted upon their 
decision to refer or admit a patient to ICU. 45.8% of consultant 
gastroenterologists and 48.5% of consultant intensivists answered ‘yes’.  
If the respondent answered ‘yes’ they were asked to explain how aetiology 
influenced their decision. Gastroenterologists believed those with alcoholic liver 
disease had a poorer prognosis than other aetiologies, in particular if the 
individual continued to drink precluding the suitability for liver transplant. One 
gastroenterologist explained the significance of recent therapies to successfully 
treat viral hepatitis and the positive impact on prognosis. Likewise, when 
intensivists were asked how aetiology influenced their decision a number of 
individuals believed that alcoholic liver disease would limit options for 
treatment and potential for transplant. One respondent replied that if the liver 
disease was “secondary to substance abuse and continuing then the patient 
takes responsibility for continuing health or lack of”. Intensivists made 
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reference to the modification of risk factors, reversibility of liver disease and 
potential for ICU rehabilitation. 
3.6 Discussion 
The results from both surveys indicate that decision-making in the referral and 
admission of cirrhotic patients to intensive care is multifactorial, with 
agreement between gastroenterologists and intensivists in the significance of 
Child-Pugh score measured when the patient is stable. Inconsistencies exist in 
the impact of underlying aetiology, however it is clear the presenting complaint 
is pertinent to the decision. Results from Survey 2 suggest that there may be 
patients who would be accepted for intensive care but who are not deemed 
suitable by the referring team, whilst intensivists were reluctant to continue 
care or readmit patients who had not previously survived to home discharge. For 
stable cirrhosis intensivists estimated a lower mortality for Child-Pugh A and B 
whilst an increased mortality for Child-Pugh C admitted to the ICU. 
3.6.1 Interpretation of findings  
3.6.1.1 Criteria for admission to ICU 
The findings from this study demonstrate universal agreement between 
gastroenterologists and intensivists in the value of utilising Child-Pugh score 
when stable as the most significant factor in their decision as to whether a 
patient with liver disease is appropriate for intensive care. In contrast Child-
Pugh score measured at the time of potential admission was given less 
significance by both specialties. This result is interesting given that studies have 
shown that Child-Pugh score and encephalopathy and PT, components of the 
score, predict mortality of cirrhotic patients in ICU if measured at the time of 
ICU admission (118, 124). Whilst the score gives a reflection of the severity of 
liver disease its use may be limited as it does not reflect organ failure in the 
form of cardiovascular, respiratory or renal dysfunction (129). Many studies 
demonstrate that scores specific to ICU which reflect the degree of organ 
failure, are more accurate in predicting ICU mortality than those reflecting the 
severity of liver disease (section 1.6) (117, 124, 177, 222, 223).   
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Results from this study suggest that reversibility of either the precipitant factor 
or liver disease and potential for definitive treatment are perceived as relevant 
factors by both specialties. Therapeutic advances in both endoscopic and 
pharmacological treatment for variceal bleeding have led to dramatic 
improvements in mortality of cirrhotic patients which explains why the majority 
of consultants in both specialties opted for ICU management of all grades of 
Child-Pugh cirrhosis with gastrointestinal bleeding (224).  A single centre study 
demonstrated a reduction in mortality from 70% to 32% in Child-Pugh class C 
patients between 1980 and 2000 (225).  
The significance placed upon listing for liver transplantation could be due to 
various factors and with a 96% 90 day survival following elective transplant, UK 
survival rates following liver transplantation are high (section 1.5.5) (226). If an 
individual has been selected for definitive treatment of their liver disease, onus 
may be placed on specialists to offer ICU management in order that they have 
optimal chance of survival to transplant. Selection for liver transplant in the UK 
is stringent with involvement of a multidisciplinary team, assessment of 
comorbidity, drug and alcohol use plus a thorough physiological and 
psychological assessment (123, 227). To proceed to listing, patients must be 
predicted to have a 5 year survival after transplant of over 50% (228). If 
individuals are assessed when stable and predicted to survive transplantation 
this information may inform the decision regarding ICU care and help predict if 
the patient will have reserve to survive critical illness. The MELD score used to 
determine urgency for transplantation in the USA and the MELD-Na score was 
utilised by one intensivist in their decision whether to admit cirrhotic patients to 
ICU (145). Evidence suggests that both serum sodium and MELD score predict 
survival in those awaiting liver transplantation (149, 229).   
Significance was placed on the importance of 6-month abstinence from alcohol 
by both specialties. Alcohol dependence is associated with increased hospital 
mortality, sepsis and septic shock (230). Alcoholics develop more complications 
following ICU admission, with longer hospital stays (231, 232). Within 3 months 
of abstinence liver function improves, there is reversal of cardiac dysfunction, 
improvement in immune function and normal cortisol response to stress (233, 
234). Consideration of ICU admission must deliberate not only survival but 
recovery to an acceptable QOL. Critical illness is associated with muscle wasting 
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and weakness which impact upon rehabilitation (235). In those with liver disease 
capacity for recovery is further compromised by the skeletal muscle myopathy 
resulting from alcohol dependence (236). As is evident in the responses to the 
survey, some clinicians consider alcoholic liver disease as a self-inflicted 
disease, whereby the patient must take responsibility for the progression of 
disease. Others may view problematic alcohol intake as a mental health issue. 
There has been a reluctance in the past to offer treatment, however, national 
guidelines recommend that patient care should be based on need irrespective of 
whether the patient’s actions have contributed to the cause (204, 237, 238). 
The findings from this study demonstrate a difference in the significance placed 
upon age with respondents placing greater importance on whether an individual 
was under 30. Whilst the results are unclear whether consultants would be more 
or less likely to admit younger patients with liver disease, a number of factors 
are relevant. Age is included in many scoring systems used within critical care to 
predict hospital mortality (such as APACHE II) and has been demonstrated to play 
a role in ICU triage decisions (164, 215). Evidence in the general ICU population 
suggests advanced age is an independent risk factor for death, but the role of 
premorbid functional status, comorbidity and severity of disease is significant 
(239-241). The burden of comorbidity and physiological reserve of each 
individual is a considerable factor in ICU survival and QOL following critical 
illness (119, 242). Both are difficult to quantify with existing tools such as the 
Charlson comorbidity index not shown to predict ICU mortality or use of 
resources (119, 243).  
The importance placed upon nutritional status and BMI below 18.5 by both 
specialties is supported by studies outwith the critical care population, including 
one meta-analysis which found extremes of weight to be associated with 
increased mortality and morbidity (244, 245). In a study of 11,326 Canadians 
through the National Population Health Survey, the adjusted relative risk of 
death was 1.89 in those with a BMI of under 18.5 and 1.48 in those with a BMI of 
over 35 when compared to a BMI of 22.5 to 25 (245). Studies suggest that 
critically ill patients who are underweight have higher mortality and are less 
likely to return to baseline health following discharge when compared to 
overweight or obese individuals (246, 247). It is hypothesised that underweight 
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individuals may lack nutritional reserve to adequately respond to the increased 
metabolic demand of critical illness (248-250). 
Deprivation, sex, employment, smoking and drug use were not given any 
weighting in the decision to refer or admit a patient by either specialty. This 
finding is not that surprising with a 2001 Swiss study of 232 intensive care 
doctors determining socioeconomic status, drug and alcohol use to have little 
influence on their decision to admit patients to ICU (251). The association of 
socioeconomic deprivation and poor health has previously been explored (section 
1.2.5.3) and whilst socioeconomic status may influence access to healthcare in 
certain countries such as the USA, the universal access to the NHS removes this 
barrier in the UK (252). A 2002 cross-sectional study of 46,587 admissions to ICUs 
in England, Wales and Northern Ireland demonstrated gender differences in ICU 
admission with certain conditions – however cirrhosis was not considered (253). 
Few studies exist in the literature which examine the role of substance abuse in 
the decision to refer or admit a patient to the ICU. 
Patient and family wishes were noted to influence the decision to offer intensive 
care, reflecting other studies which have documented a move towards patient 
autonomy in decision-making (251, 254). Whilst self-determination of treatment 
is ideal, conflict will still arise if a patient wishes to seek intensive care but the 
clinician believes it to be futile. Although it was not noted by any of the 
respondents, QOL has been demonstrated to have an important role in the 
decision to offer intensive care in another study performed at the same centre 
(255). This is further explored in Chapter 7. 
Peer standards appear to play a pivotal role with a previous study from the same 
centre demonstrating that intensivists were keen to seek opinion of their 
colleagues within the ICU and consensus of opinion was deemed important 
between the referring gastroenterologist and receiving intensivist (255). It was 
noted that referring doctors may have prior knowledge of a patient’s resilience 
or their compliance with therapy which may help predict patient approach to 
ICU rehabilitation. In their editorial on intensive care triage, Levin and Sprung 
highlighted the persistence of the referring clinician and seniority of doctors 
involved in the decision as important (217). 
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3.6.1.2 Aetiology of chronic liver disease 
The findings of the initial survey demonstrated that whilst intensivists gave some 
significance to aetiology of chronic liver disease, referring gastroenterology 
consultants did not feel aetiology impacted on their decision. This opinion was 
further explored in the second survey where 48.5% of consultant intensivists and 
45.8% of consultant gastroenterologists stated aetiology impacted upon their 
decision to offer ICU management. The apparent change in attitude by 
gastroenterologists between surveys is difficult to explain. The first survey was 
distributed in October 2014 and the second in July 2015 and during this time 
period there were no landmark studies published regarding aetiology of liver 
disease and ICU management. It is possible that different consultants responded 
to each survey or since completing the initial survey, consultant intensivists had 
reconsidered their opinion.  
Respondents of both specialties highlighted prognosis as an important factor, 
stating that those with alcoholic liver disease had a poorer outcome with 
ongoing alcoholism impacting upon potential for transplantation. This is 
contraindicated by a single centre American study of 40 patients with cirrhosis 
where mortality of critically ill cirrhotics was found to be lower in those with an 
underlying diagnosis of alcoholic liver disease than other causes of liver disease 
(115). Furthermore, in those with decompensated cirrhosis secondary to viral 
hepatitis, recent studies have reported that antiviral therapy is beneficial for 
those with Hepatitis B and Hepatitis C (256, 257). Certainly, the potential for 
definitive treatment influences the decision to offer ICU care.  
3.6.1.3 Child-Pugh and mortality 
With little difference in the management of all grades of Child-Pugh cirrhosis 
with gastrointestinal bleed, there is disagreement in the level of care offered to 
individuals with Child-Pugh C cirrhosis and sepsis with the majority of 
intensivists reluctant to offer ICU admission. This finding was consistent with 
intensivists estimating a higher ICU mortality for those with Child-Pugh C than 
gastroenterologists. In a single centre Scottish study of long-term outcomes by 
the MD student and colleagues (Chapter 6) Child-Pugh C ICU mortality was 50%, 
which was closer to the 65% estimated by gastroenterologists (258). Both groups 
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estimated higher ICU mortality of those with Child-Pugh A and B than the study. 
Whilst agreement existed between specialties for the 1-year mortality of stable 
Child-Pugh C cirrhotics, gastroenterologists estimated higher mortality for both 
Child-Pugh A and B cirrhotics. A 2005 systematic review of 118 studies concluded 
1-year survival of Child Pugh A, B and C to be 95%, 80% and 45% supporting the 
estimates of intensivists (53).  
In all case studies, intensivists were more likely to offer ICU admission to 
patients than gastroenterologists were to refer patients. Whilst it is difficult to 
draw firm conclusions this finding would suggest that in practice certain patients 
would be offered intensive care by intensivists but may never be referred by 
their gastroenterology consultant. The 2013 NCEPOD report into management of 
patients with alcoholic liver disease found that 31% of patients deemed eligible 
for intensive care were denied escalation of care either by referring clinician or 
intensivist (109). When ICU admission was deemed appropriate a greater 
proportion of intensivists would offer multi-organ support rather than limiting 
treatment to single organ support in comparison to gastroenterologists. This is 
perhaps a reflection of a view held by many intensivists that critically ill patients 
should initially be offered multi-organ support to give greatest chance of survival 
and if multi-organ failure persists after a number of days then treatment should 
then be limited (204, 255). It could also reflect the belief that if renal failure is 
present in the context of cirrhosis then prognosis is poor and to offer renal 
replacement therapy would be futile (259). In every case study, fewer 
intensivists would support readmission to ICU during the same hospital stay 
compared to gastroenterologists. A number of studies, including a large 
prospective multicentre cohort, demonstrated that mortality is higher amongst 
patients readmitted to ICU and the lack of enthusiasm amongst intensivists to 
readmit patients may represent a feeling of futility (260, 261). This was mirrored 
in those patients surviving to home discharge. The majority of consultants in 
both specialties would consider intensive care for patients with previous ICU 
admissions on subsequent admissions, however there was a reluctance to offer 
ICU care to those with reduced functional ability and continued alcohol intake.   
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3.6.1.4 Future directions  
Given the survey design it was necessary to use vignettes to explore clinicians’ 
decision-making. To further investigate themes that have arisen in this chapter 
it may be valuable to perform a prospective study. This would involve identifying 
all critically ill individuals with decompensated cirrhosis and exploring the 
factors used to decide on their escalation of therapy in real-time. This study 
would facilitate analysis of the factors used to admit or deny ICU admission. 
Using all routinely available data, specialists involved in making the decision 
would be asked to estimate mortality for the individual, which could be 
compared to actual mortality.    
3.6.2 Limitations 
Sixty-seven Scottish consultant intensivists and 35 consultant gastroenterologists 
responded to Survey 1, however fewer individuals responded to Survey 2. As the 
survey was distributed in an identical manner the fall in responses rate could be 
attributable to response fatigue (221). Response rates to web based surveys 
differ widely, the response rate is higher than other similar web-based surveys 
of critical care practice (262, 263). There are no accurate national figures 
published for the number of consultant intensivists and gastroenterologists in 
Scotland making it difficult to identify a denominator and thus a response rate. 
Each ICU in Scotland was contacted directly to confirm the number of consultant 
intensivists within the department. Confirming the number of gastroenterologists 
proved challenging as those responsible for liver disease in Scotland encompass 
hepatologists, gastroenterologists and consultants in general medicine. To 
establish an approximate denominator, a website was used to identify 
consultants with an interest in liver disease and in addition all consultant 
members of the SSG were emailed an invitation to participate (219). These 
numbers rely on current email addresses and may include those who are no 
longer practising, who now work outwith Scotland and there is the possibility 
that newly appointed consultants have been excluded. There were barriers to 
access clinicians in ICU with the equivalent professional body to the SSG 
contacted but unable to distribute the survey link to consultant intensivists. 
Although the response rate was not lower than other similar surveys it is difficult 
to generalise these results to reflect national practice as it would appear the 
  111 
 
majority of consultants did not give their view. As highlighted in the survey 
design (section 3.4.1) the results of this study may reflect an element of 
responder bias. It remains unknown how representative those consultants 
responding to the survey were of current Scottish practice. Few details were 
recorded about the responder to the survey, thus it was not possible to identify 
the frequency of which a consultant was required to refer or admit a patient to 
ICU. It could be that individuals who participated were those who more 
frequently referred or admitted patients to ICU and thus envisaged greater 
utility of the results of the survey (264). Performing data collection in the form 
of structured interviews would facilitate the recording of more detailed data, 
however, those individuals willing to participate in any method of data 
collection would be biased towards those who view the subject as relevant and 
the responder would lose anonymity. In addition, performing structured 
interviews can introduce desirability bias, leading the respondent to give an 
answer they perceive to be socially acceptable or the ‘correct’ answer they 
believe the interviewer would agree with.  
The design of both surveys limits how the results of this chapter can be applied 
to clinical practice. Whilst the vignettes are designed to mirror common 
scenarios, the decision to admit or refer a patient is multi-factorial and may 
well involve the availability of further information. 
3.7 Conclusion 
This chapter presents the results of 2 surveys exploring the factors involved in 
the referral and admission of patients with cirrhosis to intensive care. The 
results demonstrate: 
• The only factor given a median rating of 5 by both gastroenterologists and 
intensivists was Child-Pugh score when stable 
• Child-Pugh score at time of ICU referral was given a median rating of 3 by 
both specialties 
• In Survey 1 aetiology of liver disease was given a median rating of 1 by 
gastroenterologists and 3 by intensivists, however in Survey 2, 45.8% of 
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gastroenterologists and 48.5% of intensivists felt aetiology impacted upon 
their decision to offer intensive care 
• Only 33.3% of intensivists felt intensive care was appropriate for cirrhotics 
with Child-Pugh C and sepsis compared to 76.4% of gastroenterologists 
• In every vignette more intensivists than gastroenterologists would offer 
intensive care 
• Likewise a greater proportion of intensivists would offer multi-organ 
support rather than single organ support 
• In each vignette where the patient survived their initial presenting 
complaint but developed a new clinical problem requiring intensive care a 
greater proportion of gastroenterologists supported continuation of care 
• Fewer intensivists supported ICU readmission during the same hospital 
stay compared to gastroenterologists 
• One year mortality for those with stable Child-Pugh A and B cirrhosis was 
estimated to be higher by gastroenterologists 
• ICU mortality of cirrhotics with Child-Pugh C was estimated to be 74% by 
intensivists and 65% by gastroenterologists 
The next chapter of this MD thesis will explore the timing of Child-Pugh scoring 
and outcome.   
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Chapter 4 The utility and timing of the Child-Pugh 
score 
4.1 Introduction 
In Chapter 3, the study of consultant practice in Scotland reported that Child-
Pugh score calculated when a patient was stable, was found to be the only 
variable given a rating of 5 out of 5 by both intensivists and gastroenterologists 
in their decision to admit patients with chronic liver disease to intensive care. 
Conversely, Child-Pugh score calculated at time of referral to intensive care was 
given a rating of 3 out of 5 by both specialties. This finding is noteworthy as 
there are no studies within the literature to suggest optimum timing for scoring 
of Child-Pugh so as to inform decision-making or mortality prediction. 
This chapter investigates the timing of the calculation of the Child-Pugh score in 
patients with chronic liver disease admitted to intensive care. 
4.2 Child-Pugh score 
The Child-Pugh score has been discussed in detail in Chapter 1 (section 1.6.1.1). 
The score comprises the 5 clinical variables bilirubin, albumin, PT, ascites and 
encephalopathy. 
4.2.1 Bilirubin 
As described in section 1.2.2 one function of the liver is to eliminate substances 
from the body. Bilirubin is produced in the liver as a product of the metabolism 
of proteins such as red blood cells and myoglobin (265). Unconjugated water-
insoluble bilirubin is transported to the liver attached to albumin (265). Bilirubin 
is taken up into the hepatic cell membrane where it becomes water-soluble and 
excreted into bile (265). The majority of measured serum bilirubin is 
unconjugated (265). Whilst it is used as a marker of liver disease, a raised serum 
bilirubin level is not specific to chronic liver disease severity and a rise in 
bilirubin levels may result from haemolysis, post-hepatic obstruction from 
cholestasis, liver cell injury or inflammation (16). Bilirubin levels may also 
increase in response to acute processes such as sepsis (266). 
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4.2.2 Albumin 
Albumin is a plasma protein which is produced solely in the liver and utilised in 
the body as a transport molecule for water-insoluble substances such as 
bilirubin, hormones and drugs (67, 265). Albumin level indicates the synthetic 
function of the liver (265). It is required to maintain intravascular oncotic 
pressure and acts as a buffer within the body. In addition albumin has both 
antioxidant and immunomodulation properties (267). Liver dysfunction results in 
decreased albumin synthesis and impaired albumin function, leading to 
complications such as ascites (267).  
Serum albumin concentration is not specific to liver disease, which may affect 
its reliability within the Child-Pugh score. A reduced level of albumin can result 
from excess albumin loss in renal disease or secondary to malnutrition (265, 
268). In critical illness, albumin is redistributed between the intravascular and 
extravascular fluid compartments (268). Further, in the acute phase response to 
inflammation or sepsis albumin synthesis is reduced (268). Intravenous albumin is 
widely administered to cirrhotic patients, in particular it is given to those 
undergoing therapeutic paracentesis as a volume expander (69). It has been 
hypothesised that intravenous albumin administration may prevent endothelial 
dysfunction, improve response to bacterial translocation and reduce oxidative 
stress (267).   
4.2.3 Prothrombin time 
PT is a measure of coagulation performed on citrated plasma by adding calcium 
and tissue factor (67). With the exception of factor VIII, all coagulation factors 
are produced in the liver and thus PT indicates synthetic liver function (265). PT 
measures the extrinsic and common pathways of clotting and a time of 11 to 15 
seconds is found in those without impaired coagulation, although this is varies 
between different laboratories (67). In order to overcome the variability 
between laboratories, PT can be measured in a ratio to a control sample and 
reported as the INR (67). An INR in healthy subjects measures between 0.8-1.2 
(67). In response to differences between PT and INR, some versions of the Child-
Pugh score have been modified to include INR instead of PT.  
  115 
 
Whilst PT and INR measure coagulation, neither measure accurately represents 
an overall view of haemostasis for an individual with chronic liver disease 
(section 1.4.7). Both PT and INR may be altered by medication such as vitamin 
K, blood products or anticoagulation, introducing uncertainty into the timing of 
measurement of the Child-Pugh score. 
4.2.4 Ascites 
As discussed in detail in section 1.4.1, although ascites is the most common 
complication of chronic liver disease, it is not specific and may result from other 
disease processes (68, 69). Assessment of ascites is acknowledged to be 
subjective despite improved visualisation with the use of ultrasound (section 
1.6.1.1). 
4.2.5 Hepatic encephalopathy 
Hepatic encephalopathy has been explored earlier in the thesis, with the 
nomenclature and classifications agreed upon at the 1998 World Congresses of 
Gastroenterology discussed in detail in section 1.4.3 (80). Similar to ascites, the 
grading of hepatic encephalopathy is subjective. In particular challenges exist in 
grading those with fluctuations in neurological function or individuals with co-
existing neurological disease (section 1.6.1.1).  
4.3 Validation and utility of the Child-Pugh score 
Chapter 1 described the development of the Child-Pugh score as a modification 
of an existing scoring system described on a consecutive case series of 38 
patients between 1966 and 1972 who underwent transthoracic ligation of 
oesophageal varices for portal hypertension (141, 269). Despite this small 
specific case series the Child-Pugh score has been demonstrated to be of value 
for prognostication in both surgical and medical populations. 
Preoperative Child-Pugh score has been shown to predict mortality in those with 
cirrhosis undergoing both elective and emergency abdominal operations (270). 
Child-Pugh score was found to be an independent predictor of survival for 
individuals with known varices given medical prophylaxis to prevent variceal 
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bleeding (271). In those undergoing TIPS, the Child-Pugh score has been shown 
to be of equal value to the MELD score in predicting survival (272).  
Child-Pugh score has been independently demonstrated to predict mortality in 
those with ascites and cirrhosis irrespective of underlying aetiology and a small 
Dutch study showed that a higher Child-Pugh score predicted future episodes of 
hepatic encephalopathy (273, 274).  
Child-Pugh score has been validated for use in multiple aetiologies of liver 
disease by independently predicting survival in hepatocellular carcinoma and 
cirrhosis secondary to both Hepatitis C virus and alcohol (275-277). In addition, 
Child-Pugh score was demonstrated to predict survival in those with primary 
sclerosing cholangitis, primary biliary cirrhosis and Budd-Chiari syndrome (278-
280). 
Before 2002 the Child-Pugh score was used by the United Network of Organ 
Sharing (UNOS) in the USA to prioritise patients requiring liver transplantation 
(281). It was replaced by the MELD score due to perceived weakness in the 
subjective measurement of ascites and encephalopathy, lack of inclusion of 
renal function and inability to differentiate between candidates for transplant, 
as the Child-Pugh score allocates a maximum score of 3 per variable (145, 281). 
The MELD score has subsequently been adopted for use in Europe (281). Despite 
this change in practice, a systematic review published in 2006 demonstrated 
that the MELD score was not superior to the Child-Pugh score in predicting 
mortality following liver transplant or for those individuals with cirrhosis on the 
transplant waiting list (140). One advantage of the Child-Pugh score over MELD is 
that it can be calculated easily without a computer model (53). In the UK, the 
UKELD score is used to determine allocation in liver transplantation (281).  
In the critical care population multiple scoring systems exist which measure 
severity of disease and organ dysfunction such as APACHE and SOFA (section 
1.6.2). Although scoring systems such as CLIF-SOFA and RFH exist there is no 
liver-specific scoring system designed for critically ill cirrhotic patients which 
has been demonstrated to be superior to Child-Pugh score. However, studies of 
cirrhotics admitted to ICU have demonstrated that non-disease specific scoring 
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systems appear to have superior predictive value in predicting mortality (116, 
140, 177).  
There is a paucity of literature examining the changes in the results of scoring 
systems if measured at a time of stability compared to the score at a time of 
critical illness. One of the few studies which exists explores a UK population of 
critically ill cirrhotic patients and found that Child-Pugh score increased by 2.5 
points between measurement when stable and on admission to ICU (156). 
Despite reporting the change in Child-Pugh score this study did not explore any 
association between the timing of scoring and outcome. 
4.4 Study question and aims 
4.4.1 When should the established prognostic scoring tool Child-
Pugh be measured to inform the decision to admit a 
patient? 
Child-Pugh score has been used throughout the literature in studies of both 
medical and surgical patients with liver disease. Given the emphasis placed upon 
stable Child-Pugh score found in Chapter 3 it is postulated that clinicians use the 
score as a reflection of chronic illness progression, rather than relying upon 
Child-Pugh score at a time of acute illness when it can be altered by a number of 
factors.  The time point within disease progression at which Child-Pugh score is 
most useful in predicting mortality for those individuals admitted to intensive 
care remains unknown.  
As Child-Pugh score is used in both acute and chronic illness, it is widely 
documented within patient case notes. This provides an opportunity to perform 
a study examining patient survival predicted by Child-Pugh score on admission to 
ICU and historical Child-Pugh scores.  
4.4.2 Aims 
• To identify any relationship between ICU and hospital survival and Child-
Pugh score measured when a patient is clinically stable  
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• To identify any relationship between ICU and hospital survival and Child-
Pugh score measured when a patient is admitted to ICU 
4.5 Methodology 
4.5.1 Design 
This study was performed by creating a dataset of 134 patients who had been 
admitted to intensive care between June 2012 and December 2014 with a 
confirmed diagnosis of cirrhosis. The study incorporated both retrospective and 
prospective elements as case notes were reviewed retrospectively to determine 
Child-Pugh score, whilst the ICU score on admission was recorded prospectively 
at the time of admission by medical staff. Case notes in the ICU at GRI are 
computerised with medical and nursing staff inputting all clinical variables 
including observations, laboratory values and medical notes, including past 
medical history. Individual computerised case notes were reviewed to record 
clinical reason for admission to intensive care. Admission diagnosis was coded 
into 6 groups comprising respiratory failure, gastrointestinal bleed, sepsis, 
encephalopathy and other causes. Child-Pugh score was calculated on ICU 
admission using recorded clinical variables and each individual was graded into 
Child-Pugh A, B or C. The aetiology of cirrhosis was recorded as alcoholic or non-
alcoholic. Both ICU and hospital survival were recorded.  
Existing medical records were reviewed to calculate Child-Pugh score when a 
patient was deemed clinically stable - prior to hospital admission with critical 
illness. Firstly, a pre-existing database of known cirrhotic patients reviewed in 
the outpatient liver clinic was searched to identify patients based on their 
Community Health Index (CHI) number. This database was designed and 
implemented by a consultant gastroenterologist at GRI, Dr Stephen Barclay. The 
database records clinical variables and documented Child-Pugh score for each 
patient reviewed in the outpatient liver clinic by medical or nursing staff. The 
last episode recorded at a liver outpatient clinic was used as a stable Child-Pugh 
score as it was assumed that the patient was not acutely unwell nor requiring 
hospital inpatient stay.  
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For those patients not reviewed in the liver outpatient clinic their NHS Greater 
Glasgow and Clyde electronic patient record was examined (section 2.1.4). This 
is an electronic system which records secondary care contact and includes 
outpatient letters, inpatient case notes, laboratory values and radiology reports. 
It is used throughout NHS Greater Glasgow and Clyde and thus would include any 
attendances at hospitals across the health board. Any patient contact with 
healthcare services where blood tests were obtained and comment made on 
presence of encephalopathy or ascites was recorded. This included outpatient 
clinic appointments with other specialties or on discharge from hospital 
admissions. At these points of review, Child-Pugh score was calculated and was 
labelled as stable as the patient did not require hospital admission or was 
deemed fit for discharge. If variables within the Child-Pugh score were not 
measured or recorded then patients were scored ‘1’ as this is the lowest point 
available for each variable in the Child-Pugh score.  
If a patient had no record of contact with secondary care, laboratory values 
taken by primary care were used to identify a Child-Pugh score. A method of 
single imputation was used to replace missing values in the assessment of ascites 
or encephalopathy. Both clinical variables were given values of ‘1’ as there was 
no record obtainable of these clinical variables. The relationship between Child-
Pugh score when stable and on admission to ICU and both hospital and ICU 
survival was then explored. 
4.5.2 Participants 
Subjects studied had been admitted for Level 3 care at GRI between June 2012 
and December 2014. Demographic and clinical data used within this study were 
routinely recorded on the electronic patient record (section 2.1.4). All patients 
over the age of 18 with a diagnosis of cirrhosis were included in the study. The 
diagnosis of cirrhosis was based upon pre-existing diagnosis, clinical findings 
consistent with chronic liver disease such as ascites or encephalopathy and 
radiological findings consistent with cirrhosis (187). Sixteen individuals were 
readmitted to intensive care and were removed from the dataset.  
  120 
 
4.6 Statistical analysis 
All data was found to be non-parametric data and each factor was described 
using the median and IQR (179). Bivariate analysis was performed using the chi-
squared test to determine whether there was any relationship between Child-
Pugh class and survival. Data were then analysed using logistic regression to 
determine if Child-Pugh score was able to predict ICU or hospital survival. A 
logistic regression model was used as the outcome variable (survivor or non-
survivor) was categorical and the predictor variable (change in raw Child-Pugh 
score from stable to acute) was continuous. The linearity assumption was 
assessed by visualising the residuals, which demonstrated a linear trend. The OR 
was then calculated to determine whether there was a change in the odds of 
survival for every point score change in raw Child-Pugh score. To reflect similar 
studies a 95% CI was calculated for each OR. Likewise a logistic regression model 
used to analyse survival and change in Child-Pugh score on admission to ICU. 
Similarly the outcome variable (survivor or non-survivor) was categorical and the 
predictor variable (change in raw Child-Pugh score on presentation to ICU) was 
continuous. 
4.7 Results 
4.7.1 Demographics 
Figure 4-1 outlines a flowchart of patients admitted to ICU with cirrhosis who 
were included in the dataset. Individuals who had been readmitted to ICU within 
the study period and those with no previous recorded contact with healthcare in 
NHS Greater Glasgow and Clyde and were excluded from further analysis.  
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Figure 4-1 Flowchart of patient recruitment 
 
 
Of the 113 patients included in the main analysis, 36 required Level 3 support 
following respiratory failure, 19 were admitted following a gastrointestinal 
bleed, 21 had sepsis, 5 required ICU admission secondary to seizures, 5 required 
admission secondary to encephalopathy and 27 patients required ICU admission 
for another reason (Table 4-1). For the majority of patients (77.0%) alcohol was 
the underlying aetiology of their liver disease.  
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Table 4-1 Survival, demographics and reason for admission of 113 cirrhotic 
patients admitted to ICU 
 All ICU 
admissions ICU  
 Hospital  
Number of 
Survivors n, (%) 
113.0 
(100.0) 
72.0 
(63.7) 
 60.0 
(53.1) 
 
 
All ICU 
admissions   
(n=113) 
ICU 
survivors  
(n=72) 
Patients 
who 
died in 
ICU 
(n=41) 
Hospital 
survivors  
(n=60) 
Patients who 
survived ICU 
but died 
within 
hospital 
(n=12) 
Age, mean 
(range) 
52.7 (27.0-
85.0) 
53.4 
(31.0-
85.0) 
51.5 
(27.0 -
77.0) 
52.3 
(31.0-
85.0) 
58.0 (40.0-
80.0) 
Male gender, n 
(%) 82 (72.6) 
54.0 
(75.0) 
28.0 
(62.3) 
46.0 
(76.7) 
8.0 (66.7) 
SIMD quintile, 
median (IQR) 
1.0 (1.0-
2.0) 
1.0 (1.0-
2.3) 
1.0 
(1.0-
2.0) 
1.0 (1.0-
2.0) 
1.5 (1.0-3.3) 
Social 
deprivation, n 
(%) 
86.0 (76.1) 54.0 (75.0) 
34.0 
(82.9) 47.0 (78.3) 
7.0 (58.3) 
APACHE score, 
median (IQR) 
23.0 (18.0-
29.0) 
22.0 
(18.0-
29.0) 
24.0 
(18.8-
29.0) 
21.0 
(17.0-
27.0) 
27.0 (23.5-
33.0) 
Length of ICU 
stay (Days), 
median (IQR) 
5.0 (3.0-
13.0) 
5.5 (3.0-
14.0) 
5.0 
(3.0-
10.0) 
5.5 (3.0-
14.3) 
5.5 (2.0-
11.0) 
Reason for Admission 
Gastrointestinal 
bleed, n(%) 
19 (16.8) 11 
(15.
3) 
8 (19.5) 9 
(15.0) 
2 (16.7) 
Respiratory 
failure, n(%) 
36 (31.9) 23 
(31.
9) 
13 (31.7) 21 
(35.0) 
2 (16.7) 
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Sepsis, n(%) 
21 (18.6) 12 
(16.
7) 
9 (22.0) 9 
(15.0) 
3 (25.0) 
Seizures, n(%) 5 (4.4) 5 (6.9) 
0 (0.0) 3 
(5.0) 
2 (16.7) 
Encephalopathy, 
n(%) 
5 (4.4) 3 
(4.2) 
2 (4.9) 3 
(5.0) 
0 (0.0) 
Other, n(%) 
27 (23.9) 18 
(25.
0) 
9 (22.0) 15 
(25.0) 
3 (25.0) 
Alcohol 
Aetiology, n(%) 
87 (77.0) 54 
(75.
0) 
33 (80.5) 46 
(76.7) 
8 (66.7) 
Child-Pugh grade on ICU admission 
Child-Pugh A, 
n(%) 
17 (15.0) 13 
(18.
1) 
4 (9.6) 13 
(21.7
) 
0 (0.0) 
Child-Pugh B, 
n(%) 
50 (44.2) 35 
(48.
6) 
15 (36.6) 31 
(51.7
) 
4 (33.3) 
Child-Pugh C, 
n(%) 
46 (40.7) 24 
(33.
3) 
22 (53.7) 16 
(26.7
) 
8 (66.7) 
Child-Pugh grade when clinically stable 
Child-Pugh A, 
n(%) 
49 (43.4) 36 
(50.
0) 
13 (31.7) 30 
(50.0
) 
6 (50.0) 
Child-Pugh B, 
n(%) 
49 (43.4) 27 
(37.
22 (53.7) 24 
(40.0
3 (25.0) 
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5) ) 
Child-Pugh C, 
n(%) 
15 (13.3) 9 
(12.
5) 
6 (14.6) 6 
(10.0
) 
3 (25.0) 
 
The median Child-Pugh score recorded when the patient was clinically stable 
was 7 (IQR 6-8), representing a Child-Pugh Class B. The majority of variables for 
calculation of Child-Pugh score were measured at outpatient appointments. A 
total of 51 Child-Pugh scores were calculated at liver outpatient clinic 
appointments and 13 Child-Pugh scores were calculated from information 
recorded at outpatient appointments for other specialties. Some 33 patients had 
Child-Pugh scores calculated from blood results and medical notes at discharge 
from a hospital inpatient stay. Sixteen individuals had Child-Pugh scores 
calculated from blood results taken in primary care.  
The median time between measurement of Child-Pugh score when clinically 
stable and on admission to ICU was 127 days (IQR 70-247), with a maximum time 
of 1381 days. When clinically stable, 49 patients were calculated as Child-Pugh 
A, 49 patients were calculated as Child-Pugh B and the remaining 15 calculated 
as Child-Pugh C (Table 4-1). 
Using variables measured on ICU admission to calculate the Childs-Pugh score, 
the documented median score was 9 (IQR 7-11), graded as Child-Pugh Class B. 
Seventeen patients were Child-Pugh A, 50 patients were Child-Pugh B and 46 
were Child-Pugh C (Table 4-1).  
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Table 4-2 Change in Child-Pugh score and survival 
Change in Child-
Pugh Score from 
stable to ICU 
admission 
Number of 
patients, n (%)  
(n=113) 
ICU Survival n,(%) Hospital Survival 
n,(%) 
-3 1 (0.9) 1 (100.0) 1 (100.0) 
-2 4 (3.5) 4 (100.0) 4 (100.0) 
-1 9 (8.0) 6 (66.7) 6 (66.7) 
0 22 (19.5) 14 (63.6) 13 (59.1) 
1 17 (15.0) 15 (88.2) 14 (82.4) 
2 22 (19.5) 12 (54.5) 10 (45.5) 
3 14 (12.4) 7 (50.0) 4 (28.6) 
4 10 (8.8) 6 (60.0) 2 (2.0) 
5 7 (6.2) 5 (71.4) 4 (57.1) 
6 3 (2.7) 1 (33.3) 1 (33.3) 
7 2 (1.8) 0 (0.0) 0 (0.0) 
8 2 (1.8) 1 (50.0) 1 (50.0) 
 
4.7.2 Child-Pugh score and survival 
Of the 113 patients included in the analysis, 72 (63.7%) survived to ICU discharge 
and 60 (53.1%) survived to hospital discharge. ICU and hospital survival for each 
class of Child-Pugh graded at a period when the patient was clinically stable and 
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on ICU admission are shown in Table 4-1. ICU and hospital mortality for each 
change in Child-Pugh grade is presented in Table 4-2. There was no significant 
difference in either ICU or hospital survival in those with an underlying aetiology 
of alcoholic liver disease. 
Child-Pugh score measured when the patient was clinically stable was not 
significantly associated with ICU (p= 0.159) or hospital survival (p=0.264). Child-
Pugh score measured on admission to the ICU was significantly associated with 
hospital survival (p=0.003), however, it was not significantly associated with ICU 
survival (p=0.095). 
The change in total Child-Pugh score between the score measured when stable, 
reflecting the severity of chronic liver disease, and the score measured on 
admission to ICU was then assessed for change in risk of survival. For an 
individual patient, every increased point in the total Child-Pugh score from the 
point of being stable to ICU admission involved a 20% decrease in ICU survival 
(OR 0.80 CI 0.66-0.95) and a 27% decrease in hospital survival (OR 0.73 CI 0.60-
0.87). Thus the greater change in Child-Pugh score from stable to acute 
presentation to ICU the higher the risk of mortality. This was a multiplicative 
effect and not additive, thus mortality does not increase linearly with change in 
Child-Pugh.  
When considering the Child-Pugh scale of scores from 5 to 15, for every 
increased point in total Child-Pugh score on admission to ICU there is a 21% 
decrease in ICU survival (OR 0.79 CI 0.67-0.92). With every unit increase in raw 
Child-Pugh score on admission to ICU there is a 28% decrease in hospital survival 
(OR 0.72 CI 0.60-0.84). For example, a patient with a total Child-Pugh score of 
15 would have a 21% decrease in ICU survival and a 28% decrease in hospital 
survival when compared to a patient with a Child-Pugh score of 14. As before, 
this was not a linear relationship as the effect was multiplicative. 
When considering Child-Pugh score when stable, for every increased point in 
total Child-Pugh score from 5 to 15 there is a 12% decrease in ICU survival (OR 
0.88 CI 0.72-1.09) and a 15% decrease in hospital survival (OR 0.85 CI 0.69-1.05). 
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4.8 Discussion 
4.8.1 Interpretation of findings 
4.8.1.1 Timing of Child-Pugh scoring 
Whilst the utility of the Child-Pugh score has been extensively investigated, as 
far as can be established this is the first study in the literature to examine 
survivorship and the time point when Child-Pugh score should be carried out in 
the critically ill population. Moreover, the findings from this study suggest that 
there is a relationship between Child-Pugh score measured on admission to the 
ICU and hospital survival for critically ill patients with cirrhosis. However, no 
statistically significant relationship was found between Child-Pugh score 
measured when a patient was clinically stable and ICU or hospital survival.  
On further analysis of the results using a regression model, there appears to be a 
trend between an increase in mortality and an increase in Child-Pugh score, 
measured both on ICU admission and when stable. However, as presented in the 
results, the confidence interval crosses 1 when Child-Pugh is measured when 
stable. Increasing the sample size would aim to increase the precision of the 
results and decrease the margins of the confidence interval.  
Few studies in the literature discuss different time points for assessment using 
scoring systems. One paper which discussed outcomes and scoring systems in 
critically ill cirrhotic patients at 2 non transplant centres in London, measured 
Child-Pugh at time of critical illness and when individuals were stable (282). In 
that study the median Child-Pugh scores on admission to ICU and when stable 
were comparable to our findings, which suggests the population in our study is 
similar to other UK cohorts. Median Child-Pugh score increased by 2 points in this 
study and by 2.5 points in the London cohorts (282). This paper reported on a 
limited number of 137 patients admitted during a 20-month period between 
2007 and 2009 (282). Of those patients with cirrhosis, determining a stable 
Child-Pugh score was only possible in 84 patients and the authors do not detail 
when or how the stable Child-Pugh score was calculated (282). Similar 
limitations exist to this this study, with difficulties arising in the grading of 
hepatic encephalopathy outwith hospital admission. The authors state that they 
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believe all critically ill patients with cirrhosis have a degree of hepatic 
encephalopathy and as such equated documentation of a ‘normal’ neurological 
status to Grade I/II hepatic encephalopathy, allocating this a score of 2 rather 
than 1 in Child-Pugh grading (282). 
The relationship between Child-Pugh score measured on admission to the ICU 
and hospital survival contradicts the findings from the national survey of Scottish 
intensivists and gastroenterologists discussed in Chapter 3. That survey found 
that Child-Pugh score measured when stable was the most significant factor 
utilised by both intensivists and gastroenterologists in the decision whether to 
admit patients to ICU. There are a number of potential explanations for the 
difference in these findings. The relationship of Child-Pugh score measured on 
ICU admission to hospital survival may reflect the fact that Child-Pugh score 
encompasses physiological variables known to predict prognosis in acute illness 
(283). Established scoring tools designed to measure severity of organ 
dysfunction in the critically ill utilise similar variables, with the SOFA score 
encompassing bilirubin and neurological status (139). Castera et al. examined 
variables associated with survival in 243 patients with cirrhosis (118). That study 
demonstrated that in addition to a requirement for mechanical ventilation, PT, 
creatinine and encephalopathy measured on admission to ICU were significant 
variables in predicting mortality. 
As the responses to the survey in Chapter 3 are likely to mirror daily practice, 
the significance placed upon stable Child-Pugh score in decision-making is likely 
to be multifactorial. It may reflect an understanding that ICU survival is 
determined by resilience and physiological reserve prior to ICU admission, with 
Child-Pugh score used as a surrogate indicator (242). The use of stable Child-
Pugh score to reflect the severity of chronic disease may also reflect historical 
cohorts of patients in whom many aetiologies of liver disease were considered 
irreversible. However, recent advances in the treatment of viral hepatitis and a 
widening of transplant criteria to include those with alcoholic liver disease, 
represent an opportunity for reversal of the course of disease for select patients 
(14). In the majority of patients Child-Pugh score measured when an individual is 
clinically stable will be lower than when an individual is critically ill. Using a 
Child-Pugh score to determine ICU admission, a larger proportion of individuals 
would be offered admission if a stable score was used. Clinicians may argue that 
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this gives a greater number of patients with chronic liver disease access to ICU 
and thus improves a patient’s chance of survival. 
Survivorship in those with cirrhosis is impacted by disease trajectory, with a 
difference between those patients who have compensated and decompensated 
cirrhosis (53). As this study examined only two time points in the patient 
journey, it is impossible to determine the specific course of disease for each 
patient prior to ICU admission, and whether the Child-Pugh score when stable 
was associated with compensated or decompensated cirrhosis. However, the 
results demonstrate that with every increase in point in total Child-Pugh score 
there is a 20% decrease in ICU survival and 27% decrease in hospital survival, 
thus the degree of change in the severity of liver disease remains significant 
irrespective of the Child-Pugh score when stable.  
Little evidence exists regarding the change in severity of cirrhosis following ICU 
survival, however it is known that in other populations of critical illness 
survivors, such as elderly patients, there is significant decline in function 
following ICU stay (284). For example, Ferrante et al. found functional 
trajectory prior to ICU stay to be an independent predictor of mortality in their 
elderly cohort (284). An observational cohort study of 33,324 Canadian ICU 
admissions found that whilst death in the first 30 days following ICU admission 
was determined by acute illness, survival after 90 days following ICU admission 
was influenced by age and comorbid conditions (285). It may be that long-term 
survivorship in the cirrhotic cohort could be significantly related to Child-Pugh 
score when stable and Child-Pugh score could be used as a surrogate marker for 
chronic comorbidity. Whilst severity and reversibility of disease is an important 
factor in the decision to admit an individual to ICU, establishing a baseline 
functional state and the impact of comorbidity might give an assessment of 
potential resilience. Although the outcome for those who died in ICU or hospital 
is known, for those who survive it was beyond the scope of this study to 
investigate progressive Child-Pugh scores. It would be valuable to discover if and 
when patients return to their baseline Child-Pugh score. 
An important finding of this study was that Child-Pugh score on ICU admission 
was significantly associated with hospital survival but not ICU survival. As Child-
Pugh score has been used extensively as a marker of liver disease severity it may 
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be that the variables measured in Child-Pugh play a greater role in determining 
long-term survival. Those with a greater degree of liver impairment may be at 
greater risk of subsequent deterioration prior to discharge, struggle with 
rehabilitation and are more likely to be denied ICU readmission. Individuals with 
chronic liver disease are known to have increased endotoxin and cytokine 
concentrations, predisposing them to ongoing inflammation (286).  
4.8.1.2 Individuals without medical history 
Five individuals admitted to ICU in this dataset were excluded from analysis as 
they had no existing clinical information or laboratory values to enable stable 
Child-Pugh scoring. This may represent a challenging cohort of individuals with 
advanced yet asymptomatic liver disease who present in decompensated liver 
disease. This group of patients pose challenges in deciding whether or not to 
offer intensive care as little is known of their functional state, physiological 
reserve and engagement or compliance with therapy, factors demonstrated to 
be important in Chapter 3. 
The results of this study suggest that an isolated measurement of the Child-Pugh 
score on ICU admission can be useful for those with an unknown past history. 
The results demonstrate a marked increase in both ICU and hospital mortality 
with each additional point attained on Child-Pugh score. However, this finding 
would require validation in a larger cohort of patients.  
4.8.1.3 Alcoholic liver disease 
Alcohol was recorded as the underlying cause of cirrhosis in the majority of the 
patients included in the dataset although this was not significantly associated 
with either ICU or hospital survival. This reflects a similar population of ICU 
admissions with cirrhosis admitted to 2 non-transplant ICUs in London (156). 
Over the last 30 years UK hospital admission rates for those with liver cirrhosis 
have increased dramatically by 71% in men and 43% in women (287). Hospital 
admissions for those with cirrhosis caused by alcohol doubled over a similar 
period (287). The relationship between Child-Pugh score on admission to ICU and 
survivorship found in this study must be interpreted with caution as it may not 
be representative of all aetiologies of cirrhosis with some patients having more 
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than one aetiology of chronic liver disease. Worldwide, the underlying aetiology 
of cirrhosis differs with Hepatitis B and C more prevalent than alcoholic liver 
disease in sub-Saharan Africa and Asia (14).  
4.8.2 Limitations 
This study examines the timing of Child-Pugh score and the relationship to both 
ICU and hospital survival. The cohort of patients examined is small and comes 
from a single centre in Glasgow, as such the results may not be generalisable to 
other populations worldwide. Given the small number of patients there is 
potential for a type 2 error. It may be that there is a relationship present 
between survival and Child-Pugh score when stable which was not detected as 
the relationship did not reach statistical significance. The confidence intervals 
presented show that the increase in mortality differs widely for both Child-Pugh 
score measured when stable and on admission to ICU. Notably, the confidence 
interval for Child-Pugh when stable crosses 1, suggesting that for some an 
increase in score can lead to a decrease in mortality. This loss of precision 
reflected in the width of the confidence intervals is in part due to the small 
sample size.   
The reason for admission to ICU was recorded, however, there may have been 
more than one underlying diagnosis. The small numbers in this dataset prevented 
meaningful assessment of any relationship between diagnosis requiring ICU 
admission and survivorship. With larger numbers it would be possible to analyse 
each subgroup of admissions. Moreover, it is recognised in the literature that 
multi-organ failure is associated with increased mortality (129). This study did 
not record any subsequent diagnoses once patients were admitted to ICU, which 
may have an impact upon survival and would be of clinical use in determining 
outcome.  
Some studies have criticised Child-Pugh score as the measurement of ascites and 
hepatic encephalopathy can be subjective and lead to error within calculation. 
In particular, the grading of hepatic encephalopathy and ascites is challenging in 
the critically ill patient who may be intubated. The score does not account for 
changes occurring with treatment, as such the total score may be iatrogenically 
altered. One example of this is seen in the administration of exogenous albumin 
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in the critically ill or in those undergoing therapeutic paracentesis which may 
lead to temporary improvement in Child-Pugh score (267). Further fluid 
replacement given in the management of acute illness can have a detrimental 
effect on coagulopathy and drugs administered to facilitate intubation alter 
neurological status can prevent accurate assessment of encephalopathy. The 
Child-Pugh score gives equal weighting to each variable, with no consideration 
for alteration with management. Giving equal weighting may mean that the 
impact of each variable is either under or over estimated. Specific points in the 
score may be of greater value in certain clinical situations and it could be 
argued that in many circumstances the variables are not independent of each 
other.  
Calculation of Child-Pugh score for those admitted to ICU relied upon accurate 
input of variables by medical staff on admission. The assessment of degree of 
encephalopathy may become impossible once patients are sedated and 
ventilated in ICU. This measurement requires precise documentation of a 
neurological examination of the patient prior to induction of anaesthesia. 
Laboratory variables scored in Child-Pugh are continuous, however, patients with 
severe liver disease can only score the maximum 15 points. Durand and Valla 
describe this as a ‘ceiling effect’ preventing separation of the most severely 
unwell patients with deranged bilirubin, albumin or coagulation (288). This limits 
the clinical use of the score in determining differences in mortality within a 
Child-Pugh class. In the cohort of patients in this study it may facilitate 
identification of the characteristics of a subgroup of the Child-Pugh C patients 
who died. Furthermore, with such high rates of mortality secondary to bacterial 
infections (section 1.4.8) it would have been useful to note further clinical 
details of this cohort, such as underlying cause of sepsis or whether any of the 
patients admitted developed sepsis during their ICU stay.  
This study investigated Child-Pugh score when clinically stable. Those patients 
who had been assessed by liver specialists and included in the chronic liver 
database were potentially more accurately scored than those patients scored 
outwith this clinic due to focus on severity of liver disease. The study relied 
upon medical documentation of clinical findings in patient notes and an 
assumption that a patient would be clinically stable if fit for discharge. It was 
acknowledged that patients scored solely on blood tests performed by their 
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General Practitioner (GP), would potentially receive lower Child-Pugh scores as 
there was no documentation relating to ascites or encephalopathy available for 
inclusion. A method of single imputation was chosen to replace missing values 
for those patients who did not have grade of ascites or encephalopathy recorded 
in primary care. It is recognised that imputation of values will reduce statistical 
power and introduce bias to the results. Single imputation was chosen due to the 
low numbers of individuals with missing values and the likelihood that if ascites 
or encephalopathy was present in primary care the patient would have most 
likely been referred to hospital and have an associated admission or clinic 
review. An alternative method of imputation would be listwise deletion, 
however, with the limited number of individuals in this dataset it was felt that 
this would prevent further statistical analysis. Another method to overcome 
missing values would be to use a complete case analysis and use multiple 
imputation. A complete case analysis and multiple imputation was beyond the 
scope of this thesis. 
4.9 Conclusion 
This chapter discusses the utility and timing of the Child-Pugh score in predicting 
ICU and hospital survivorship in those with cirrhosis and critical illness. The 
results demonstrate: 
• The median Child-Pugh score measured in this cohort when the patients 
were clinically stable was 7 (IQR 6-8) which increased to 9 (IQR 7-11) on 
admission to ICU 
• There was no statistically significant relationship demonstrated between 
Child-Pugh score measured when a patient was clinically stable and ICU or 
hospital survival 
• Child-Pugh score measured when the patient was admitted to ICU was not 
significantly associated with ICU survival   
• Child-Pugh score measured when the patient was admitted to ICU was 
significantly associated with hospital survival (p=0.003) 
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• With every unit change in Child-Pugh score between the score measured 
when stable and a score measured on admission to ICU there is a 20% 
decrease in ICU survival and a 27% decrease in hospital survival 
• For every unit increase in total Child-Pugh score on admission to ICU there 
is a 21% decrease in ICU survival and a 28% decrease in hospital survival 
This chapter examined the utility and timing of Child-Pugh score in determining 
ICU and hospital survival. The following chapter examines the use of a proxy to 
measure alcohol intake in critically unwell individuals admitted to ICU. 
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Chapter 5 Use of a proxy to measure alcohol 
history for patients in intensive care 
5.1 Introduction 
Previous chapters have discussed the factors involved in deciding whether a 
patient with cirrhosis will benefit from ICU admission. This chapter discusses one 
of the preventable aetiologies of chronic liver disease, alcohol and its impact on 
intensive care and individuals with critical illness. It aims to assess whether a 
proxy can be used as a reliable source of information to provide an alcohol 
history on behalf of a critically unwell individual. 
5.1.1 Burden of alcohol in Scotland 
The 2018 Global status report on alcohol published by the WHO revealed that 
13% of men and 4.7% of women in the UK had an alcohol use disorder (289). 
Further data reported 2.2% of men and 0.7% of women in the UK had alcohol 
dependence (289). The 2016 Scottish Health Survey reported that approximately 
25% of adults drink above the recommended 14 units of alcohol per week in 
Scotland (290). Moreover, men were twice as likely as women to drink above the 
recommended weekly limits (290). Data from the Scottish Health Survey 2015 
concluded that 82% of Scots were abstinent or drank low levels of alcohol, 15% 
exhibited hazardous levels of alcohol intake, 2% drank to harmful levels and 1% 
demonstrated alcohol dependence (291). Men are 1.7 times more likely to die 
from alcohol-related causes in Scotland than in England and Wales (292, 293). In 
2009 it was reported that 5% of deaths in Scotland were linked to alcohol and 
whilst alcohol-related deaths decreased from the early 2000s to 2010, more 
recent trends now show an increased mortality from 2012 in 2016 (290, 293).  
National data published in 2016 demonstrated that NHS Greater Glasgow and 
Clyde had the highest rate of alcohol-related hospital admissions in Scotland 
with alcohol-related mortality rates between 1979 and 2011 higher in Glasgow 
than the rest of Scotland (294, 295). According to the SIMD, approximately 50% 
of those who reside in Glasgow live in the 20% of the most deprived areas of 
Scotland (295). Areas of deprivation are reported to experience a greater 
number of acute and psychiatric hospital admissions secondary to alcohol-
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related problems (294). However, when compared to other UK cities with similar 
levels of deprivation, such as Manchester or Liverpool, alcohol-related mortality 
in Glasgow remains significantly higher (295).  
There are substantial economic implications caused by alcohol misuse in 
Scotland and the Scottish Government estimate that alcohol problems cost the 
NHS over £140 million every year (296). Furthermore alcohol problems cost 
social work services £80 million and the justice system £268 million annually 
(297). Loss of earnings secondary to alcohol problems total over £405 million 
annually with 1.7 million working days lost in Scotland due to alcohol (290, 297). 
Alcohol problems cost Scotland in excess of £3.6 billion every year (298). Put 
into context, alcohol problems have a greater financial impact on the health 
budget than drug misuse, stroke or Alzheimer’s disease (297, 299).  
In order to ease this socioeconomic burden the Scottish Government aims to 
reduce the volume of alcohol consumed, modify harmful behaviours surrounding 
alcohol intake and change the “cultural focus on intoxication” (297). Strategies 
implemented include a reduction in drink-drive limits compared to the rest of 
the UK and setting a minimum price per unit of alcohol (290, 300). The Alcohol 
(Scotland) Act 2010, limited discounts in the bulk buying of alcohol, introduced a 
Challenge 25 age policy and restricted alcohol marketing (290). 
5.1.2 The health impact of alcohol 
The excessive consumption of alcohol and alcohol withdrawal cause a wide range 
of physical and mental health disorders and may have considerable impact upon 
an individual, their family and friends (301). A recent Scottish survey stated that 
1 in 2 people reported harm from another individual’s drinking (302). One in 10 
presentations to the ED in Scotland are linked to alcohol, with 3% of acute 
hospital admissions in Scotland related to alcohol (297). Worldwide it is 
estimated that 3.8% of deaths are caused by alcohol with excess alcohol 
consumption being linked to wide number of acute and chronic diseases in most 
systems of the body (21). It can also exacerbate existing comorbidities (303). 
The consumption of alcohol is a direct causative factor in alcoholic liver disease 
and alcohol-induced pancreatitis (21). A number of different cancers can arise 
from excess alcohol consumption and include oesophageal, mouth, liver, breast 
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and colon cancer (21). Furthermore diabetes, epilepsy, ischaemic heart disease 
and cerebrovascular disease are also linked to excess alcohol intake (21). In the 
pregnant woman alcohol can cause fetal abnormalities, whilst psychiatric 
disorders such as depression are commonly caused by alcohol (21). Unintentional 
or self-inflicted injury such as falls, poisoning, drowning and road traffic 
accidents can be directly attributed to alcohol (21). The Scottish Trauma Audit 
Group reported that alcohol was a factor in 26% of males presenting with major 
trauma in 2015 (304). 
5.1.3 The impact of alcohol on critical care 
Mental and behavioural disorders are documented as the most prevalent cause of 
acute hospital admissions related to alcohol in Scotland (294). Thereafter the 
most common cause of admissions are those related to alcoholic liver disease 
(294). The number of Scottish hospital admissions due to alcohol withdrawal are 
relatively low, however, the total is reported to have increased every year since 
1997 (294). A recent study in Glasgow reported that 35% of admissions to critical 
care had an alcohol use disorder, with the number of alcohol-related admissions 
to critical care increasing (187, 305). The Intensive Care National Audit and 
Research Centre (ICNARC) database for England and Wales demonstrated that 
critical care admissions for alcoholic liver disease tripled between 1996 and 2005 
(306). The Scottish data between 2005 and 2010 shows that those admitted to 
ICU with alcoholic liver disease are more likely to have a longer hospital stay and 
be readmitted than other patients admitted to ICU (4). A systematic review of 
patients with alcoholic liver disease who were admitted to critical care 
concluded that mortality of this group ranged from 34-63% (122). Moreover 
alcohol consumption is associated with an increased mortality within 1 year of 
discharge from ICU (307). Both the acute and chronic implications of excess 
alcohol consumption are of considerable concern in critical care. Excess alcohol 
consumption is independently related to sepsis, prolonged mechanical 
ventilation, bacterial infection, ARDS and a higher risk of readmission (230, 308-
310). 
Alcohol withdrawal increases susceptibility for ICU related delirium (311). 
Approximately 80% of intubated patients develop delirium which may result in 
excess sedation, inhibit attempts to successfully wean patients from ventilators, 
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cause long term cognitive impairment and can lead to a reluctance to transfer 
patients from the ICU to a ward (312). Consequently there is an incentive to 
prevent and treat delirium effectively to reduce the length of ventilation, the 
time in ICU and hospital reducing the associated medical and economic costs 
(313). Furthermore critically ill patients may experience seizures, autonomic 
hyperactivity and hallucinations as part of an alcohol withdrawal syndrome 
(314). This causes tachycardia, hypertension, pyrexia, decreased cerebral blood 
flow, increased oxygen consumption, a respiratory alkalosis and electrolyte 
disturbances (314). These clinical findings may complicate diagnosis and 
management of the underlying presentation and thus it is advantageous to 
promptly identify patients at risk and prevent withdrawal occurring. 
5.1.4 Measurement of alcohol intake 
Historically, research into excessive alcohol intake concentrated on severe 
alcohol dependence or alcoholism (315). The focus now has shifted to include 
hazardous or harmful alcohol intake in an attempt to identify those at risk from 
the consequences of excess alcohol consumption (186). Widespread use of 
appropriate screening tools in healthcare settings can help identify patients at 
risk of alcohol related disorders allowing targeted intervention to reduce 
potential harm (316). To reduce alcohol use disorders, primary prevention 
requires national strategies at government level (317). Secondary prevention 
concerns detection and treatment of individuals with existing hazardous alcohol 
consumption, which can be undertaken in both the primary and secondary care 
setting (317). An American study published in 2008 demonstrated that screening 
for alcohol misuse was as cost effective as other interventions such as screening 
for hypertension, colorectal cancer, vision or influenza vaccination (318). The 
study of primary care interventions concluded that the effectiveness of 
screening relied upon four factors which included adherence with screening, 
sensitivity of screening tools, the ability of existing strategies in producing 
behavioural change and how effective behaviour change was in reducing the 
consequences of pre-existing excessive alcohol consumption (318).  
The WHO, National Institute of Alcohol Abuse and Alcoholism (NIAAA) and the 
American Psychiatric Association (APA) proposed that individuals could be 
classed into different groups based on their pattern of drinking (Table 5-1) (319). 
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A systematic review identified that ‘at-risk, hazardous, heavy or problem 
drinking’ were terms used to describe individuals at risk of consequences from 
alcohol, either due to volume or pre-existing comorbidities (319).  
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Table 5-1 Classification of alcohol intake (319) 
Category Organisation Definition 
Moderate 
alcohol 
consumption 
NIAAA Men ≤ 2drinks/day 
Women ≤1 drink/day 
Over 65 ≤1 drink/day 
At-risk alcohol 
consumption 
NIAAA Men >14 drinks/week or >4 drinks/occasion 
Women >7 drinks/week or >3 drinks/occasion 
Hazardous 
alcohol 
consumption 
WHO At risk of adverse consequences from alcohol 
Harmful 
alcohol 
consumption 
WHO Physical, psychological or socio-economic harm 
from alcohol 
Alcohol abuse APA ≥1 of the following per year; failure to fulfil 
major role obligations, recurrent use in 
hazardous situations, recurrent alcohol-related 
legal problems, continued use despite social 
problems caused or exacerbated by alcohol 
Alcohol 
dependence 
APA Alcohol use Disorder 
≥3 of the following per year; tolerance, require 
alcohol to prevent symptoms of withdrawal, 
time spent obtaining or using alcohol or 
recovering from its effect, unable to perform 
significant activities, more alcohol consumption 
than intended, failure to reduce intake, use 
despite awareness of physical, psychological or 
social problems caused by alcohol 
 
5.1.5 Biochemical measures of alcohol intake 
Despite the high sensitivity of alcohol screening questionnaires, it is recognised 
that alcohol history is not always reliable or easily obtainable (320). A number of 
biochemical markers exist which are objective measures of regular heavy 
drinking (320). Measurement of blood, breath or urine ethanol levels can 
  141 
 
indicate chronic levels of drinking (321). Ethanol levels over 33mmol/L without 
clinical intoxication or over 65mmol/L at any point indicate increased tolerance 
and should raise suspicion of chronic alcohol consumption (321).  
Gamma-glutamyltransferase (GGT) is a membrane-bound enzyme which 
catalyses glutathione to peptide acceptors (321). Serum levels of GGT rise in 
response to a number of conditions including increased alcohol intake and 
medications making it a non-specific marker of alcohol excess (321). Heavy 
drinking is indicated by a serum GGT measurement of over 35 units per Litre 
(units/L) (322). Alcohol consumption can lead to a change in the structure of 
transferrin and prolonged heavy drinking is indicated by a measurement of 
carbohydrate-deficient transferrin (CDT) in excess of 20 units/L (322, 323). The 
liver function tests aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) are markers of liver injury with a raised AST to ALT ratio 
suggestive of alcohol aetiology (321, 324). A multinational study of 120 
individuals found the serum biomarkers of alcohol excess; GGT, AST and CDT to 
be comparable with sensitivity of 33 to 40% and specificity of 85 to 94% (325). A 
full blood count may indicate excess alcohol intake with macrocytosis noted in 
70.3% of alcoholics and a mean corpuscular volume (MCV) over 100 fl in 49.5% of 
alcoholics in a study of 398 individuals with chronic liver disease (326). Koivisto 
et al. demonstrated a dose-dependent response in MCV in relation to volume of 
alcohol intake (327).  
At present biochemical measurement of alcohol excess can give some indication 
of chronic alcohol use but the majority of such measurements lack sensitivity 
and incur the expense of a laboratory test. A German study comprising 1233 
individuals presenting to the ED found that using a questionnaire based approach 
was superior to biomarkers in identifying individuals with alcohol use disorders 
(328). Furthermore use of biomarkers in combination with a questionnaire-based 
screening tool did not show any improvement in sensitivity or specificity (328). 
5.1.6 Alcohol screening tools 
The following section of this chapter discusses a number of different alcohol 
screening tools. The tools discussed are the most frequently used questionnaires 
discussed within the literature and in use clinically. 
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5.1.6.1 Michigan Alcohol Screening Test 
The Michigan Alcohol Screening Test (MAST) was published in 1971 and was the 
first questionnaire which enabled an individual to self-report current and past 
alcohol consumption (329, 330). The test can be completed in 5 minutes and 
consists of 25 dichotomous yes or no questions on problem drinking and 
behaviour associated with excess alcohol intake (330). A score of 0-3 suggests a 
problem with alcohol is unlikely, a score of 4 describes a possible problem with 
alcohol intake and a score of 5 or over suggests that the individual may be a 
problem drinker (330). As with other alcohol screening tests the results rely on 
an individual answering truthfully and the MAST will not identify a problem 
drinker in denial (331). The MAST also fails to distinguish between responses 
linked to current alcohol consumption from responses concerning previous 
alcohol behaviour (329). A meta-analysis concluded that the MAST had a 
reliability of 0.78-0.84 (183).  
5.1.6.2 Cutting down, Annoyance by criticism, Guilty feeling, 
and Eye-openers 
In 1974 Mayfield et al. published a paper describing 4 interview questions to 
screen for an alcohol use disorder (332). The questions encompass Cutting down, 
Annoyance regarding criticism about alcohol use, feelings of Guilt about drinking 
and whether alcohol was required as a morning Eye-Opener (CAGE) (333). Each 
positive response scores a point, with a score of 2 or more suggesting alcohol 
dependence and a maximum score of 4 indicating a likely diagnosis of alcoholism 
(334). Whilst it is one of the first alcohol screening tools described in the 
literature, the CAGE questionnaire remains one of the fastest to complete taking 
approximately 30 seconds (320). The CAGE tool was designed to screen 
hospitalised patients for alcohol problems and unlike the Alcohol Use Disorders 
Identification Test (AUDIT) tool it reflects long-term alcohol consumption and its 
consequences rather than quantifying alcohol intake or the pattern and 
frequency of alcohol intake (334). A systematic review published in 2000 
revealed that sensitivity to detect at-risk drinkers ranges from 14-84% with a 
specificity of 95-97% (319). In those who drank excessive volumes of alcohol the 
sensitivity was between 49-69% and specificity of 75-95% (319). A review of 
reliability studies demonstrated a reliability 0.80-0.95 (335).  
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5.1.6.3 Alcohol Use Disorders Identification Test 
The AUDIT was developed by the WHO in 1987 with the aim of screening 
individuals for excess alcohol consumption (336, 337) (Appendix 3). In addition 
to identifying those with alcohol dependence the tool is designed to identify 
individuals with hazardous and harmful drinking behaviour (336). The AUDIT 
consists of 10 questions (336, 338). The first 3 questions gauge hazardous alcohol 
use and cover the frequency and quantity of alcohol consumed (336). The 
subsequent 3 questions identify symptoms of dependence and include impaired 
control of drinking, increased salience of drinking and morning drinking (336). 
The final 4 questions concern harmful alcohol use and cover feelings of guilt, 
blackouts, alcohol-related injuries and concern from other individuals (338). 
There is a maximum score of 40, with scores of 8 or above indicating problem 
drinking (338). Studies have also shown that the tool may perform differently in 
men and women, with a suggestion that a score lower than 8 be used to indicate 
problem drinking in women (339). At present the WHO does not advise any 
differences in interpretation of the AUDIT score based on gender. 
The tool has been validated in 6 countries within primary care settings and can 
be performed in 2 minutes (338). It has been used within an employment setting 
to assess alcohol problems in the police force and in secondary care settings 
(339). However, in certain clinical settings such as the ED, Hodgson et al. raised 
concern that the AUDIT takes too long to complete when faster screening tools 
are available (315).  
The AUDIT is unique in the fact that it concentrates on current alcohol 
behaviour, it was constructed utilising responses from a multinational sample 
and identifies hazardous drinking rather than long-term dependence (340). A 
systematic review of the screening tools available to detect alcohol problems in 
primary care demonstrated that the AUDIT tool had sensitivities of between 51%-
97% and a specificity of between 78%-96% in detecting individuals with at-risk, 
hazardous or harmful alcohol intake (319). In addition the AUDIT has been 
proven to have a median reliability of 0.81 (341). The AUDIT remains one of the 
few tools which aims to not only identify alcohol dependence but detect 
individuals with ‘at-risk’ drinking behaviour, potentially providing opportunity 
for early intervention to avoid harm (339). 
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Few studies exist which examine use of the AUDIT in the ICU population. One 
American study of outpatient veterans screened individuals using the AUDIT-C - a 
shorter version of the AUDIT tool, and subsequently followed up this population 
to determine the incidence of ICU admission (342). It concluded that those with 
severe alcohol problems were more likely to be admitted to ICU (342). The same 
group of researchers have investigated use of the AUDIT in those with ARDS 
(343). Using a lower threshold value of 5 on the AUDIT they found 23% of those 
with ARDS screened positive for an alcohol use disorder (343).  
5.1.6.4 The Fast Alcohol Screening Test 
Following criticism that the AUDIT was not used routinely in time pressured 
clinical scenarios such as the ED, the Fast Alcohol Screening Test (FAST) was 
developed based on specific questions from the AUDIT (315). The FAST consists 
of 4 questions and the first question concerns frequency of consuming more than 
8 alcoholic drinks for men and 6 for women (315). The second question concerns 
inability to remember events the night before due to alcohol excess (315). The 
third questions the frequency that the individual is unable to complete tasks 
expected of them due to drinking (315). The fourth question asks the individual 
if anyone has expressed concern regarding their alcohol intake or suggested 
reduction in alcohol intake (315). Whilst the questions are different, the themes 
covered are similar to those within the CAGE questionnaire. To increase speed at 
which FAST can be performed the first question can be used as a filter and 
eliminate the need for the remaining questions in over 50% of patients (315). 
The FAST is negative if the individual does not drink more than 8 (for men) or 6 
(for women) alcoholic drinks (315). If consumption exceeds this number of drinks 
on a weekly or daily basis the test is positive (315). Whilst the FAST can be 
performed in 12 seconds it has not been validated as extensively as the AUDIT 
nor does it differentiate between hazardous or harmful alcohol intake and 
alcohol dependence (315). 
Despite the number of instruments available no biochemical test or screening 
tool have been validated to measure the volume of alcohol consumed. 
Furthermore, to date none of the alcohol screening tools discussed have been 
validated within the ICU setting. The majority of ICUs in the UK document 
volume of alcohol consumed, based on patient or relative history, rather than 
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using a screening tool (344). Accurately gauging alcohol intake is challenging and 
participation in the use of any assessment tool is compromised if the patient is 
sedated or ventilated, as is often the case in critical care. Moreover, up to 80% 
of all intubated patients experience delirium, which also has an association with 
alcohol withdrawal (312). This may impact upon validity of a history following 
extubation and self-reporting of alcohol consumption. In any setting, self-
reporting of alcohol intake may be inaccurate and the value of an alternative 
source of information, such as a collateral history can prove to be useful (345, 
346). 
5.1.7 Proxy studies  
A proxy is defined by the Oxford English Dictionary as a “person authorised to 
act on behalf of another” (347). Existing studies have investigated use of a proxy 
to measure alcohol intake using questionnaires such as CAGE and MAST (348). 
Chermack et al. found that reported alcohol consumption using the CAGE 
questionnaire did not differ significantly between patient and proxy in a study of 
581 cases (348). Likewise the MAST questionnaire was demonstrated to correlate 
between partners for those with known excess alcohol consumption in 2 studies 
(349, 350). Use of a collateral informant to assess alcohol use using the AUDIT 
has been found to correlate with the patient’s own assessment of alcohol intake 
in the ED (345). Patients enrolled to that study had screened positive for alcohol 
problems and were predominantly young, educated men (345). There is a 
paucity of studies which investigate use of a collateral history in the literature, 
despite routine clinical use and description in national guidelines for patients 
with an inability to provide an accurate history, such as those with dementia 
(351).  
The use of a collateral informant to provide insight into alcohol history has not 
yet been investigated within an ICU environment nor where the patient is unable 
to self-report alcohol history (344). If a proxy is found to be a reliable substitute 
to provide information on alcohol intake then this method may provide an 
opportunity to gauge alcohol intake more accurately. This could potentially 
enable identification and treatment of patients most likely to be at risk of 
alcohol withdrawal. The findings may empower clinicians to target appropriate 
alcohol treatment programmes to those patients who require such support. 
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There is evidence to suggest that ICU admission provides an opportunity to 
deliver interventions to reduce preventable causes of disease such as cigarette 
smoking and excess alcohol consumption (352).  
5.2 Study question and aims 
5.2.1 Can a proxy be used to measure alcohol intake in a patient 
admitted to intensive care? 
Alcoholic liver disease is one of the preventable causes of chronic liver disease 
and cirrhosis. Prompt recognition and treatment of patients who consume excess 
alcohol would inform acute medical management and facilitate targeted health 
intervention. However, obtaining an accurate alcohol history is challenging, 
particularly if the patient is critically ill. If a proxy is able to supply a reliable 
alcohol history this would provide valuable information in the intensive care 
setting. 
5.2.2 Aims 
• To identify whether intensive care patients’ self-evaluation of alcohol 
intake correlates with that of a proxy evaluation of alcohol intake 
• To identify whether frequency, nature and mode of contact between 
patient and proxy has any influence on the correlation of results  
5.3 Methodology 
5.3.1 Design 
This study was a prospective questionnaire, designed to consist of identical 
paired questionnaires given to a patient and a proxy at different stages of the 
patient journey.  
Potential proxies were provided with a letter of invitation when they visited 
their friend or relative in ICU and invited to participate in the study. They were 
approached by a member of the research team who consisted of the MD student, 
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the MD supervisors: Dr Joanne McPeake and Dr Tara Quasim, Dr Jill Selfridge or 
one of the clinical research nurses based at GRI or QEUH. 
Potential proxy participants were given an information sheet detailing the 
research team, the purpose of the study, their involvement, risks and benefits of 
participation, how information would be stored and how information gathered 
would be used (Appendix 6). The potential proxy was then approached during 
the same patient visit after they had read the information sheet. 
Following consent, the proxy completed the AUDIT, answering the questions on 
behalf of the patient using their perception of the patient’s alcohol behaviour. 
The proxy provided further information regarding their relationship to the 
patient and frequency of contact with the patient. Once extubated and deemed 
fit to step down from a Level 3 care, the patient was approached by a member 
of the research team, provided with a letter of invitation to participate in the 
study and given an information sheet. Following consent the patient was asked 
to complete the 4 ‘A’s Test (4AT) (Appendix 4) (353). This screening tool was 
used to exclude patients with severe cognitive impairment or delirium. If the 
patient did not screen positive on the 4AT they were then asked to complete the 
AUDIT.   
Prior to ethical approval all aspects of the study were reviewed by former 
patients and members of the public attending an ICU follow-up clinic (354). This 
included conduct, approach and documentation, ensuring readability and 
identification of any ambiguity within the questions. 
5.3.2 Questionnaires 
5.3.2.1 Alcohol Use Disorders Identification Test 
The AUDIT tool is described in detail in section 5.1.6. It was selected for use in 
this study as it is able to detect current or recent detrimental drinking whilst 
providing insight into an individual’s drinking pattern and behaviour (345). 
Published by the WHO, the AUDIT tool is available for use provided it is not 
utilised for commercial purposes (336) (Appendix 3). In keeping with other 
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studies a threshold score of 8 was used within the study to determine 
problematic drinking (319). 
5.3.2.2 The 4 ‘A’s Test  
The 4AT is an assessment designed to detect cognitive impairment or delirium 
(353) (Appendix 4). It measures patient alertness, attention, acute or fluctuating 
change in mental function and incorporates the abbreviated mental test (AMT) 
comprising patient age, date of birth, location and current year. If no cognitive 
impairment or delirium is present a score of 0 will be achieved. A score of 1 to 3 
over all questions indicates possible cognitive impairment and a score of over 4 
indicates possible delirium or cognitive impairment, with a maximum score of 
12. The tool is considered to be useful in assessment of individuals with severe 
agitation or drowsiness and can be performed in less than 2 minutes. The 4AT 
tool has been validated in a number of studies including an Italian study of 236 
individuals aged over 70 who were admitted to hospital and a study of 111 
admissions to an acute stroke unit in GRI - the same site as the present study 
(353, 355). Permission to use the 4AT questionnaire in this study was granted by 
the author, Dr Alasdair MacLullich on 5 September 2014.  
5.3.3 Participants 
Proxies enrolled into the study were recruited following admission of a relative 
or friend to the GRI or the QEUH ICU. There was no randomisation and any 
identified proxy of every patient who met the inclusion criteria admitted to the 
ICU within the data collection period was approached, provided another proxy 
had not completed the AUDIT questionnaire on behalf of the patient. 
Patients were invited to participate in the study when they were deemed fit for 
discharge from Level 3 care. The initial recruitment was planned over a 9-month 
period from 07/03/2015 until 07/12/2015. However, due to low recruitment 
levels, further ethical approval was granted to add a second recruitment site at 
the QEUH, Glasgow. Recruitment was then extended until 19/07/2016. 
Following discussion with a statistician it was decided that the study would 
require 206 patients to power the study to 99% at a 0.05 significance level. This 
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would enable differentiation between proxy and patient, in determining whether 
the patient’s alcohol intake was harmful, hazardous or dependent – the three 
groups of patients classified by the AUDIT. With approximately 750 patients 
admitted to GRI ICU in 9 months it was initially predicted that sufficient 
participants would be recruited to power the study.  
5.3.4 Inclusion Criteria 
• Over 16 years old 
• Competent to give consent 
• Identifiable proxy over the age of 16 
• No cognitive impairment on 4AT 
• No delirium on 4AT 
• English Speaking 
5.3.5 Exclusion Criteria 
• Refusal to consent 
• Death before discharge from intensive care 
5.3.6 Centres 
Data collection was initially commenced at the GRI ICU, however, the 
recruitment target was not met in the single site. Subsequently the QEUH, 
Glasgow was approved an additional recruitment site. Details of both hospitals 
are provided in section 2.1.4. 
5.3.7 Informed consent 
All participants (proxies and patients) were fully informed that they were being 
asked to participate in a research study. Each was provided with a participant 
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information sheet (Appendix 6). A signed consent form was obtained and 
retained by the investigators. Participants who were patients were made aware 
that their case notes could be accessed by staff involved in the research and 
independent research monitors in their inspection of documentation. Their GP 
was also informed of participation in the study. All participants were provided 
with a telephone number of an independent party to contact should they wish to 
discuss participation in the research and a telephone number of an investigator 
should they have any further enquires. It was emphasised to the proxy and 
patient that any data collected would not inform treatment as it was primarily 
looking at correlation of results between patient and proxy. Participants were 
made aware that completion of the AUDIT could prompt either the patient or 
proxy to assess and address their own alcohol drinking patterns and behaviour.  
5.3.8 Confidentiality and data management 
In addition to the procedures previously detailed (section 2.1.7) each patient 
and proxy pair was given a unique identifier within the study in order to link the 
results of both completed AUDIT questionnaires. This identifier was exclusive to 
the study and it was not possible to identify the patient from this number. The 
results of each AUDIT completed, the 4AT assessment and further questions 
completed by the proxy regarding relationship to the patient were entered into 
an anonymised data collection sheet for analysis.  
5.3.9 Ethics 
The study was granted ethical approval by the West of Scotland Research Ethics 
Committee 3 on 27 January 2015 (REC reference: 15/WS/0014 Chair: Dr Adam 
Burnel) (Appendix 5). Further ethical approval was granted to add a second site 
(Queen Elizabeth University Hospital) on 17 November 2015 and to extend the 
study for 12 months on 18 February 2016. 
5.3.10 Statistical Analysis 
All data were found to be non-parametric data and as such each factor was 
described using the median and IQR (179). A Wilcoxon signed-rank test was used 
to analyse whether the distribution of answers given by the patient and the 
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proxy significantly differed. As multiple testing was performed on the data a 
Bonferroni adjustment was made to the p values to reduce the Type I error 
(182). A Type I error would mean that significant differences between the proxy 
and patient AUDIT answers could be falsely demonstrated (182). Answers given 
by patient and proxy were then tested to identify the interrater level of 
agreement using a weighted Cohen’s Kappa. A weighted Cohen’s kappa was used 
as it would assign more significance to greater levels of disagreement between 
patient and proxy. As a threshold score of 8 has been used to identify those with 
‘problem drinking’ further analysis was performed to assess levels of agreement 
using this score using a weighted Cohen’s Kappa. 
5.4 Results 
5.4.1 Demographics 
One hundred and thirty-one proxies were recruited to the study across the 2 
recruitment sites. Of the 131 proxies, only 37 (28.2%) patients were recruited. 
The low recruitment rate was caused by a range of factors. Thirty-four (26.0%) 
patients died whilst in ICU and could therefore not be recruited, 31 (23.7%) were 
discharged from hospital before they were recruited, 13 (9.9%) were transferred 
to a different hospital prior to discharge, 6 (4.6%) declined to take part in the 
study, 4 (3.1%) patients did not have capacity to complete the AUDIT following 
screening with the 4AT. Of the remaining patients, 1 (0.8%) patient was under 
arrest and therefore could not be recruited and 5 (3.8%) patients remained Level 
3 admissions at the end of the recruitment period. 
Of the 37 proxy-patient pairs recruited the majority of proxies (35.1%) were the 
partner of the patient. 29.7% of proxies were the patient’s child, 16.2% were 
parents of the patient, 13.5% of proxies were siblings of the patient and the 
remaining 5.4% were friends of the patient. The most frequent reported contact 
with the patient was in person in 27 (73.0%) cases, whilst 8 proxies and patients 
spoke most frequently by telephone (21.6%) or in 2 (5.4%) cases by text. The 
majority of proxies (73%) reported contact with the patient on a daily basis, 
whilst 7 (18.9%) proxies described weekly contact. Only 2 (5.4%) proxies had 
contact with the patient on a monthly basis, whilst 1 (2.7%) proxy had contact 
with the patient every 6 months. 
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5.4.2 Proxy and patient assessment of alcohol 
The median total AUDIT score from the proxy assessment was 4 (IQR 0-9). The 
median total AUDIT patient score was 3 (IQR 0-8). There was no significant 
difference found between the total score for the AUDIT for proxy or patient 
(p=0.54). Moderate agreement was demonstrated between patients and proxies 
when assessing total AUDIT scores, with a kappa statistic of 0.51 (p=4.67-05) 
(Table 5-3). 
A score of 8 has been suggested as a threshold for problematic drinking by the 
AUDIT’s authors (336). When scored by the proxy, 13 patients (35.1%) achieved 8 
or above on the AUDIT tool, with 10 patients (27.0%) achieving a score of 8 or 
above on self-reporting. When assessing levels of agreement using a threshold 
value of 8, a Kappa statistic of 0.67 (p=4.67-05) was demonstrated between 
patients and proxies suggesting substantial agreement between groups (356). 
Each group of questions within the AUDIT was subsequently analysed. The initial 
3 questions concern hazardous alcohol consumption with the median proxy group 
score of 3 (IQR 0-6) and the median patient group score of 3 (IQR 0-6). There 
was no significant difference found between the proxy and patient answers 
(p=0.61). The second 3 questions concern alcohol dependence symptoms, with 
the proxy group median of 0 (IQR 0-0) and patient median of 0 (IQR 0-0). There 
was no significant difference found between the proxy and patient answers 
(p=0.96). The final 4 questions concern harmful alcohol consumption, with a 
median proxy group score of 0 (IQR 0-2) and a median patient group score of 0 
(IQR 0-2), again there was no significant difference found (p=0.71).  
Proxy and patient answers for each question were then analysed in turn. There 
was no significant difference demonstrated in the answers between proxy and 
patient (Table 5-2). Differing levels of agreement were noted between individual 
AUDIT questions. Using a kappa value of 0.41 or above to identify agreement, 5 
questions had at least moderate agreement between patient and proxy (Table 5-
3).  
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Table 5-2 Distribution of patient and proxy responses to AUDIT questions 
AUDIT Question Patient median 
score (IQR) 
Proxy median 
score (IQR) 
p 
value 
1. Frequency of alcoholic drink 1 (0-2) 1 (0-3) 0.30 
2. Typical number of drinks 
consumed per day 
1 (0-2) 1 (0-2) 0.62 
3. Frequency more than 1 drink 0 (0-2) 1 (0-2) 0.33 
4. Unable to stop drinking in past 
year 
0 (0-0) 0 (0-0) 0.52 
5. Failed to do what was normally 
expected 
0 (0-0) 0 (0-0) 0.72 
6. Drink first thing in the morning 0 (0-0) 0 (0-0) 0.58 
7. Guilt or remorse following 
alcohol 
0 (0-0) 0 (0-0) 0.80 
8. Inability to remember previous 
night’s events due to intoxication 
0 (0-0) 0 (0-0) 0.61 
9. Someone else injured because of 
respondents alcohol intake 
0 (0-0) 0 (0-0) 0.09 
10. Someone else suggesting a 
reduction in alcohol intake 
0 (0-0) (0-0) 0.32 
Total AUDIT score 3 (IQR 0-8) 4 (IQR 0-9) 0.54 
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Table 5-3 Levels of agreement between patient and proxy responses to AUDIT 
questions 
AUDIT Question Kappa value Z statistic p value 
1. Frequency of 
alcoholic drink 
0.79 6.86 6.87-12 
2. Typical 
number of drinks 
consumed per 
day 
0.56 4.69 2.73-06 
3. Frequency 
more than 1 drink 
0.61 5.16 2.42-07 
4. Unable to stop 
drinking in past 
year 
0.28 2.20 0.03 
5. Failed to do 
what was 
normally 
expected 
0.15 1.23 0.22 
6. Drink first 
thing in the 
morning 
0.21 1.47 0.14 
7.Guilt or 
remorse following 
alcohol 
0.41 3.95 7.70-05 
8. Inability to 
remember 
previous night’s 
events due to 
0.38 3.23 0.01 
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intoxication 
9. Someone else 
injured because 
of respondents 
alcohol intake 
-0.05 -0.33 0.74 
10. Someone else 
suggesting a 
reduction in 
alcohol intake 
0.59 3.95 7.84-05 
Total AUDIT score 0.51 4.08 4.55-05 
AUDIT score of 8 0.67 4.07 4.67-05 
 
5.5 Discussion 
5.5.1 Interpretations of findings 
5.5.1.1 Use of a proxy to provide an alcohol history 
This study is understood to be the first study in the literature to examine the use 
of a proxy in ICU to provide an alcohol history. There is a paucity of research 
investigating use of a proxy for any history-taking in ICU despite the widespread 
use of a collateral historian to provide information on behalf of a patient who is 
often unable to provide their own history due to critical illness, drugs or 
intubation. However, given the under recruitment in this study the results can 
only be used to indicate possible associations and as such it is not possible to 
form firm conclusions. 
Furthermore the results of this study demonstrate that there is no significant 
difference in both levels of agreement and distribution of total AUDIT scores 
reported by proxy or patient. This suggests that a proxy could be used to provide 
an accurate reflection of the patient’s alcohol intake, which would be useful to 
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aid recognition and early treatment of alcohol withdrawal. This study supports 
the findings of previous research, which demonstrated agreement between proxy 
and patient scores following completion of the AUDIT in trauma patients (345). 
The study reported by Donovan et al. in 2004 consisted of patients presenting to 
a single centre American ED and participants were predominantly young, white 
males (345). Whilst the study recruited good numbers of patients, almost half of 
the American patients had undergone treatment for alcoholism in the past (345). 
Unlike the study performed by Donovan et al., the study reported in this chapter 
recruited patients irrespective of a known or suspected alcohol use disorder.  
Due to poor recruitment, no firm conclusions could be made as to whether the 
type of relationship, frequency of contact and mode of contact between proxy 
and patient has a role in determining the correlation of AUDIT results. However, 
studies investigating the use of a proxy in reporting QOL for critically ill patients 
have found that living in the same household or the type of relationship between 
proxy and patient did not influence results (357, 358). One Italian paper 
reported on QOL prior to ICU for 172 patients with critical illness (357). The 
authors reported similar difficulties in recruitment with exclusion of patients 
who were unable to co-operate with the questionnaire, concluding that the 
results would potentially exclude those with the most severe critical illness 
(357). Of note, the study reported greater concordance in topics covering 
physical or witnessed impairment rather than emotional impairment (357). This 
may equate to differences observed between patient and proxy agreement in 
questions in the AUDIT, reported in this study. Similarly, a UK study of 99 
patients admitted to ICU reported agreement between patients and proxies in 
functional aspects of QOL (358). This study reported significant loss to follow-up 
with patients excluded due to age, lack of willingness to participate or inability 
to administer the questionnaire due to timing of discharge (358). 
Using a threshold value of 8 scored on the AUDIT, substantial agreement was 
demonstrated between patient and proxy when identifying the incidence of a 
suspected problem with alcohol consumption, with 35.1% of proxies identifying a 
problem and 27.0% of patients self-reporting problem-drinking. These figures are 
comparable to the incidence of an alcohol use disorder in ICU patients which was 
reported to be 35% in a study at the same centre (187). Other investigations 
report the incidence of an alcohol use disorder to be between 16.7%-33% in the 
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general ICU population (305, 307, 359-361). The choice of a value of 8 in the 
AUDIT to identify those with problem drinking has been debated within the 
literature (362). The original AUDIT cut-off score was 11 and a decrease was due 
in part to a reduction in drink drive limits, however, this differs between 
countries (362). Further, there remains discussion regarding use for specific cut-
off scores for different populations of patients and for alternative uses such as 
prediction of risk or intervention (362). 
Interestingly, the number of proxies who scored a relative or friend as a problem 
drinker exceeded the number of patients who identified themselves as such. 
Patients may under-report their alcohol consumption or falsely answer questions 
regarding their behaviour due to denial of their alcohol intake or reluctance to 
share sensitive information as they are concerned that this may not be kept 
confidential or prejudice future medical care (346, 363-365). Over-reporting of 
alcohol consumption by the proxy may reflect their attitude or a lack of 
awareness regarding the patient’s behaviour (345). The proxy may feel that this 
is one route to highlight their concerns and a means to seek help for the patient 
(345).  
The distribution of patient and proxy scores were similar for each question 
across the different subgroups of hazardous alcohol consumption, harmful 
alcohol consumption and alcohol dependence. Levels of agreement differed 
between questions, however, at least moderate agreement was identified in half 
of the questions. The first 3 questions in the AUDIT score cover frequency and 
quantity of alcohol consumption and showed good levels of agreement, which is 
perhaps not surprising for objective or witnessed actions. Further, it is 
reassuring that there was agreement for subjective questions such as guilt after 
drinking. This finding mirrored that of the previous study of trauma patients 
(345). Poorer levels of agreement were shown in questions covering dependence 
symptoms such as impaired control and salience, which are perhaps difficult to 
assess on behalf of another individual. Poor agreement was demonstrated in 
questions covering memory problems due to alcohol and morning drinking which 
may be explained by the fact that these behaviours can be unwitnessed and 
without explicitly asking the patient a proxy is unable to provide this 
information. Without a comparative population it is difficult to determine 
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whether the spread of scores across questions was representative of other 
critically unwell individuals.  
5.5.1.2 Incidence of delirium and cognitive impairment 
Prior to recruitment all patients were screened for delirium and cognitive 
impairment using the 4AT. Of the patients who survived their ICU stay only 4 
(8.5%) of the possible 47 approached for recruitment screened positive for 
cognitive impairment or delirium. With up to 80% of ICU developing delirium this 
number is perhaps lower than expected (366). As delirium is known to extend 
ICU length of stay and mortality it would have been useful to identify whether 
those who died or remained in Level 3 care during the study would have 
screened positive for delirium whilst in ICU. The low incidence of delirium in our 
cohort may be explained by the resolution of delirium by the time of testing, a 
lower incidence of delirium in the study sites or it may be that a large 
proportion of those with delirium did not survive to ICU discharge. 
5.5.2 Limitations 
This study suggests that a proxy can be used to provide information regarding 
alcohol consumption in critically ill patients admitted to ICU. However, these 
findings are based on the results of a screening questionnaire and due to the 
study design no clinical information was recorded. Whilst the use of 
questionnaire based screening tools have been proven to be more sensitive than 
biochemical results such as GGT, CDT and liver function tests, using such tests 
may have added to accuracy regarding findings (319). 
There was a considerable loss to follow up within this study and, despite the 
addition of a second site for recruitment, the numbers of patients recruited 
remained low. A significant number of patients with proxies died prior to 
completion of the AUDIT. It is well established that the critically ill with alcohol 
use disorders have a higher mortality and it is possible that the subgroup of 
patients recruited may have been skewed towards those without an alcohol use 
disorder (187). Furthermore, as a member of the study team was not 
permanently present in the ICU or GRI a number of patients were discharged 
prior to enrolment. This could mean that individuals with a short length of stay 
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in hospital, potentially those who with fewer chronic co-morbidities were not 
recruited.  In any future study it would be useful to record clinical and 
demographic data to facilitate analysis of those individuals recruited and seek 
permission to follow up discharged patients in a postal survey. 
Although the AUDIT has been validated in a number of different populations at 
present this has not included a population of ICU patients. A number of studies 
conclude that the cut-off score of 8 suggested by the authors should be lowered 
for females or older patients (339). Without large numbers and demographic 
data it is not possible to analyse such subgroups within this study. In this study, 
focussing on levels of agreement between total AUDIT scores and the threshold 
value of 8 rather than upon individual questions aimed to reduce the error 
introduced by small numbers of participants. It was acknowledged that a greater 
number of participants would be required to improve the power of the study and 
reduce the probability of a type 2 error. 
Furthermore, assessment of interrater agreement with small numbers of 
participants is challenging and introduces the concepts of precision and accuracy 
in determining utility of a test and in this study, the utility of a proxy (356). The 
kappa statistic was chosen as it reported precision. It was decided that this 
would provide information on the magnitude of agreement between patient and 
proxy, rather than focussing upon the accuracy of agreement for individual 
questions (356). The kappa statistic is altered by both prevalence of the disease 
(alcohol use disorder) and bias, both of which are beyond the scope of this 
thesis, but it is important to acknowledge that any further studies beyond this 
prospective study would need to address such issues. 
5.6 Conclusion 
This chapter discusses the results of a prospective study to evaluate the use of a 
proxy to provide accurate information on alcohol consumption and behaviour for 
patients admitted to ICU using the AUDIT. The results illustrate: 
• Substantial agreement between proxy and patient in the identification of 
an alcohol use disorder using the AUDIT and predetermined threshold 
score of 8 
  160 
 
• Moderate levels of agreement and no significant difference in the 
distribution of total AUDIT scores between proxy and patient  
• No significant difference between proxy and patient in each of the 3 
subgroups of AUDIT questions examining hazardous alcohol consumption, 
harmful alcohol consumption and alcohol dependence 
• 8.5% of ICU survivors approached for recruitment screened positive for 
cognitive impairment or delirium 
This chapter evaluates the use of a proxy to aid identification of ICU patients 
with alcohol use disorders and identify those at risk of alcohol withdrawal. The 
next chapter will explore long-term survivorship in critically ill cirrhotic 
patients.  
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Chapter 6 The factors associated with long-term 
outcome of patients admitted to 
intensive care with cirrhosis 
6.1 Introduction 
Chapter 4 explored the utility and timing of Child-Pugh score in predicting ICU 
and hospital outcome in critically ill cirrhotic patients whilst Chapter 5 
investigated the use of a proxy to report alcohol history once a patient is 
admitted to ICU. This chapter investigates the long-term survival of patients 
with cirrhosis admitted to a UK general intensive care unit.  
6.2 Survivorship following admission to intensive care of 
individuals with cirrhosis 
6.2.1 Short-term survival 
Short-term survival of critically ill patients with cirrhosis has been discussed in 
detail earlier in this thesis (section 1.5.7). Short-term outcomes for critically ill 
cirrhotics have been reported since the 1980s when ICU mortality was stated to 
be up to 100% in patients with septic shock, severe cirrhosis, acute hepatitis or 
renal failure (5-7). Both ICU and hospital mortality have improved with the most 
recent study of short-term outcome in the UK reporting a 31% ICU mortality and 
46% hospital mortality (120). However, mortality figures increased in those with 
liver disease caused by alcohol, compared to those of other aetiologies (120). 
The short-term outcome of the critically ill cirrhotic population studied in this 
chapter are comparable to other contemporary studies and report an ICU 
mortality of 30% and hospital mortality of 46% (18). 
6.2.2 Long-term survival 
Whilst both ICU and hospital mortality have been extensively reported, there are 
fewer studies examining long-term survival of critically ill cirrhotic patients 
beyond 6 months. The 6-month mortality of those with cirrhosis of any aetiology 
admitted to a general ICU has been reported as 56% at in a German study (177). 
A meta-analysis, published in 2017, of 13 studies examining 2523 critically ill 
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cirrhotic patients reported 6-month mortality at 75.1% (367). Only 3 of the 
studies included were performed outwith tertiary referral centres, with just 1 of 
those 3 studies reporting outcome at 1-year. This French study of patients 
admitted to ICU with severe hepatic encephalopathy reported 1-year mortality 
at 54% (368). Additionally, 1-year mortality was reported in an American study of 
420 critically ill cirrhotics admitted to ICU in a tertiary referral centre offering 
liver transplantation, demonstrating a 1-year mortality of 69% and a 5 year 
mortality of 77% (167).  
Aetiology of underlying liver disease may influence long-term mortality with a 
Scottish tertiary liver ICU reporting a 78%, 6-month and 81%, 12-month mortality 
in those with decompensated alcoholic liver disease (369). A recent study 
published national Scottish mortality data for those with alcoholic liver disease 
admitted to ICU (4). The authors reported an ICU mortality of 44% and a 5-year 
mortality of 79.2% for those admitted between 2005 to 2010 (4). Long-term 
mortality was greater than other critically ill patients including those admitted 
with chronic disease such as severe cardiovascular, respiratory or renal disease, 
where 5-year mortality was reported as 75.3% (4).  
6.2.3 Factors known to affect survival 
A range of different clinical factors have been shown to predict survival in 
critically ill cirrhotics. The underlying cause of admission to ICU is known to 
impact upon long-term survival in cirrhosis secondary to alcoholic liver disease 
(369). Individuals admitted to a Scottish tertiary ICU with sepsis had a higher 
mortality than individuals presenting with gastrointestinal haemorrhage or 
encephalopathy (369). This has been reflected in a number of studies reporting 
lower mortality in critically ill cirrhotics of any aetiology presenting with upper 
gastrointestinal haemorrhage (118, 123). Indeed, in the specific subgroup of 
cirrhotics requiring intensive care due to an upper gastrointestinal haemorrhage, 
6-month mortality has been reported to be as low as 50%, with a 92% mortality 
for cirrhotics requiring Level 3 care for other reasons (118). Admission with 
severe encephalopathy or sepsis has been widely demonstrated to predict both 
poor short and long-term survival (118, 123, 367). 
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Whilst few studies support any demographic associations with survival, one 
French study of 138 patients reported that age greater than 50 to be predictive 
of initial ICU mortality (117). Opinion differs regarding the predictive value of 
the clinical findings of liver disease, with the same study finding no prognostic 
value in the presence or severity of ascites or varices (117). The study 
performed by Campbell et al. examining short-term outcomes found that the 
presence of ascites predicted ICU mortality in a London dataset of patients (18). 
However, both short and long-term mortality in a separate cohort of cirrhotic 
patients was associated with the presence of jaundice in combination with a 
high APACHE III score and requirement for vasopressor (167). Short-term 
mortality in critically ill cirrhotics has been associated with higher 
measurements of INR or PT ratio, bilirubin, ALT, creatinine, lower albumin levels 
and the presence of HRS (18, 116-118, 367, 370). 
Severity of acute illness, measured by the number of separate organ failures has 
been demonstrated to predict in-hospital mortality (117, 127). A number of 
studies report an association between both short and long-term mortality and 
higher severity of illness scores such as APACHE II and APACHE III (119, 123, 167). 
The SOFA score has been demonstrated to predict short-term mortality (367, 
370). One recent meta-analysis which examined mortality following ICU 
admission concluded that Child-Pugh class C and MELD predicted outcome at 6 
months (367). 
Requirement for interventions such as mechanical ventilation, vasopressors or 
renal replacement therapy whilst in ICU has been demonstrated to be associated 
with poor short and long-term survival (118, 119, 123, 127, 167, 367, 370). In the 
cohort of patients reported in this study a previous investigation demonstrated 
that lactate was an independent predictor of ICU mortality and a modified 
scoring system of Child-Pugh + Lactate was proposed (17, 18). Furthermore, a 
retrospective cohort analysis of critically ill cirrhotics demonstrated that in 
those who developed renal failure, the degree of renal dysfunction determined 
both ICU and hospital mortality, as did the presence of septic shock (125). 
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6.3 Study question and aims 
6.3.1 What is the long-term survival of patients admitted to 
intensive care with cirrhosis? 
Multiple studies demonstrate that the short-term survival of patients with 
cirrhosis admitted to intensive care is improving. However, there are few studies 
reporting the long-term survivorship of patients with cirrhosis admitted to 
intensive care outwith tertiary referral centres or beyond 6 months. Information 
on the long-term outcomes could inform the clinical decision whether to admit 
patients to ICU and give valuable information to patients who have the capacity 
to make the decision to undertake intensive treatment.   
6.3.2 Aims 
In a cohort of critically ill patients with chronic liver disease admitted to a 
general non-transplant ICU in Glasgow: 
• To identify the 12 month survival of those individuals with cirrhosis 
• To detect any factors associated with patient survival at 12 months 
• To explore the predictive ability of existing scoring systems in 
determining long-term outcome 
6.4 Methodology 
6.4.1 Design 
This is an observational cohort study of adult patients with liver cirrhosis 
admitted to GRI ICU between June 2012 and December 2013. The short-term 
outcomes of this population have already been published (18). The study site has 
been described in section 2.1.4. 
The ICU at GRI utilises electronic patient record systems, enabling clinical data 
to be collected prospectively at the time of ICU admission. Demographic data 
collected included age, gender, reason for ICU admission and aetiology of liver 
  165 
 
disease. Postcode of each patient was recorded which enabled calculation of the 
SIMD (40). For the purpose of this study if a patient lived in one of the 20% most 
deprived areas they were considered to be socially deprived (40). 
6.4.2 Participants 
Participants were diagnosed with cirrhosis if they had a documented positive 
liver biopsy or clinical features of cirrhosis such as evidence of portal 
hypertension, ascites or encephalopathy or oesophageal varices (18). Patients 
displaying signs of liver cirrhosis on ultrasound were also included. All diagnoses 
of liver cirrhosis were checked by a second independent clinician who was a 
consultant intensivist at GRI. 
6.4.3 Ethics 
This research was approved by the West of Scotland Research Ethics Committee 
on 20 March 2012 (REC reference; 12/WS/0039 Chair; Dr Gregory Ofili).  
 
6.4.4 Statistical analysis 
Bivariate analysis was performed to determine whether there were any 
relationships between measured variables and survival at 12 months. Normally 
distributed data were assessed using the independent t-test and presented as 
mean and standard deviation. Data found to be non-parametric were assessed 
using the Mann-Whitney U test and described as median and IQR. Proportions 
were compared using the Chi-squared test for association. 
Multivariate analysis was then performed to examine the relationship between 
multiple variables and mortality at 12 months. As mortality is a categorical 
variable a stepwise backward multivariate logistic regression model was used to 
assess the relationship between independent clinical variables and mortality.  
Survival analysis was performed to determine the survival of this population of 
critically ill cirrhotics. The variable of interest was time until death. Cumulative 
survival was plotted against days of survival following ICU admission. In order to 
determine patient survival following ICU admission, data were analysed using 
Kaplan–Meier curves. Three curves were plotted to reflect survival of Child-Pugh 
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Class A, Class B and Class C. Using each Kaplan-Meier curve it was possible to 
estimate survival at any time point from ICU admission. A log rank test was used 
to determine whether there was a statistically significant difference in survival 
between each Child-Pugh class. 
ROC curves were then plotted for different scoring systems used within critical 
care and chronic liver disease. To ascertain the performance of each scoring 
system for this population the AUC for each ROC curve was calculated (200).  
6.5 Results 
6.5.1 Demographics 
Between June 2012 and December 2013 there were 611 admissions of critically 
ill patients to GRI ICU. Of these admissions, 84 (13.7%) were identified with 
cirrhosis (Figure 6-1). Of those with cirrhosis the mean patient age was 50.2 
years (+/-11.2) and 59 (70.2%) were male (Table 6-1). Fifty-six (66.7%) 
individuals with cirrhosis lived in an area of social deprivation. Liver disease 
secondary to excessive alcohol intake was the most common cause of cirrhosis in 
this cohort and was found in 70 (83.3%) admissions.  
In 68 (81.0%) individuals included in the study this was their first admission to 
ICU (Figure 6-1). The remaining 16 (19.0%) were readmissions to the unit within 
the same hospital stay and were excluded from survival analysis. No patient had 
previously been admitted to this ICU on a previous hospital admission. The mean 
ICU length of stay was 5 days (IQR 1-12.8) (Table 6-1).  
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Figure 6-1 Flowchart of patient recruitment 
 
At the time of arrival to the ICU, 58 admissions (69.0%) were receiving 
mechanical ventilation, with pneumonia the most common diagnosis in 19 
(22.6%) of all admissions with cirrhosis. ICU admissions were of varying 
aetiologies as outlined in Table 6-1.  
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Table 6-1 Demographics and clinical variables of 68 cirrhotics admitted to a 
general ICU 
 All 
admissions 
(n=68) 
Survivors at 12 
months (n =30) 
Non-
survivors at 
12 months 
(n=38) 
p value 
Age (mean +/- SD, 
range) 
51.2 +/- 
11.5, (29-
80) 
48.5 +/- 10.3, 
(29-64) 
53.3 +/- 
12.0, (32-80) 
0.125 
Male gender, n (%) 45 (66.2) 21 (70.0) 24 (63.2) 0.738 
SIMD quintile, 
median (IQR) 
1 (1-2) 1 (1-2) 1 (1-2) 0.633 
Social deprivation, 
n (%) 
56 (82.4) 25 (83.3) 31 (8.6) 1 
Alcohol-related 
disease, n (%) 
55 (80.9) 24 (80.0) 31 (81.6) 1 
Ventilated on 
admission, n (%) 
52 (76.5) 25 (83.3) 27 (71.1) 0.369 
ICU admission reason 0.141 
Pneumonia/ARDS, 
n (%) 
23 (33.8) 10 (33.3) 13 (34.2)  
GI Haemorrhage, n 
(%) 
10 (14.7) 5 (16.7) 5 (13.2)  
Sepsis, n (%) 5 (7.6) 0 (0.0) 5 (13.2)  
Encephalopathy, n 
(%) 
4 (5.9) 2 (6.7) 2 (5.3)  
GI perforation, n 
(%) 
3 (4.4) 0 (0.0) 3 (7.9)  
Trauma/Burns, n 
(%) 
5 (7.6) 3 (10.0) 2 (5.3)  
Decompensated 
cirrhosis, n (%) 
3 (4.4) 0 (0.0) 3 (7.9)  
Seizures, n (%) 4 (5.9) 3 (10.0) 1 (2.6)  
Othera, n (%) 7 (11.9) 4 (13.3) 3 (7.9)  
Drug related, n (%) 3 (4.4) 3 (10.0) 0 (0.0)  
Pancreatitis, n (%) 1 (1.5) 0 (0.0) 1 (2.6)  
Length of ICU stay 
(Days), median 
(IQR) 
4.5 (1.0-
12.0) 
4 (1.25-12.0) 5 (1.0-8.8) 0.323 
Sodium (mEq/L), 
median (IQR) 
136.5 
(132.0-
142.0) 
139.0 (135.0–
142.8) 
133.0 (131.0–
140.0) 
0.035 
Potassium 
(mEq/L), median 
(IQR) 
3.8 (3.5-
4.4) 
3.8 (3.5-4.2) 3.9 (3.5-4.7) 0.418 
Urea (mmol/L), 
median (IQR) 
8.1 (4.0-
12.3) 
6.0 (3.5-11.2) 9.2 (4.4-14.1) 0.112 
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 All 
admissions 
(n=68) 
Survivors at 12 
months (n =30) 
Non-survivors 
at 12 months 
(n=38) 
p value 
Lactate (mmol/L), 
median (IQR) 
2.0 (1.4-
2.7) 
1.5 (1.1-2.1) 2.4 (1.7-5.3) 0.003 
Bilirubin (µmol/L), 
median (IQR) 
47.5 (19.8-
111.3) 
25.5 (14.0-57.0) 74.0 (40.8-
206.0) 
<0.001 
Creatinine 
(µmol/L), median 
(IQR) 
81.0 (57.0-
151.8) 
71.5 (57.0-
109.0) 
131.5 (60.8-
192.3) 
0.080 
White cell count 
(×10−9/L), median 
(IQR) 
12.4 (7.8-
17.3) 
13.5 (8.1-17.3) 10.4 (7.6-
17.2) 
0.422 
Albumin (g/L), 
median (IQR) 
20.5 (17.0-
26.0) 
24.0 (19.3-28.0) 18.0 (16.0-
22.5) 
0.001 
PT ratio, median 
(IQR) 
1.5 (1.2-
2.1) 
1.3 (1.1-1.5) 1.8 (1.5-2.5) <0.001 
Platelet count 
(×10−9/L), median 
(IQR) 
103.5 
(75.8-
164.3) 
133.5 (93.8 – 
186.8) 
90.5 (59.3 -
132.3) 
0.009 
PaO2/FiO2 ratio 
(kPa), median 
(IQR) 
21.8 (12.5-
36.4) 
29.3 (15.1-40.0) 18.0 (11.7-
32.3) 
0.342 
Glasgow coma 
score, median 
(IQR) 
10.0 (3.0-
14.0) 
9.0 (3.0-11.0) 11.0 (3.0-
15.0) 
0.333 
Ascites, n (%) 27 (39.7) 7 (23.3) 20 (52.6) 0.012 
Encephalopathy, n 
(%) 
24 (35.3) 9 (30.0) 15 (39.5) 0.800 
 
a Other includes urinary tract infection, renal failure, respiratory failure (not 
secondary to infection and does not meet criteria for ARDS), acute cholecystitis, 
biliary obstruction, diabetic ketoacidosis and post-cardiac arrest 
 
6.5.2 Factors predictive of long-term survival  
Following bivariate analysis, a number of factors were associated with survival at 
12 months (Table 6-1). They included increased arterial lactate (p=0.003), serum 
bilirubin concentration (p<0.001), PT ratio (p<0.001), serum albumin (p=0.001), 
ascites (p=0.012), serum sodium concentration (p=0.035) and platelet count 
(p=0.009). No significant association was found between 12-month survival and 
an underlying aetiology of alcohol or social deprivation.  
As readmission to ICU during the same hospital stay is both a subjective and 
multifactorial decision this was removed from further analysis. Multivariate 
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analysis revealed age (OR 1.09, 95% CI 1.03-1.15, p=0.002), arterial lactate on 
admission (OR 1.57, 95% CI 1.12-2.20, p=0.01), serum bilirubin on admission (OR 
1.01, 95% CI 1.00-1.02, p=0.015) and PT ratio on admission (OR 4.82, 95% CI 
1.38-16.82, p=0.014) were all significantly associated with long-term survival 
(Table 6-2).  
Table 6-2 Factors predictive of mortality at 12 months following logistic 
regression analysis 
 Odds ratio 95% confidence interval p value 
Age (years) 1.09 1.03, 1.15 0.002 
Lactate (mmol L-1) 1.57 1.12, 2.20 0.010 
PT ratio 4.82 1.38, 16.82 0.014 
Bilirubin (μmol L-1) 1.01 1.00, 1.02 0.015 
 
6.5.3 Scoring systems and survival prediction 
A number of existing scoring systems for survival prediction in critical illness and 
chronic liver disease were applied to this population. They included APACHE II, 
SOFA, CLIF-SOFA, SOFA-Lactate, Child-Pugh, MELD, UKELD, RFH and Child-Pugh + 
Lactate. All scoring systems were found to predict mortality at 12 months, with 
statistically significant values (p<0.001). The p value for Child-Pugh score was 
slightly higher but remained statistically significant (p=0.001). There were no 
significant differences between the scoring systems based upon 95% confidence 
intervals. Only two scoring systems had AUC of over 0.80, the threshold for 
clinical use. They were MELD (AUC=0.82, 95% CI 0.74-0.91) and Child-Pugh + 
Lactate (AUC=0.80, 95% CI 0.71-0.90) (Table 6-3).  
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Table 6-3 Utility of scoring systems predicting 12-month outcome in patients 
with cirrhosis admitted to a general ICU 
 Area under ROC curve 95% Confidence Interval 
APACHE II 0.763 0.662, 0.864 
SOFA 0.748 0.642, 0.855 
CLIF-SOFA 0.782 0.684, 0.880 
SOFA-Lactate 0.769 0.667, 0.871 
Child-Pugh 0.718 0.609, 0.828 
MELD 0.823 0.735, 0.911 
UKELD 0.778 0.675, 0.882 
RFH 0.779 0.679, 0.879 
Child-Pugh + Lactate 0.804 0.712, 0.896 
 
6.5.4 Long-term survival  
Following removal of readmissions to ICU, the survival of 68 ICU admissions with 
cirrhosis was analysed. Twenty-four (35.2%) patients did not survive to ICU 
discharge and a further 12 (17.6%) died prior to hospital discharge. Following 
hospital discharge a further 2 (2.9%) patients died. Cumulative mortality at 12 
months following ICU admission was 55.9% (Figure 6-2). 
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Figure 6-2 Kaplan-Meier curve of the survival of 68 patients admitted to a 
general ICU with cirrhosis 
 
6.5.5 Child-Pugh and survivorship 
Sixty-eight patients were grouped into Child-Pugh Class A, B and C based on 
their clinical and laboratory findings measured on arrival to ICU. Six (8.8%) 
patients were found to be Child-Pugh Class A, whilst the majority were Class B 
(34 patients, 50.0%) and Class C (28 patients, 41.2%) (Table 6-4). Kaplan-Meier 
curves for 12-month survival for each Child-Pugh Class were plotted and a 
significant difference (p=0.002) was found between the different grades (Figure 
6-3). Mortality at 12 months was 0.0% for those in Child-Pugh Class A on ICU 
admission, 50.0% for those in Child-Pugh Class B and 75.0% in Child-Pugh Class C. 
Table 6-4 Child-Pugh score on admission to ICU and survival 
 Child-Pugh A 
(n=6) 
Child-Pugh B 
(n=34) 
Child-Pugh C 
(n=28) 
p 
value 
Alive at ICU discharge 6 (100.0%) 24 (70.6%) 14 (50.0%) 0.015 
Alive at hospital 
discharge 
6 (100.0%) 18 (52.9%) 8 (28.6%) 0.002 
Alive at 12 months 
post admission 
6 (100.0%) 17 (50.0%) 7 (25.0%) 0.001 
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Figure 6-3 Kaplan-Meier survival curve stratified by Child-Pugh class on ICU 
admission 
 
6.6 Discussion 
6.6.1 Interpretation of findings 
6.6.1.1 Long-term mortality 
This investigation represents one of the few studies in the literature that 
examines long term outcomes beyond 6 months in critically ill cirrhotics 
admitted to ICU and is the only UK study published from a non-transplant centre. 
In comparison to other studies, this cohort of patients had high levels of social 
deprivation and the majority had an underlying aetiology of alcoholic liver 
disease. 
Recent studies in the literature suggest that both short and long-term survival 
for critically ill cirrhotics is improving. The ICU mortality in this study is 
comparable to other recent UK studies reporting ICU mortality to be 31-38% 
(120, 156). However, in our study only 41.2% were classified Child-Pugh C. In 
similar studies in the literature which examine the outcome of critically ill 
cirrhotics the incidence of Child-Pugh C is between 53-89% when scored on ICU 
admission (156). This may mean that the patients in our cohort had less severe 
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disease and as such lower mortality would be expected. Moreover, the mortality 
found in the present cohort is lower than the ICU mortality of patients with 
alcoholic liver disease admitted to all ICUs in Scotland between 2005 and 2010 
(4). The higher mortality outlined by Lone et al. incorporated outcomes from all 
critical care units in Scotland, including a tertiary referral centre offering liver 
transplantation and excluded cirrhotics of non-alcoholic aetiologies (4). Our 
study did not show any association between survival and an underlying aetiology 
of alcoholic liver disease. This finding may have occurred due to the high 
incidence of underlying alcoholic liver disease in this cohort or reflect other 
research which fails to demonstrate a link between aetiology of alcohol and 
mortality (367).  
Hospital mortality in this cohort is comparable to the conclusions of a meta-
analysis of 13 studies published in 2017 (367). However, a recent large UK study 
of 31,363 ICU admissions of patients with cirrhosis demonstrated lower hospital 
mortality of under 50% (120). Without examining the details for each hospital 
death it is not possible to deduce the reasons behind the mortality differences. 
It would be helpful to explore whether cirrhotics who died in hospital were 
denied readmission to ICU, given limits to future intervention and whether 
mortality was due to acute illness or secondary to complications of chronic liver 
disease (117). Readmission to ICU was associated with survival in this cohort and 
there are a number of potential explanations for this finding. Firstly, there are 
no data to expose the number of discharges who deteriorated following ICU 
discharge and who were not readmitted to ICU due to perceived futility by 
clinicians or patient refusal, as explored in Chapter 3. Secondly, readmissions 
can incorporate patients who have potentially reversible complications from an 
intensive care stay such as the PICS (4). Thirdly, those who are readmitted have 
had a period of assessment in ICU, as such there is medical insight into disease 
reversibility and the physiological reserve of a patient which is lacking in the 
initial decision to admit a patient (117).   
The 12-month mortality of 55.9% reported in this cohort of patients is consistent 
with other studies which conclude that the long-term survival of critically ill 
cirrhotics admitted to general ICUs is improving (367, 370). The overall 
improvement in mortality for critically ill patients is likely in part to medical 
advances, which include lung protective ventilation and prompt antibiotic 
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administration (371-373). Specific to cirrhotic patients are the improvements in 
use of interventions such as endoscopy and TIPS and efficacious use of 
pharmacological agents such as Terlipressin (129). It has been hypothesised that 
improved ICU survival may be due to changes in patient selection criteria, 
denying ICU admission to those least likely to survive (117). The improvement in 
survival may be due to trends in earlier referral to critical care or the 
introduction of goal-directed therapy (374). 
In this study, mortality following hospital discharge decreased suggesting that 
cirrhotic patients who recover from their acute illness have good long-term 
survival. This finding reflects other contemporary studies in the literature (117, 
371). It has been suggested that patient selection criteria for ICU admission may 
influence such results, with critical care offered only to those with good 
premorbid functional state or good physiological reserve with an improved 
chance of recovery (371).  
6.6.1.2 Factors predictive of long-term mortality 
Factors found to predict long-term mortality in this cohort of patients were age, 
serum lactate, bilirubin and PT ratio. Previous studies have demonstrated the 
predictive value of age in determining short and long-term mortality of critically 
ill patients, including those with cirrhosis (117). Age is incorporated into widely 
accepted and validated scoring systems used to measure disease severity and 
predict hospital mortality in the critically ill, such as APACHE II (163). It is now 
hypothesised that survival following ICU admission is predicted by different 
factors in two distinct phases (285). Short-term survival is determined by the 
acute illness and severity of organ failure, whilst age, chronic comorbidity and 
frailty have greater roles in predicting long-term survival (117, 285, 375). This 
may account for the predictive value of serum bilirubin and PT ratio found in 
this study, as both are recognised markers of severity of chronic liver disease. 
Indeed the significant association between liver function and long-term outcome 
has been recognised in a meta-analysis of 13 studies of cirrhotic patients 
published in 2017 (367). 
Hyperlactataemia can result from excess lactate production due to tissue 
hypoxia and anaerobic metabolism or reduced clearance, evident in chronic liver 
  176 
 
disease (376, 377). Raised serum lactate has been shown to correlate with 
mortality in those with sepsis, acute kidney injury and acute liver failure (377-
380). Furthermore, serum lactate has been demonstrated to predict short-term 
mortality in cirrhotic patients (129, 154). However, this is the first study in the 
literature to find an association between serum lactate measured on ICU 
admission and long-term mortality. It may be that those individuals with raised 
lactate on admission to ICU represent a subgroup of patients with more severe 
chronic liver disease with reduced clearance of lactate.   
6.6.1.3 Scoring systems to predict long-term mortality 
All scoring systems analysed performed well in predicting long-term mortality 
and there was no significant difference between those designed for use in the 
critically ill population and those specific to liver disease. Both MELD and Child-
Pugh+Lactate were found to have an AUC over the pre-determined threshold, 
although this is of limited use in clinical application (18, 142). A recent meta-
analysis of studies exploring outcomes in critically ill cirrhotics concluded that 
scores incorporating measures of liver function such as MELD and CLIF-SOFA 
predicted mortality at 6 months (367).  
When our cohort of patients was split into Child-Pugh group on admission there 
were statistically significant differences in long-term outcome. Whilst all 
patients graded Child-Pugh class A were alive at 12 months following admission, 
studies show the majority of patients with cirrhosis admitted to ICU are Child-
Pugh class B or C (129, 156). Child-Pugh grading does not identify which patients 
within each class have the highest risk of short or long-term mortality. The 
limitations of Child-Pugh scoring have been discussed in detail in Chapter 4 and 
the ‘ceiling’ effect described in the literature fails to discriminate the severity 
of liver disease within the Child-Pugh class C patients (288). Those patients 
scoring a maximum of 15 points in their Child-Pugh score may experience further 
deterioration in their liver function, which would not be recognised by a change 
in Child-Pugh score. Results outlined in Chapter 4 found that the change in raw 
Child-Pugh score measured when a patient was clinically stable and at the time 
of ICU admission was associated with survival. Chapter 4 further discussed how 
the components of Child-Pugh score such as albumin and PT ratio may reflect 
critical illness rather than severity of liver disease (117).  
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The Child-Pugh+Lactate score, which was described in earlier work by our 
research group, had an AUC over the predefined threshold for clinical use (201). 
However, as previously explored in this thesis, this includes measurement of 
ascites and encephalopathy, which introduce subjectivity (18, 142). The MELD 
score was also demonstrated to have reached the threshold for clinical use in 
our study but its design in listing for liver transplantation does not facilitate 
classification of patients nor is it designed for use in critical illness (156). 
6.6.2 Limitations  
Whilst the conclusions of our study are limited to a small sample of patients 
from a single centre, it is one of the few studies to report survival at 12 months 
in patients admitted to a centre which does not offer tertiary hepatology 
services or liver transplantation. This study showed that those readmitted to ICU 
during the same hospital episode had improved survival. With no assessment of 
the criteria used to inform the decision to readmit it was not possible to 
conclude what factors were deemed relevant in this decision. As with the 
majority of similar studies within the literature, the number of critically ill 
cirrhotic individuals who were not referred or readmitted to ICU is unknown. It 
would be useful in any future study to determine the characteristics and survival 
of critically ill patients who were not admitted to ICU based on futility.  
Within the group of patients admitted to ICU there was no consistent record of 
the proposed level of escalation of care, such as whether a patient would be 
offered renal replacement therapy. It is known that cirrhotics with renal failure 
have a poorer prognosis and it would be valuable to ascertain whether certain 
patients were not offered further intervention whilst in the ICU (127, 128). 
To ascertain the performance of each scoring system on this population area 
under the ROC curves were utilised. Whilst it was beyond the scope of this 
thesis, the ROC curves could have been analysed further to identify cut-off 
values and be used as a ‘rule out’ test to determine survival. An alternative 
method would be to evaluate likelihood ratios to compare test performance. It 
has been suggested in the literature that likelihood ratios give greater insight 
into the ‘rule in’ or ‘rule out’ abilities of a test and are easier to interpret 
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clinically (137). Further, to test across ROC curves a DeLong or Venkatraman test 
could be utilised, however, this was beyond the scope of this thesis. 
Whilst long-term mortality is an important outcome to measure when deciding 
whether to admit a patient to ICU, the morbidity of a patient following ICU 
survival is also of great importance. Individuals are known to experience physical 
and psychological deterioration following ICU stay (381). It would have been 
useful to know the QOL in those ICU survivors on admission to ICU, however, 
gaining baseline QOL prior to ICU admission is challenging. QOL is further 
explored in Chapter 7. In addition, inclusion of the comorbidities of critically ill 
cirrhotics would have been useful to determine whether concurrent chronic 
disease impacted upon long-term survival.         
6.7 Conclusion 
This chapter discusses the long-term survival of patients with chronic liver 
disease admitted to a UK general intensive care unit. The results illustrate: 
• An ICU mortality of 35.2%, which is in keeping with contemporary studies, 
but lower than historical cohorts 
• A decrease in mortality following hospital discharge suggesting that 
cirrhotic patients who recover from their acute illness have good long-
term survival, with lower mortality at 12 months (55.9%) following ICU 
admission than many previous studies 
• Long-term mortality was predicted by age, serum lactate, bilirubin and PT 
ratio 
• No association with an underlying aetiology of alcoholic liver disease and 
long-term outcome 
• Statistically significant differences in long-term outcome between 
different grades of Child-Pugh cirrhosis 
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• No statistically significant difference in scoring systems when used to 
predict long-term outcome 
This chapter has explored long-term mortality as a primary outcome following 
ICU admission. However, the long-term morbidity and QOL experienced by 
patients following critical illness is of equal importance and is examined in the 
next chapter. 
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Chapter 7 Quality of life and sleep disturbance in 
critical illness survivors 
7.1 Introduction 
This chapter discusses QOL and insomnia in critical illness survivors, pertaining, 
in particular to those admitted to critical care with cirrhosis.  
7.2 Quality of life 
7.2.1 Defining quality of life  
The WHO defined QOL in 1995 as an individual’s “perception of their position in 
life in the context of the culture and value systems in which they live and in 
relation to their goals, expectations, standards and concerns” (382). Defining 
QOL is complex with both subjective and objective facets (383). The WHO 
proposed 6 areas to be considered in measurement of QOL; physical functioning, 
psychological status, level of independence, social roles and relationships, 
environment and spirituality (382). However, other areas have been argued to 
impact upon QOL including work, usual activities and role functioning (384-386). 
QOL also encompasses negative aspects such as pain, dependence on 
medication, death and positive aspects such as role functioning, mobility and 
happiness (387). This research concerns health related QOL, focussing upon the 
impact of disease on an individual (388). A global assessment of health 
encompasses health status, level of function and QOL (388). 
Measurement of QOL can be discriminative at a single time point, or evaluate 
changes over a period of time (388). Tools designed to measure QOL can provide 
an overall summary of health or focus upon a specific disease, patient cohort or 
functional domain (388). Assessment of QOL provides clinicians with invaluable 
information on the impact of a disease or treatment and can help predict both 
patient outcome and future health resource utilisation (389). 
7.2.2 Quality of life following critical care admission 
As the numbers of individuals surviving critical care increase, there has been a 
shift in focus towards the QOL of those who do survive (381, 390, 391). Critical 
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care survivors have subsequent high mortality and morbidity as a consequence of 
both their critical illness and the intensive treatment strategies required for 
survival (381). Whilst there is considerable variability, a significant proportion 
will suffer physical, psychological and cognitive deterioration following critical 
care admission (392). The term ‘postintensive care syndrome’ (PICS) was 
introduced in 2012 by expert consensus at the Society of Critical Care Medicine 
conference (393). PICS incorporated any new or worsening physical, 
psychological or cognitive impairment following critical illness (393). There was 
an appreciation of the impact of critical illness on caregivers with the term PICS-
F adopted to describe this group of individuals (393).    
Assessing change in QOL is challenging in the ICU population as many individuals 
will be admitted to critical care unexpectedly, with few studies measuring QOL 
prior to admission (381). Accurately assessing QOL in hindsight incurs challenges 
with risk of recall bias and change in patient perception (394). An American 
proxy study reported that use of a proxy to measure pre-hospitalisation QOL did 
not correspond well with patient responses in those admitted to critical care 
with respiratory failure (395). 
Whilst many studies focus on QOL in those with specific diseases, studies 
reflecting the overall population of critical care survivors show QOL following 
critical care discharge is lower than the age and sex matched general population 
(396). In the majority of studies, critical care survivors show significantly lower 
scores across all domains contributing to QOL including physical and social 
functioning, mental health and role limitation (396-402). Despite the reduction 
in QOL noted following discharge for a large proportion of patients, one study 
noted 35% of critical care survivors had an improvement in QOL compared to 
their pre-admission baseline (397). Whilst deterioration in QOL may not persist 
for all survivors, few studies demonstrate any long-term improvements in both 
general and mental health (390, 398, 399, 403). 
Measurement of QOL in subpopulations of critically ill survivors has 
demonstrated marked differences based upon underlying aetiology of disease. A 
2010 systematic review of studies pertaining to QOL following intensive care 
revealed those admitted with ARDS, trauma and septic patients had the most 
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significant impairment to QOL in comparison to individuals surviving cardiac 
arrest, pancreatitis, acute kidney injury or oesophagectomy (404).  
Studies have identified a number of demographic and clinical factors believed to 
influence QOL. Age impacts upon the deterioration in QOL, with older individuals 
perceiving less loss to QOL or adapting more successfully to the change in health 
or function, particularly if they are less socioeconomically deprived and have an 
established social network (405-407). However, as Montuclard et al. note in their 
study of 1888 critical care survivors aged over 70, there remains a selection bias 
in older individuals offered intensive care (405). Those with substantial 
comorbidity and poor existing QOL less likely to gain admission to the ICU. Pre-
existing co-morbidity is known to influence both ICU and hospital survival (408). 
Change to QOL in critical care survivors is influenced by both pre-existing 
disease and functional status prior to hospital admission (406, 409, 410). 
Severity of injury in trauma patients requiring critical care is known to 
determine QOL, in addition to any surgical complications (411-413). Outwith the 
trauma population, severity of illness does not appear to influence change in 
QOL for critical care survivors (399, 414). It remains unknown which features of 
the critical care admission have the greatest influence on QOL. A number of 
studies have found that increasing length of mechanical ventilation and duration 
of stay predict QOL (406, 413, 415-417). However, this is not the case in studies 
focussing on ARDS patients (418, 419) where QOL is most influenced by the 
degree of pulmonary impairment, cognitive impairment and development of 
posttraumatic stress disorder rather than length of mechanical ventilation or 
stay (418, 419).  
7.2.3 Quality of life in liver disease 
In the literature QOL is described in patients with chronic liver disease, 
however, there are few studies of critical illness survivors with liver disease. A 
2001 American study of 353 outpatients with chronic liver disease found their 
QOL was comparable to individuals with chronic obstructive pulmonary disease 
or congestive cardiac failure and lower than the general population (420). A 
2001 Italian multicentre study measured QOL in 544 individuals with cirrhosis 
during hospital admission, following resolution of any acute illness or at 
outpatient appointment (421). In this population QOL was affected by 
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complications of disease such as pruritus, cramps and ascites, physical health, 
severity of liver disease and the number and type of medications (421). 
Aetiology of the liver disease was not found to affect QOL (421). Despite other 
studies, it remains unclear if the underlying aetiology of chronic liver disease 
can influence QOL (422). There is discussion within the literature of the effect 
on QOL of anxiety due to chronic viral disease or the emotional impact of 
ongoing alcohol intake (421). Subsequent QOL studies in those with liver disease 
in the USA, Spain, Sweden and Germany largely support the findings of 
Marchesini et al. and have concluded hypoalbuminaemia, anaemia and 
comorbidities also contribute to a reduction in QOL (420, 423-426). However, in 
results that conflict with the Italian study, a study of 203 individuals attending a 
German tertiary referral centre reported that severity of liver disease as 
measured by Child-Pugh did not correlate with QOL (425). It has been 
hypothesised that individuals diagnosed with chronic disease adapt their 
expectations for QOL with disease progression which they term ‘response shift’ 
(427). 
In the Marchesini et al. study, individuals with liver disease scored lower in all 
domains measured by the 36-Item Short Form Survey (SF-36) and Nottingham 
Health Profile (NHP) QOL questionnaires, with the exception of pain, when 
compared with the normal Italian population (421). The greatest differences 
were observed in the physical and emotional role limitation and general health 
(421). Córdoba et al. in their study of Hepatitis C, noted some deterioration in 
all domains of the SF-36 except emotional role and mental health (423). 
Younossi et al. also found as the severity of liver disease increased, the physical 
and disease-specific domains of the SF-36 declined but mental health did not 
deteriorate (420). Despite small differences between studies in the significance 
of certain domains measured to assess QOL in those with chronic liver disease 
and cirrhosis, there is universal agreement in the deterioration of QOL as 
compared to the normal population.  
7.2.4 Sleep and quality of life 
Sleep fulfils an important role in in the cognitive, psychological and physiological 
recovery of a critically unwell individual (428, 429). Within the ICU, sleep can be 
disrupted by environmental factors such as light and noise coupled with patient 
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factors including underlying medical disease, existing sleep disorders and the 
psychological upset caused by critical illness (429). Survivors of critical illness 
are known to have impaired sleep patterns, although the underlying cause of this 
is likely to be multifactorial (428). Few long-term studies examine changes to 
sleep patterns in critical care survivors. However, it is hypothesised that 
persistent insomnia is related to age and pre-existing comorbidities rather than 
events during the ICU stay (430). Adequate quantity and quality of sleep is an 
important contributor to QOL, with insomnia proven to reduce QOL (431, 432).  
Orwelius et al. investigated sleep disturbance in a population of 497 Swedish 
critical care survivors at 6 and 12 months following hospital discharge (430). 
Compared to a reference group taken from a Swedish public health survey, the 
critical illness survivors described problems falling asleep, impaired quality of 
sleep and frequent wakening (430). The authors excluded patients over the age 
of 74 as these individuals were not present in the reference group (430). It was 
reported that up to 38% of critical care survivors had sleep disturbance at 12 
months following discharge, compared to a prevalence of between 16-19% in a 
reference cohort (430). The group of survivors reported reduced QOL in domains 
of pain, mental health, physical limitations, general health and vitality (430). 
This study was limited to patients and a reference group from a specific area of 
Sweden and as the authors identify, the choice of reference group used in the 
study prevented comparison by comorbidity (430). Given the methods used by 
the authors, an element of recall bias may be present when patients reported 
sleep history (430). A Portuguese study of 464 critical care survivors from 10 ICUs 
found 41% had ongoing sleep disturbance and decreased QOL in all domains 
measured at 6 months following ICU discharge (433). Whilst QOL and sleep 
disturbance was measured by a postal questionnaire, some patients were also 
engaging with critical care by attending an ICU follow-up clinic. One 
questionnaire used within the Portuguese study to measure recollection, stress 
and sleep disturbance was designed by one of the authors and had not been 
tested for face or content validity, as such the answers may be subject to bias 
(433). Léger at al. found that those in the general population suffering from 
severe insomnia also described greater pain, impacting upon QOL (434). 
Whilst sleep disturbance has been investigated in survivors of critical illness, 
there appear to be a lack of studies in those admitted to critical care with 
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cirrhosis. Outwith the critical care population, an association between sleep 
impairment and chronic liver disease is well recognised (435). Sleep disturbance 
is reported to be more prevalent in those with cirrhosis compared to the general 
population or those with other chronic diseases such as renal failure (436). In the 
UK general population the prevalence of insomnia is reported to be between 10-
48% (437, 438). An American study of insomnia in 3445 individuals with chronic 
illnesses including previous myocardial infarction and diabetes found 16% had 
severe insomnia and 34% had mild insomnia (439). Changes in sleep may herald 
the development of hepatic encephalopathy, however, sleep disturbance is 
frequently reported in cirrhotics without hepatic encephalopathy and is thought 
to result from changes to circadian rhythm (436). In those without 
encephalopathy the prevalence of sleep disturbance is reported to be around 
35% (436). Specific aetiologies of chronic liver disease are linked to fatigue, such 
as primary biliary cirrhosis and Hepatitis C (435). Furthermore, sleep 
disturbances may occur as a side-effect of treatment such as antiviral 
medications (435). 
7.2.5 Questionnaires used to measure quality of life 
Questionnaires exist which have been used to measure QOL in studies of critical 
care patients admitted to intensive care (Table 7-1). There is no gold standard 
questionnaire specifically designed for, or utilised within, this population to 
measure QOL. In response to this the 2002 Brussels Roundtable event gathered 
expert opinion to discuss survival after intensive care and it was recommended 
that QOL should be measured using either the 36-Item short form survey (SF-36) 
or the Euroqol Five Dimensions (EQ-5D) (391).  
There has been a recent move towards the use of core outcome sets (COS) in 
critical care research. A COS consists of an agreed set of tools for outcome 
measurement in a population and should guide any future research in a 
particular field (440). A study investigating the use of a COS in physical 
rehabilitation after critical illness published after the study within this thesis, 
supports the use of the SF-36 and the EQ-5D in measuring QOL in survivors of 
critical illness (441). Further a COS published for research into survivors of acute 
respiratory failure recommended that either the EQ-5D or SF-36 should be used 
to measure QOL (442). 
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Table 7-1 Questionnaires to measure QOL 
Questionnaire Year Country  Domains  
EuroQol Five 
Dimensions 
(EQ-5D) 
(384) 
1990 Europe (UK, Netherlands, 
Sweden, Finland, Norway) 
5 Domains  
• Mobility 
• Self-care 
• Activity 
• Social Relationship 
• Pain  
• Mood 
36-Item Short Form 
Survey 
(SF-36)  
(385) 
1992 USA 8 Domains 
• Vitality 
• Physical Function 
• Bodily Pain 
• General Health 
Perception 
• Physical role 
functioning 
• Emotional role 
functioning  
• Social role 
functioning 
• Mental Health 
Nottingham Health 
Profile (NHP)  
(443) 
1981 UK Part 1 – 6 Domains 
• Mobility  
• Pain 
• Sleep  
• Energy 
• Emotion 
• Social Isolation 
Part 2 – 7 Domains 
• Occupation 
• Housework 
• Social Activity 
• Sex life 
• Home life 
• Hobbies 
• Holidays 
Sickness Impact 
Profile (SIP)  
(386) 
1981 USA 12 Domains 
• Work 
• Recreation 
• Emotion 
• Alertness 
• Sleep 
• Home management 
• Self-care 
• Eating 
• Ambulation 
• Mobility 
• Communication 
• Social Interaction 
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7.2.6 EuroQol Five Dimensions 
The EQ-5D consists of a descriptive system in which respondents rate each of the 
5 domains by severity and an EQ VAS – a visual analogue scale. There are three 
current versions of the EQ-5D – the EQ-5D-3L, EQ-5D-5L and EQ-5D-Y. In the EQ-
5D-3L respondents rate each of the 5 domains into one of 3 levels of severity - ‘ 
1 - no problems’ ‘ 2 - some problems’ or ‘ 3 - extreme problems’, in the EQ-5D-
5L there are 5 levels of severity and the EQ-5D-Y was designed for use in 
children. The rating of each domain results in a number which when combined 
with the ratings for all 5 domains provides a 5 digit number which defines the 
respondent’s current state of health. The EQ VAS provides a vertical scale from 0 
‘the worst health you can imagine’ to 100 ‘the best health you can imagine’ and 
respondents are asked to place a mark on the scale.  
The EQ-5D-3L and the EQ VAS were used for this study, with permission from the 
EuroQol research foundation. The project was registered on the EuroQol 
Research Foundation Website.  
In addition to the COS recommendation, this questionnaire provided a number of 
advantages (442). The EQ-5D has been validated in a UK population, it is 
straightforward, enabling self-reporting and brief to complete, with the 
advantage of a visual analogue scale should participants be unable to understand 
individual questions.  
7.2.7 Measurement of insomnia 
With a paucity of studies investigating insomnia in critical care survivors, there 
are no recognised tools specifically designed to enable self-reported 
measurement of quality of sleep in this population. Existing studies have used 
the Basic Nordic Sleep Questionnaire, the 15D instrument of health-related QOL 
and the Insomnia Severity Index (ISI) (430, 444, 445). The ISI was used in this 
study due to previous use in critical care survivors, ease of use and because it is 
designed take less than 5 minutes to complete and less than 1 minute to score 
(445).  
  188 
 
The ISI was designed to enable self-measurement of insomnia and the impact 
that sleep disturbance has on the respondent (445). The questionnaire reflects 
the recognised diagnostic criteria for insomnia outlined in the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV) produced by the American 
Psychiatric Association. The questionnaire has 5 domains examining severity of 
insomnia, sleep satisfaction, interference with daily function, how noticeable 
sleep impairment is to those in contact with the respondent and how worried the 
respondent is about their sleep impairment (445). Each domain is scored from 0 
to 4 with a maximum score of 28 (445). A score of 15 indicates clinical insomnia 
whilst a score of 22 suggests a diagnosis of severe clinical insomnia (445).  
7.3 Study question and aims 
7.3.1 What is the long-term quality of life of patients who 
survive intensive care? 
With improvements in survival, QOL following intensive care stay is considered 
to be one of the most important long-term outcomes. Sleep is known to 
contribute to QOL but research into sleep disturbance following ICU discharge is 
lacking. Moreover, little is known about the QOL and sleep in the subgroup of 
critical illness survivors with cirrhosis. Determining the long-term QOL and 
prevalence of insomnia in survivors of critical illness could inform patients about 
recovery following discharge and facilitate targeted interventions if QOL or sleep 
were found to be impaired. 
7.3.2 Aims 
In a cohort of ICU survivors: 
• To identify the long term QOL  
• To identify factors which predict a reduction in QOL 
• To explore any relationship between QOL and cirrhosis 
• To determine the prevalence of insomnia 
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• To identify factors which predict long term sleep disturbance 
• To explore any relationship between long term sleep disturbance and 
cirrhosis 
7.4 Methodology 
7.4.1 Design 
This observational cohort study was performed by postal distribution of 2 
questionnaires – the EQ-5D and the ISI (384, 445). The EQ-5D and ISI 
questionnaires were delivered together in May 2015.  
A postal questionnaire was chosen as it enabled the participants to complete the 
questionnaires at a convenient time, whilst telephone or face-to-face interviews 
may have improved response rates this was not possible due to time constraints. 
Email addresses are not stored with the hospital medical records so distribution 
via the internet was not feasible. To improve the response rate, respondents 
were supplied with a stamped addressed envelope and both a reminder and 
questionnaires were posted 6 weeks later to individuals who had not returned 
the original questionnaire (446). Participant information sheets and 
questionnaires were short, examined for readability and straightforward to 
complete (446). Study information outlined the purpose of the study and that 
any information would be used for non-commercial research (446). Prior to 
ethical approval, both the participant information sheet and questionnaires were 
reviewed by former patients and members of the public attending an ICU follow-
up clinic (354). This review ensured both the readability and clarity of 
documentation, whilst confirming that aspects of the study including conduct 
and subject matter were appropriate.  
7.4.2 Participants 
Participants had been admitted for Level 3 care at the GRI (section 2.1.4) 
between June 2012 and December 2013. Clinical and demographic data for this 
prospective cohort had been recorded, analysed and published for a study which 
investigated whether alcohol use disorders were associated with long term 
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survivorship outcomes in intensive care survivors and published in Critical Care in 
2015 (187). Of this cohort 34.4% had been identified as having an alcohol use 
disorder. The study for this thesis concerned only the survivors of this cohort 
(irrespective of whether they had an alcohol use disorder or not) and assessed 
the different outcomes of QOL and insomnia.  
All patients in the existing database were screened using NHS Greater Glasgow 
and Clyde electronic patient record to ensure that they were alive, identify a 
fixed address and determine issues related to consent before the postal survey 
was distributed. Those excluded from the study included those with no fixed 
address recorded, address within prison or a medical condition incompatible 
with informed consent such as those with severe learning difficulties or 
dementia.  
Previous studies at this centre have defined deprivation as the lowest 2 deciles 
of the SIMD (SIMD 1 and 2) and to facilitate comparison the same definition was 
utilised in this investigation (187).  
7.4.3 Ethics 
This research was approved by the East of Scotland Research Ethics Service on 22 
May 2015 (REC reference: 15/ES/0084, Chair: Dr Carol Macmillan).  
There were a number of ethical issues in this study identified by the MD student. 
Correct identification of the participant’s address relied upon accurate medical 
records and whilst the letter was addressed to the former patient there was no 
guarantee that the letter would not be opened by another individual. To reduce 
potential for harm no clinical or demographic information was included on the 
patient information with the exception of a statement that the individual had 
been a former patient. A contact telephone number for the research team was 
provided should the recipient have wished to discuss the research in further 
detail.    
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7.4.4 Statistical analysis 
Bivariate analysis was performed to determine whether there were any 
relationships between measured variables, the presence of cirrhosis, QOL or 
insomnia. Normally distributed data were assessed using the independent t-test 
and presented as mean and standard deviation. Data found to be non-parametric 
were assessed using the Wilcox and the Kruskal-Wallis tests and described as 
median and IQR. Proportions were compared using the Chi-squared test and 
Fisher’s exact test for association.  
A boxplot was used to demonstrate the distribution of Health Utility Scores for 
those with and without clinical insomnia. It enabled comparison between the 2 
populations and identification of outliers.  
Multivariate analysis was performed to examine the relationship between 
multiple variables and 16 incomplete records were removed during this analysis. 
Two prediction models were created; one for health utility score (HUS) to 
predict QOL and another for insomnia. ANOVA was used to compare both 
forwards and backwards stepwise linear regression models to assess the 
relationship between clinical variables and health utility scores. An R2 value was 
used to assess how well the final prediction model fitted the data. As insomnia 
was measured as a categorical variable a logistic regression model was used to 
assess the relationship between independent clinical variables and insomnia. 
Results were expressed in terms of OR and 95% CI. The Wald statistic was used to 
determine how well the data fitted the final model. 
A Fisher’s exact test for count data was used to examine for a difference in the 
proportions of those with cirrhosis and without cirrhosis and the prevalence of 
clinical insomnia. 
7.5 Results 
7.5.1 Demographics 
Five hundred and eighty patients were screened using NHS Greater Glasgow and 
Clyde electronic patient record from the existing database (section 7.4.2) 
(Figure 7-1). Two hundred and seventy-seven individuals had died since inclusion 
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in the database, 8 had no fixed address or lived outwith the UK making them 
ineligible for a postal questionnaire. Two patients were in prison and 4 patients 
were noted to have a medical condition, which could impact upon informed 
consent, making them ineligible on ethical grounds. Two hundred and eighty-
nine ICU survivors were therefore sent out both the EQ5 questionnaire and ISI 
questionnaire (Figure 7-1). Eight survivors were no longer at their recorded 
address and the questionnaires were returned and 4 survivors responded but 
declined participation. Three patients had died which had not been noted on 
their medical records and 175 individuals did not respond to the questionnaires. 
Ninety-nine respondents returned their questionnaires completed, which was a 
response rate of 37.1%.  
Figure 7-1 Flowchart of participant recruitment 
 
The median time for questionnaire completion following ICU discharge was 862 
days (IQR 719-954) (Table 7-2). Respondents ranged in age from 22 to 85, with a 
mean age of 55.8 years. Male gender accounted for 55.6% of respondents and 
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49.5% of respondents resided in the lowest 2 deciles of the SIMD and were 
considered socially deprived (Table 7-2).  
In the initial database of 580 admissions, 34.4% were noted to have an alcohol 
use disorder, with 17.0% assessed as harmful or hazardous intake of alcohol and 
17.4% noted to be alcohol dependent (187). Of the 99 respondents to this study, 
32.3% had an alcohol use disorder with 13.1% noted to have harmful or 
hazardous alcohol use and 19.2% were considered to be alcohol dependent at the 
time of ICU admission.  
The majority of respondents (65.7%) had been admitted to ICU with a surgical 
diagnosis, with the remaining 34.3% admitted with an underlying medical 
diagnosis. Direct admission from the ED accounted for 34.3% of respondents, 
whilst 27.3% were referred from the ward, 25.3% from theatre and 13.1% from 
another hospital. On admission the median APACHE II score was 17.5 (IQR 14.0-
22.3). 52.5% of respondents had been diagnosed with sepsis during their ICU 
admission, with 19.2% diagnosed with septic shock. Only one respondent did not 
receive mechanical ventilation during their ICU admission, with the remaining 98 
survivors receiving mechanical ventilation for a median duration of 3 days (IQR 
2.0-7.0). The median length of stay in the ICU was 4 days (IQR 2.0-9.0) and the 
median hospital length of stay was 22 days (IQR 9.5-44.5). 
Fifteen individuals with a diagnosis of cirrhosis were identified within the cohort 
of respondents (Table 7-2). This group had a mean age of 49 years (34-64), 11 
were male (73.3%), 8 respondents (53.3%) were deprived and resided within the 
lowest 2 deciles of the SIMD. There was a significant difference in the 
prevalence of alcohol use disorders between respondents with cirrhosis on ICU 
admission and those without (p=<0.01). On admission to ICU, 66.7% of 
respondents with cirrhosis had an alcohol dependency, compared to 10.7% of 
respondents without cirrhosis. Of respondents with cirrhosis on ICU admission, 
the median APACHE II score was 20 (IQR 16.0-23.5) and the median duration of 
mechanical ventilation was 5.5 days (IQR 2.0-12.5). There was a significant 
difference in the number of days those with cirrhosis required inotrope therapy 
compared to those without cirrhosis (p=0.01). Respondents with cirrhosis on ICU 
admission had a longer ICU length of stay (p=0.02) and hospital length of stay 
(p=0.04).  
  194 
 
Table 7-2 Demographics of 99 respondents to EQ5 and ISI questionnaires 
 All patients 
(n=99) 
Cirrhosis on 
admission to 
ICU (n= 15) 
No cirrhosis on 
admission to 
ICU (n=84) 
p 
value 
Age, mean (range) 55.8 (22.0-
85.0) 
49.3 (34.0-
64.0) 
56.9 (22.0-
85.0) 
0.03 
Male gender, n (%) 55.0 (55.6) 11.0 (73.3) 44.0 (52.4) 0.22 
SIMD decile, median 
(IQR) 
2.0 (1.0-7.0) 1.0 (1.0-6.5) 2.0 (1.0-7.0) 0.45 
Social deprivation, n 
(%) 
49.0 (49.5) 8.0 (53.3) 41.0 (48.8) 1 
Alcohol, n (%) <0.01 
No use/low use 67.0 (67.7) 4 (26.7) 63.0 (75.0)  
Harmful/hazardous 
use 
13.0 (13.1) 1 (6.7) 12.0 (14.3)  
Dependency 19.0 (19.2) 10 (66.7) 9.0 (10.7)  
Source of ICU Admission, n (%) 0.45 
Emergency 
Department 
34.0 (34.3) 9 (60.0) 25.0 (29.8)  
Ward 27.0 (27.3) 4 (26.7) 23.0 (27.4)  
Theatre 25.0 (25.3) 1 (6.7) 24.0 (28.6)  
Other Hospital 13.0 (13.1) 1 (6.7) 12.0 (14.3)  
Admitting specialty, n (%) 0.45 
Medical 34.0 (34.3) 11.0 (73.3) 23.0 (27.4)  
Surgical 65.0 (65.7) 4.0 (26.7) 61.0 (72.6)  
APACHE II score, 
median (IQR) 
17.5 (14.0-
22.3) 
20.0 (16.0-
23.5) 
17.0 (14.0-
22.0) 
0.19 
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 All patients 
(n=99) 
Cirrhosis on 
admission to 
ICU (n= 15) 
No cirrhosis on 
admission to 
ICU (n=84) 
p 
value 
Sepsis, n (%) 52.0 (52.5) 7.0 (46.7) 45.0 (53.6) 0.45 
Septic shock, n (%) 19.0 (19.2) 2.0 (13.3) 17.0 (20.2) 0.79 
Days ventilated, 
median (IQR) 
3.0 (2.0-7.0) 5.5 (2.0-12.5) 3.0 (2.0-5.0) 0.13 
Renal replacement 
therapy (RRT), n (%) 
12.0 (12.1) 3.0 (20.0) 9.0 (10.7) 0.56 
Days RRT, median 
(IQR) 
3.0 (1.6-6.8) 1.0 (1.0-7.5) 4.0 (2.0-6.0) 0.40 
Inotrope therapy, n 
(%) 
48.0 (48.5) 8.0 (53.3) 40 (47.6) 0.90 
Days inotropes, 
median (IQR) 
2.5 (2.0-4.0) 4.5 (3.8-6.5) 2.0 (2.0-3.0) 0.01 
ICU length of stay 
(Days), median (IQR) 
4.0 (2.0-9.0) 9.0 (3.0-14.5) 3.0 (2.0-8.0) 0.02 
Hospital length of 
stay (Days), median 
(IQR) 
22.0 (9.5-
44.5) 
38.0 (21.0-
64.0) 
17.5 (9.0-41.0) 0.04 
Length of time to 
follow up (Days), 
median, IQR 
862.0 (719.0-
954.0) 
898.0 (724.0-
989.5) 
859.5 (715.2-
924.8) 
0.34 
 
7.5.2 Quality of life 
The median health utility score (HUS) reported by the respondents was 0.66 (IQR 
0.08 to 0.81). Sixteen respondents (16.2%) indicated an HUS of less than 0, which 
denotes a QOL less than or equal to death. In those respondents diagnosed with 
cirrhosis on admission to ICU the median HUS was 0.62 (IQR 0.05 to 0.71). Two of 
these respondents (13.3%) reported a HUS of less than 0. 
The median HUS in patients with clinical insomnia was 0.08 (IQR -0.18 to 0.52) 
and 0.74 (IQR 0.69 to 0.88) in those without clinical insomnia, which was a 
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significant difference (p<0.001). Increased ISI score was associated with low HUS 
(p<0.001) and the distribution of scores for those survivors with and without 
clinical insomnia is shown in Figure 7-2.  
Figure 7-2 Boxplot to show the distribution of Health Utility Scores in 99 
critical care survivors for those with and without clinical insomnia  
 
 
In this group of ICU survivors poor HUS was associated with smoking (p=0.003) 
and the presence of social deprivation (p=0.02). Furthermore, a low HUS was 
associated with the following clinical factors; requirement for mechanical 
ventilation (p<0.001), inotrope therapy (p=0.02), renal replacement therapy 
(p=0.03), length of stay in ICU (p<0.001) and length of stay in hospital (p=0.01). 
There was no association between a diagnosis of liver cirrhosis and HUS in this 
cohort (p=0.46). 
Multivariate analysis was performed following the removal of 16 questionnaires 
as they were only partially completed. ISI score (p<0.01), length of stay in 
hospital (p=0.03) and requirement for renal replacement therapy (p=0.04) were 
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independently associated with a lower HUS. Although smoking (p=0.09) and 
inotrope therapy (p=0.16) were not significantly associated with a lower HUS on 
multivariate analysis, a prediction model for HUS in this cohort inclusive of ISI 
score, hospital length of stay, renal replacement therapy, smoking and inotrope 
therapy was significant (p<0.05, adjusted R2=0.59) (Table 7-3).  
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Table 7-3 Model to predict health utility score  
  Non-adjusted model Adjusted model 
Factor 
associated 
with HUS 
Estimate p 
value 
95% Confidence 
Interval  
Estimate p 
value 
95% 
Confidence 
Interval 
Smoker - 0.1173 0.08 -0.2513,1.6571 -0.1079 0.09 -0.2327,0.0169 
Presence of 
social 
deprivation 
0.0314 0.63 -0.0990,1.6174 - -  
Admission 
under 
medical 
specialty 
0.0008 0.44 -0.0013,2.9405 - -  
Duration of 
mechanical 
ventilation 
(Days) 
- 0.011 0.56 -0.0481,2.6295 - -  
Use of 
Inotrope 
Therapy 
- 0.0918 0.17 -0.2232,3.9580 -0.089 0.16 -0.2138,0.0361 
Use of Renal 
Replacement 
Therapy - 0.1756 
0.07 -0.3644,1.3176 -0.1836 0.04 -0.3602,0.007 
ICU length of 
stay (Days) 
0.0009 0.60 -0.0260,4.4518 - -  
Hospital 
length of stay 
(Days) 
-0.0018 0.05 -0.0035,3.1646 -0.0018 0.03 -0.0034-0.0002 
Total 
Insomnia 
Severity 
Index Score 
(ISI) 
- 0.0287 <0.01 -0.0367,2.0628 -0.0281 <0.01 -0.0351-0.0211 
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7.5.3 Prevalence of insomnia 
The median ISI score amongst all respondents was 10 (IQR 4-18) (Table 7-4). 
Forty-one survivors had an ISI score of 7 or less, with the remaining 58 survivors 
scoring between 8 and 28. Thirty-seven respondents (37.4%) reported clinical 
insomnia. 
Of the 15 respondents with cirrhosis, the median ISI score was 18 (IQR 7-22) 
compared to a median score of 9 (4-17) in those without cirrhosis. This 
difference was not statistically significant.  
Eight respondents (53.3%) with cirrhosis on ICU admission had clinical insomnia, 
compared to 29 (34.5%) respondents without cirrhosis. Those with cirrhosis were 
found to have an increased incidence of clinical insomnia (OR 2.15 CI 0.61-7.74) 
although this difference was not statistically significant (p=0.27). 
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Table 7-4 Prevalence of self-reported insomnia in 99 critical care survivors 
 All 
respondents 
(n = 99) 
Respondents 
with cirrhosis  
(n = 15)  
Respondents 
without cirrhosis 
(n = 84) 
p 
value 
Median ISI score 
(IQR) 
10 (4-18) 18 (7-22) 9 (4-17) 0.11 
No insomnia (ISI 
0-7), n (%) 
41 (41.1) 5 (33.3) 36 (42.9)  
Sub-threshold 
insomnia (ISI 8-
14), n (%) 
21 (21.2) 2 (13.3) 19 (22.6)  
Moderate 
insomnia (ISI 15-
21), n (%) 
24 (24.2) 4 (26.7) 20 (23.8)  
Severe insomnia 
(ISI 22-28), n (%) 
13 (13.1) 4 (26.7) 9 (10.7)  
Clinical 
insomnia, n (%) 
37 (37.4) 8 (53.3) 29 (34.5) 0.27 
 
7.5.4 Severity of insomnia 
Analysis of the responses revealed the majority of respondents reported 
dissatisfaction with sleep (86.8%), early morning wakening (65.7%) and belief 
that their poor sleep impacted upon their ability to perform daily activities 
(60.6%) (Table 7-5). Over half of respondents indicated that other individuals 
had noticed problems with their sleep (66.7%) and most respondents had 
problems staying asleep (50.4%), difficulty falling asleep (58.5%) and were 
worried about sleep problems (53.5%). Fifty-two respondents (52.5%) reported 
sleep disturbance on more than 3 nights per week. 
Respondents with cirrhosis reported more severe insomnia symptoms in all of the 
categories covered by the ISI, however, no significant differences were found 
(Table 7-5). In particular, 73.3% of those respondents reported sleep disturbance 
on more than 3 nights per week, compared to 48.8% of those without cirrhosis.  
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Table 7-5 Self-reported insomnia and cirrhosis in 99 critical care survivors 
Self-reported 
insomnia 
symptom 
All respondents  
(n = 99) 
Respondents with 
cirrhosis  
(n = 15) 
Respondents 
without cirrhosis 
(n = 84) 
Dissatisfaction with sleep 
None n (%) 12 (12.1) 1 (6.7) 11 (13.1) 
Mild/Moderate n 
(%) 
42 (42.4) 5 (33.3) 37 (44.0) 
Severe/Very 
Severe n (%) 
44 (44.4) 9 (60.0) 35 (41.7) 
Early wakening 
None n (%) 19 (19.2) 3 (20.0.) 16 (19.0) 
Mild/Moderate n 
(%) 
39 (39.4) 4 (26.7) 35 (41.7) 
Severe/Very 
Severe n (%) 
26 (26.3) 6 (40.0) 20 (20.2) 
Impact on activities of daily living 
None n (%) 28 (28.3) 2 (13.3) 26 (31.0) 
Mild/Moderate n 
(%) 
28 (28.3) 7 (46.7) 21 (25.0) 
Severe/Very 
Severe n (%) 
32 (32.3) 6 (40.0) 26 (31.0) 
Notability of sleep problem 
None n (%) 33 (33.3) 2 (13.3) 31 (36.9%) 
Mild/Moderate n 
(%) 
35 (35.4) 6 (40.0) 29 (34.5) 
Severe/Very 
Severe n (%) 
31 (31.3) 7 (46.7) 24 (28.6) 
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Self-reported 
insomnia 
symptom 
All respondents  
(n = 99) 
Respondents with 
cirrhosis  
(n = 15) 
Respondents 
without cirrhosis 
(n = 84) 
Difficulty staying asleep 
None n (%) 26 (26.3) 2 (13.3) 24 (28.6) 
Mild/Moderate n 
(%) 
22 (22.2) 3 (20.0) 19 (22.6) 
Severe/Very 
Severe n (%) 
28 (28.2) 7 (46.7) 21(25.0) 
Difficulty falling asleep 
None n (%) 34 (34.3) 3 (20.0) 31(36.9) 
Mild/Moderate n 
(%) 
34 (34.3) 6 (40.0) 28 (33.3) 
Severe/Very 
Severe n (%) 
24 (24.2) 5 (33.3) 19 (22.6) 
Worry about sleep problem 
None n (%) 45 (45.5) 5 (33.3) 40 (47.6) 
Mild/Moderate n 
(%) 
30 (30.3) 5 (33.3) 25 (29.8) 
Severe/Very 
Severe n (%) 
23 (23.2) 5 (33.3) 18 (21.4) 
Sleep disturbance 
Never (0 
nights/week) 
24 (24.2) 2 (13.3) 22 (26.2) 
Occasional (1-3 
nights/week) 
22 (22.2) 2 (13.3) 20 (23.8) 
Frequent (>3 
nights/week) 
52 (52.5) 11 (73.3) 41 (48.8) 
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7.5.5 Factors which predict long term sleep disturbance 
In this study, clinical insomnia in ICU survivors was associated with smoking 
(p<0.001) and social deprivation (p=0.001). Clinical insomnia was associated with 
longer duration of mechanical ventilation (4 days versus 2.5 days, p=0.04) and 
longer length of stay in the ICU (5 days versus 3 days, p=0.02). Bivariate analysis 
revealed no association between severity of insomnia and inotrope requirement, 
vasopressor use or severity of illness on ICU admission. There was no association 
between a diagnosis of liver cirrhosis and clinical insomnia in ICU survivors 
(p=0.27). Following multivariate analysis smoking was associated with a 
threefold increased odds of clinical insomnia (OR 3.74 95% CI 1.27,11.4; p=0.02). 
Table 7-6 Adjusted logistic regression model for insomnia 
Factor associated with 
insomnia 
Odds 
ratio 
95% Confidence Interval for 
the Odds ratio 
p 
value 
Smoking 3.74 1.27,11.4 0.02 
Presence of social 
deprivation 
2.90 0.97,8.95 0.06 
Duration of mechanical 
ventilation (Days) 
1.18 0.85,1.69 0.33 
ICU length of stay (Days) 0.93 0.67,1.26 0.64 
 
7.5.6 Comorbidities 
In addition to liver cirrhosis, which was of particular relevance to this thesis, 
other pre-existing comorbidities were noted for each respondent (Table 7-7). 
Hypertension was the most common comorbidity (25.3%) whilst other co-
morbidities evident were mental health problems (19.2%), diabetes (12.1%) and 
obesity (11.1%). The median number of comorbidities was 1 (IQR 0-2), however, 
3 patients were noted to have 5 pre-existing conditions and 1 patient had 6 pre-
existing conditions recorded on admission to the ICU. In this group the number of 
comorbidities was found to be significantly associated with clinical insomnia 
(p=<0.01) and HUS (p=0.03). An association was found between poorer QOL in 
  204 
 
ICU survivors and diagnoses of mental health problems (p=0.01), peripheral 
vascular disease (p=0.03) and cerebrovascular disease (p=0.03). 
Table 7-7 Prevalence of comorbidities in 99 critical care survivors 
Disease n(%) 
Hypertension 25 (25.3) 
Mental Health 20 (20.2) 
Diabetes 12 (12.1) 
Obesity 11 (11.1) 
Chronic Obstructive Pulmonary Disease 10 (10.1) 
Rheumatological/Dermatological Disease 8 (8.1) 
Ischaemic Heart Disease 7 (7.1) 
Cerebrovascular Disease 7 (7.1) 
Pancreatitis 7 (7.1) 
Malignancy 7 (7.1) 
Asthma 6 (6.1) 
Thromboembolism 5 (5.1) 
Inflammatory Bowel Disease 5 (5.1) 
Atrial Fibrillation 4 (4.0) 
Peripheral Vascular Disease 2 (2.0) 
Hepatitis C Virus 2 (2.0) 
Hepatitis B Virus 1 (1.0) 
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7.6 Discussion 
As far as can be established, this is the first report into insomnia and long-term 
QOL in critical illness survivors in the UK. Long-term QOL reported in this study 
is comparable to similar studies performed in the UK, however, a notable 
number of individuals in this cohort rated their QOL as comparable to, or worse 
than death. Poor long-term QOL was found to be associated with smoking, social 
deprivation, mechanical ventilation, inotrope therapy, renal replacement 
therapy, ICU length of stay and hospital length of stay. In this cohort of 
respondents clinical insomnia was associated with smoking, social deprivation, 
longer duration of mechanical ventilation and longer ICU length of stay. In 
addition, the number of pre-existing comorbidities was associated with both 
poor QOL and insomnia. Although the number of individuals with cirrhosis was 
small the results suggest there may be a relationship between a diagnosis of 
cirrhosis and an increased incidence of clinical insomnia, although this 
relationship was not found to be significant.  
7.6.1 Interpretation of findings 
7.6.1.1 The impact of cirrhosis on long-term quality of life and 
sleep 
In this study, QOL in those with liver cirrhosis was comparable to the general 
population of survivors, with no relationship found between cirrhosis and QOL. 
Given the small numbers of patients with cirrhosis in this cohort it is not possible 
to draw firm conclusions as to whether QOL is different in those critically ill 
survivors with cirrhosis. This finding was not expected as the relationship 
between chronic liver disease and impaired QOL is documented within the 
literature. One explanation may be that the remaining population of critical care 
survivors without cirrhosis had other reasons for an impaired QOL, such as the 
significant number of comorbidities demonstrated or the presence of PICS. The 
results may be explained by other factors, such as change in functional status, 
which were not explored within this study. 
Whilst this study identified the presence of liver cirrhosis, no information was 
recorded on disease trajectory or the severity of liver disease either on 
admission to critical care or at the time of completion of the questionnaires. 
  206 
 
Outwith the critical care population the link between impaired QOL and life-
threatening complications of cirrhosis such as ascites, encephalopathy and 
variceal haemorrhage are established in the literature (421). One Dutch study of 
179 outpatients with cirrhosis concluded that an impaired QOL was not evident 
in all cirrhotics but was noted in those with subclinical hepatic encephalopathy 
(447). It may be that those who responded to the questionnaire had less severe 
disease or a lack of complications.  
This study demonstrated a relationship between length of stay and QOL when 
analysing the data from all respondents. It would be interesting to examine this 
further in a larger group of critically ill cirrhotic patients given they had longer 
length of both ICU and hospital stay.  
When considering sleep disturbance, those with cirrhosis reporting insomnia had 
a notably higher prevalence of clinical insomnia with reduced ability to perform 
daily tasks when compared to the whole cohort of respondents. It is challenging 
to determine whether the daytime fatigue and lethargy reported are 
manifestations of cirrhosis or as a result of sleep disturbance (448). 
Furthermore, sleep disturbance may result from iatrogenic causes linked to 
cirrhosis such as diuretic use or indicate the development of hepatic 
encephalopathy (448). It is interesting that the relationship between cirrhosis 
and insomnia was not reflected in a decreased QOL for this cohort as the link 
between sleep disturbance and QOL is established (435). 
7.6.1.2 Long-term QOL in critical care survivors 
This study reports long-term QOL for critical care survivors in a cohort of 
patients admitted to a general ICU in Scotland. Published HUS values are 
available which provide tables of values based upon age and sex matched 
population (449). It is challenging to compare the mean HUS found in this study 
with a population ‘norm’ for the UK as our cohort is heterogeneous. However, 
HUS in this study is similar to the findings reported in a population of critical 
illness survivors in Aberdeen 12 months following ICU discharge where HUS was 
reported to be 0.666 (392). It is concerning that QOL was rated as worse than, or 
equal to, death by a considerable number of individuals in this study. This may 
represent poor recovery from critical illness and the impact on functional level, 
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however, without baseline data it is not possible to identify if this poor QOL 
existed prior to ICU admission and the change in the trajectory of QOL following 
discharge. 
It has been proposed that QOL in critical care survivors has an iatrogenic 
component and is dependent upon events within the ICU stay. The relationship 
between QOL and duration of mechanical ventilation in this cohort is consistent 
with other studies in the literature (404). However, the relationship found in this 
study between QOL and inotrope therapy and renal replacement therapy 
suggests that multiple factors within the ICU stay play a role in determining 
QOL. It could be suggested that QOL is most impaired in those with a greater 
severity of illness, however, as there is no association with APACHE II or the 
incidence of sepsis this is unlikely in this cohort. Korkeila et al. examined the 
relationship between renal replacement therapy in ICU and long-term QOL in 62 
ICU survivors (450). In contrast to our results, respondents reported good QOL at 
6 months (450). The authors note that ICU mortality in those requiring renal 
replacement therapy is influenced by the underlying aetiology of the renal 
failure, whether it is in the context of multi-organ failure and the reversibility of 
renal function (450). Recording such information in our cohort would give further 
insight into this finding.  
Patient factors prior to ICU admission are known to affect QOL. Individual 
socioeconomic status has been demonstrated to impact upon self-rated QOL in 
the general population so it is unsurprising that this is replicated in critically ill 
survivors (451). The association of smoking and QOL is explored in studies of the 
general population; those with poor QOL are reported to be more likely to begin 
smoking and less likely to succeed with cessation (452, 453).  
Assessment of the QOL of a patient prior to admission to ICU would provide 
insight into the impact of pre-existing comorbidity (454). QOL following ICU can 
be influenced by a deterioration in pre-existing comorbidity or by the 
development of a new comorbidity, such as PICS, as a consequence of their 
admission. Individuals with PICS report weakness secondary to myopathy and 
neuropathy, impaired hormonal balance, susceptibility to infection and 
immobility (455). Furthermore, they experience longstanding physical and 
psychological symptoms which can affect QOL (456).  
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7.6.1.3 Sleep disturbance in critical care survivors 
Whilst studies examining sleep disturbance in critical care survivors exist this 
study adds to only a small number of reports into long-term changes to sleep 
following ICU discharge. The prevalence of long-term sleep disturbance in this 
population of critical care survivors is comparable to that reported by a Swedish 
study of 497 ICU survivors (described in section 7.4.2) and a cohort of 143 UK ICU 
survivors interviewed 3 months after ICU discharge (430, 457). These figures are 
higher than those reported in healthy volunteers studied at the Glasgow Science 
Centre (10%), individuals with dementia (12.5%) and individuals diagnosed with 
cancer (30.2%), implying that survivors of critical illness have high rates of 
insomnia (458-460). In this study insomnia was not measured until follow up, but 
a previous study of 179 Australian critical care survivors 6 months after ICU 
discharge found that sleep quality had deteriorated following ICU stay (444). 
Whilst there was some potential for recall bias, the patients enrolled in their 
study completed the initial ISI questionnaire during their ICU stay so the time 
interval was minimal (444). This Australian study was performed at a tertiary 
referral centre in Sydney and participants included those admitted to general, 
cardiothoracic and neurological ICUs for more than 2 nights and as such the 
results may lack generalisability (444). Unlike the study described in this 
chapter, the Australian cohort identified and excluded those with known sleep 
disorders which may have influenced results (444).  
Sleep deprivation and disturbance are recognised in the critically ill population 
however, the association observed between ICU length of stay, duration of 
mechanical ventilation and severity of insomnia is complex (428, 461). In a 
similar manner to QOL it is unlikely that this solely represents individuals who 
are most unwell as there is no association between insomnia and APACHE II, 
sepsis, inotropic support or renal replacement therapy. There may be an 
underlying iatrogenic component contributing to the prevalence of insomnia in 
this cohort. Whilst the total amount of time spent sleeping does not differ from 
the healthy population it is believed that around 50% of sleep in patients 
admitted to intensive care occurs during the daytime (461). Sleep is frequently 
interrupted with reduced rapid eye movement sleep and slow-wave activity 
(428, 461, 462). Mechanical ventilation disrupts normal sleeping patterns, with 
one study based in an American burns unit reporting that patients were 
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awakened up to 63 times per hour (463). In a small single-centre study of 15 
critical illness survivors who received mechanical ventilation, chronic sleep-
related breathing problems were demonstrated including hypoxaemia at night 
when compared to healthy volunteers (464). Use of sedation within the ICU may 
have an effect on sleep and QOL following discharge (428). Sedation can prolong 
the duration of mechanical ventilation and ICU length of stay (465). Sedative 
medications including benzodiazepines and opioids can reduce REM and slow-
wave activity sleep (428). Furthermore it has been postulated that high sedation 
use can increase psychological morbidity following ICU discharge, although a 
single-centre randomised controlled trial of 137 patients failed to demonstrate 
significant results (466).  
The relationship between insomnia and smoking demonstrated in this cohort is 
established in the literature, with previous studies highlighting the association 
between smoking, difficulty initiating sleep and sleep fragmentation outwith the 
critical care population (467, 468).  
Many of the factors which contribute to poor sleep such as pain, anxiety and 
depression also impact upon QOL. This makes it challenging to assess whether 
sleep disturbance causes poor QOL in critical care survivors or merely occurs as a 
result of the same factors. Sleep disturbance may occur in survivors and form 
part of a diagnosis of post-traumatic stress disorder (PTSD) or depression - 
impairing domains of QOL such as performing daily activities (469). The 
prevalence of both conditions is high in survivors of critical illness with PTSD 
reported in up to 64% of survivors whilst up to 33% are diagnosed with depression 
(470-472).   
7.6.1.4 The role of pre-existing comorbidity 
The results of this study support the established relationship between the 
number of comorbidities and both QOL and clinical insomnia. This is comparable 
to the findings of a Swedish multicentre study which reported that QOL was 
heavily influenced by pre-existing comorbidity which was discussed earlier 
(section 7.2.2) (409). The same group reported on sleep disturbance following 
ICU stay and similarly found that comorbidity was the major determinant of 
sleep (430). A 2018 study of 240 individuals admitted to ICU in Edinburgh 
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investigated the role of comorbidity, concluding that pre-existing comorbidity 
influenced QOL in the year following critical illness (410). However, there 
appears to be a paucity of literature examining the impact of specific 
comorbidities on both QOL and insomnia in survivors of critical illness. This 
prevents direct comparison with the results of this study, which demonstrated 
association between QOL and the co-morbidities of mental health problems, 
peripheral vascular disease and cerebrovascular disease. The association with 
mental health problems described in these findings is not unexpected given that 
anxiety and depression are one component of the EQ-5D (384). Likewise, 
persistent cognitive impairment experienced by critical care survivors will 
exacerbate pre-existing cerebrovascular disease and likely impair functional 
status and QOL (473).   
7.6.2 Limitations 
Assessment of both long-term QOL and insomnia is subjective and as such it 
would have been useful to have baseline scores for each individual prior to ICU 
admission to determine change in these parameters. Studies have utilised 
retrospective patient reports of QOL and sleep, but it must be recognised that 
these are vulnerable to bias. In particular studies with subjective measures are 
susceptible to ‘response shift’ whereby changes in patient perception following 
illness may alter how they would have previously answered the question (394). 
Recall bias may influence results with individuals unable to accurately score 
previous QOL or sleep. This may mean that survivors of critical illness over or 
underestimate their QOL or sleep disturbance as they are unable to accurately 
compare it to previous experience. Alternative methods to assess premorbid QOL 
and sleep include use of a patient proxy. A UK study of 88 proxy-patient pairs 6 
months after ICU discharge showed consistencies when assessing the physical 
aspects of QOL, which can arguably be assessed objectively (358). Interestingly, 
proxies were found to underestimate the negative emotional impact on patient’s 
QOL but overestimate the physical aspects (358). However, use of a proxy is not 
supported by all studies with an American study of 136 patients who had been 
admitted to ICU with an acute lung injury demonstrating only moderate 
agreement between patients and their proxies (395). Use of age and sex-
matched controls would have been useful to gain perspective on the relevance 
of results.  
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This was a single–centre study and all respondents to this study were former 
patients at GRI ICU. As discussed in the literature review (section 1.2.5.4), the 
hospital is based in an area of high deprivation and as such results may differ in 
a more affluent population and as such they may not be generalisable (40). 
Higher rates of insomnia are reported by those in lower socioeconomic groups, 
who are also reported to have lower QOL (474, 475).  
The response rate of 37.1% is comparable to other postal surveys of quality of 
life critical care survivors, including one study in the same centre conducted in 
2008 (392, 476, 477). This may represent a response bias whereby the results are 
skewed. Those who responded to the study may be most affected by their 
experience and envisage greater gain from study participation. Conversely those 
who did not respond may represent a group most affected by sleep disturbance 
and poor QOL who feel unable to engage with follow up.  
Due to the retrospective nature of the patient’s ICU admission, clinical data 
during the ICU stay is limited to the data recorded during admission. As such 
there is no record of the volume of sedation used or quality of sleep during stay, 
factors which would have been of particular value when assessing long term 
insomnia. It would be useful to measure the choice and quantity of medication 
used within the ICU stay and explore any relationship to long-term sleep 
disturbance. As previously discussed (section 7.6.1.2) sedation can prolong 
duration of ICU stay and mechanical ventilation and change sleep quality. If such 
information was recorded it may be possible to identify and address specific 
factors linked to long-term sleep disturbance. 
Delirium during ICU admission is known to impact on long-term outcomes. 
However, when this cohort of patients were admitted to the ICU, screening was 
not routinely undertaken or recorded (478). All ICU patients admitted to the 
study site are now screened daily for delirium using the Confusion Assessment 
Method for the Intensive Care Unit (CAM-ICU) (479). This would facilitate 
investigation of the duration and type of delirium to determine any long-term 
effects on QOL or sleep disturbance. Further, it would allow greater focus of 
resources on preventing delirium or minimising any long-term complications. 
  212 
 
Prevalence of comorbidity was based upon retrospective records from the ICU 
admission, which was reliant upon the admitting doctor accurately documenting 
past medical history from the patient, family and existing medical records. It 
was therefore not possible to stratify the severity or impact of each comorbidity 
on each individual respondent. The study was limited to comorbidities present 
on ICU admission, however, respondents may have developed new comorbidities 
as a consequence of their critical illness or in the time since their admission. 
Whilst the presence of an alcohol use disorder on admission to ICU was 
documented for each respondent, the level of alcohol consumption at the time 
of response to the questionnaires was unknown, which may have impacted upon 
the results. As the questionnaires were distributed by post it was not possible to 
screen individuals for cognitive impairment. Cognitive impairment is recognised 
in survivors of critical illness, influencing not only on the individual’s ability to 
execute complex tasks such as reliably completing questionnaires but also 
ongoing QOL (480).  
7.7 Conclusion 
This chapter presents the results of a questionnaire based study examining long-
term QOL and sleep disturbance in a cohort of critical care survivors, exploring a 
subpopulation of individuals with cirrhosis. It is one of the few studies in the 
literature to investigate long-term sleep disturbance in critical care survivors. 
The results demonstrate: 
• 53.3% of those with liver cirrhosis had clinical insomnia, compared to a 
prevalence of 34.5% in those respondents without cirrhosis  
• The relationship between clinical insomnia and cirrhosis was not found to 
be statistically significant 
• No relationship was demonstrated between QOL and a diagnosis of 
cirrhosis 
• QOL is lower in survivors of critical illness with clinical insomnia 
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• 16.2% of respondents indicated that their QOL was less than or equal to 
death 
• Poor QOL was associated with smoking and social deprivation 
• Poor QOL was associated with the following clinical factors; mechanical 
ventilation, inotrope therapy, renal replacement therapy, length of stay 
in ICU and length of stay in hospital 
• Insomnia in ICU survivors was associated with smoking  
• Insomnia was associated with longer duration of mechanical ventilation 
and longer ICU length of stay   
• The number of comorbidities was found to be significantly associated with 
QOL and clinical insomnia   
• A relationship was reported between poorer QOL in ICU survivors and 
diagnoses of mental health problems, peripheral vascular disease and 
cerebrovascular disease. 
This chapter has discussed the long-term QOL of critical care survivors, 
examining the prevalence of sleep disturbance. The influence of comorbidity on 
long-term QOL was demonstrated, although no relationship was found between 
QOL or insomnia and an underlying diagnosis of cirrhosis. This was despite a 
significant number of respondents documented to have excess alcohol 
consumption on admission to ICU. The next chapter provides a summary of the 
research in this thesis and future avenues of research for the MD student.   
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Chapter 8 Summary and future directions 
8.1 Introduction 
This chapter comprises a summary of the main results and findings of the 
research studies undertaken in this thesis. This is followed by a discussion of the 
application the research outcomes to daily clinical practice. Avenues for further 
research are also explored.  
8.2 Summary of results and findings 
This research primarily focussed on the impact of chronic liver disease on 
critically ill patients. The main findings of each chapter are outlined below. 
8.2.1 Chapter 1 
The narrative literature review describes the anatomy and function of the liver 
in order to understand the significant impact of liver dysfunction on body 
homeostasis. Knowledge of the multi-systemic effects of liver disease facilitates 
greater appreciation of the clinical manifestations and requirements for support 
during critical illness. Chapter 1 discusses the processes of pathophysiological 
deterioration in the development of cirrhosis and the reversible and often 
preventable nature of such changes. It highlights the role that the clinician can 
play in the trajectory of disease. The epidemiology of chronic liver disease is 
discussed, focussing upon the role of deprivation and the particular challenges 
faced in both Glasgow and Scotland. The current demand on existing liver 
services and critical care is examined whilst the projected need for service 
expansion highlights the importance of this body of research in determining 
which critically ill cirrhotic patients are admitted to critical care, how such 
patients are managed during their stay and the support required following 
discharge.      
8.2.2 Chapter 2 
Chapter 2 introduces the methodological considerations taken in research design 
throughout this study. It describes the concepts used to decide on the most 
appropriate techniques to answer the study questions. Issues of rigour were 
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explored to ensure that appropriate and reliable data were collected to help 
sustain the quality of the research. Statistical considerations were then 
discussed to explain the choice of data analysis.  
8.2.3 Chapter 3 
In this chapter the decision-making criteria used by both gastroenterologists and 
intensivists were explored using the outcomes of 2 national surveys of practice in 
Scotland. The ethical dilemmas posed in withholding or offering intensive care 
treatment were discussed with a review of the literature pertaining to this 
clinical decision. The results of the surveys confirmed the multifactorial nature 
of the decision to provide intensive care to an individual. However, they 
highlighted inconsistencies between specialties. In particular intensivists placed 
greater emphasis on the aetiology of chronic liver disease, potentially reflecting 
attitudes towards specific causes of disease. This may represent an awareness by 
gastroenterologists of the medical advances in the successful treatment of 
aetiologies such as viral hepatitis. Both specialties stressed the importance of 
reversibility and the significance of a patient’s attempts to improve health as a 
result of the abstinence of alcohol consumption. One significant finding was the 
difference in potential escalation of therapy with intensivists more likely to 
offer intensive care and multi-organ support as compared to gastroenterologists. 
Finally, emphasis was placed on the Child-Pugh score when a patient was 
considered to be clinically stable by both specialities, despite a lack of evidence 
to support when this score should be measured to indicate survival. 
8.2.4 Chapter 4 
In response to the findings of the previous chapter, Chapter 4 explored the 
timing and utility of Child-Pugh score with consideration of the impact of critical 
illness on each component of the Child-Pugh score. This chapter focussed on the 
Child-Pugh score on ICU admission, the Child-Pugh score when the patient was 
clinically stable and short-term mortality. This chapter found that Child-Pugh 
score measured at time of ICU admission, rather than when stable, was 
significantly associated with hospital mortality, which contradicted the survey 
findings in Chapter 3. However, the degree of change in Child-Pugh score 
between measurement when stable and on admission to ICU was relevant. It 
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would prove valuable to increase the sample size and re-survey the respondents 
to explore the reasons behind the significance placed upon stable Child-Pugh 
score and whether it was used as a surrogate marker for chronic disease 
severity.   
8.2.5 Chapter 5 
This chapter reported a prospective study examining the use of a proxy to report 
an alcohol use disorder in critically ill patients. Alcohol consumption has been 
highlighted as a preventable cause of chronic liver disease and abstinence can 
reverse the development of cirrhosis. Whilst the recruitment numbers were 
disappointing the results suggested that a proxy could be used as a reliable 
historian in the identification of an alcohol use disorder. To validate the results 
of this study it would be useful to perform a similar investigation, in a different 
location, to help address the problems with recruitment.  
8.2.6 Chapter 6  
The short-term survival of critically ill cirrhotics has been extensively reported 
in the literature, with a vast improvement in survival over the last 4 decades. 
However, wider research into long-term survival is limited and this study 
reported survival at 12 months for a cohort of cirrhotic patients admitted to a 
general ICU in the UK. The majority of these patients were socially deprived 
with an underlying aetiology of alcoholic liver disease. Long-term survival 
following ICU stay was reported, the findings of which are consistent with other 
studies. In this cohort Child-Pugh class (when measured on admission to ICU) was 
demonstrated to stratify patients into 3 distinctive groups for long-term survival. 
These findings further highlighted the challenges in the decision to determine 
those patients considered suitable to be admitted to the limited critical care 
resources available.   
8.2.7 Chapter 7 
Whilst survival rates are improving, recognition of the long-term sequelae of an 
ICU stay have a significant impact on the survivors of critical illness. A subgroup 
of survivors with cirrhosis were studied to identify any relationship between 
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cirrhosis and QOL or insomnia. This chapter investigated the long-term QOL and 
prevalence of sleep disturbance and found that for some survivors their QOL was 
worse than, or equal to death. QOL in those with liver cirrhosis was comparable 
to the general population of survivors, with no relationship found between 
cirrhosis and QOL. The subgroup of survivors with cirrhosis had an increased 
incidence of clinical insomnia compared to the general population of survivors 
although this relationship was not statistically significant. QOL and sleep 
disturbance were found to be influenced by pre-existing factors such as 
prevalence of comorbidity and events during an ICU stay such as mechanical 
ventilation and length of stay. These findings highlighted the lasting significance 
of events that occur during the management of critical illness and raised 
awareness of the potential difficulties some patients face in recovery.  
8.3 What does this research add to existing literature? 
The findings of this thesis add to the existing body of literature surrounding the 
critically ill patient with chronic liver disease.  
• This thesis reports the first national Scottish survey investigating decision-
making regarding admission of individuals with chronic liver disease to 
critical care. It exposes inconsistencies between specialties, in particular 
the significance placed upon underlying aetiology of chronic liver disease 
and proposed levels of escalation of organ support 
• As far as it has been ascertained this the first study to investigate the 
time point at which Child-Pugh score is used by a specialist to inform their 
decision to offer critical care to a patient. Child-Pugh score measured 
when a patient is clinically stable is used by the majority of specialists 
surveyed in Scotland 
• This is the first study to investigate the relationship between short-term 
survivorship and timing of Child-Pugh score. Although this is a small study, 
there appears to be a trend to suggest mortality increases with an 
increase in Child-Pugh score, measured both on ICU admission and when 
stable. However, statistical significance was only demonstrated between 
Child-Pugh score measured on ICU admission and hospital mortality.  
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• This is one of only a few studies reporting long-term outcome of a group 
of cirrhotic patients admitted to a general ICU in the UK. It has 
demonstrated the ability of Child-Pugh class (when measured on 
admission to ICU) to stratify patients into 3 distinctive groups for survival. 
Further it is the first study in the literature to report an association 
between serum lactate measured on ICU admission and long-term 
mortality 
• As far as can be established, this is the first report into insomnia and long-
term QOL in critical illness survivors in the UK. The findings reveal QOL is 
lower in survivors of critical illness with clinical insomnia with a 
significant number of ICU survivors reporting that their QOL is less than or 
equal to death. The number of pre-existing comorbidities was found to be 
significantly associated with both QOL and clinical insomnia   
• The number of individuals with cirrhosis was small but the results suggest 
there may be a relationship between a diagnosis of cirrhosis and an 
increased incidence of clinical insomnia, although this relationship was 
not found to be significant 
• This is the first study recorded in the literature to investigate the use of a 
proxy in reporting an alcohol history for a critically ill patient and found 
substantial agreement between proxy and patient in the identification of 
an alcohol use disorder using the AUDIT, using a threshold score of 8 
8.4 Recommendations for clinical practice 
The findings of this thesis have a number of impacts upon clinical practice.  
Firstly, it should prompt clinicians to evaluate their decision-making when 
deciding to escalate a patient to critical care. It should empower both 
intensivists and referring clinicians to engage in discussion regarding admission 
to ICU, particularly for those with severe chronic liver disease. Further this 
research should prompt discussion and the education of trainee doctors in the 
allocation of finite critical care resources. 
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Secondly, it highlights the challenges faced in determining chronic disease 
severity for those with comorbidity who develop critical illness. The limitations 
of existing scoring systems to predict mortality in liver disease are highlighted 
throughout this thesis. The findings should encourage development of systems to 
effectively determine chronic liver disease trajectory. Clinicians should support 
anticipatory care planning to ensure intensive care is not offered to those 
patients for whom it would be futile.  
Thirdly, the findings of this research can be used to further inform patients and 
their families about the likely long-term survival and recovery from critical 
illness. This supports the concept of realistic medicine, sharing decision-making 
about treatment with patients (481). The results can be used to support the 
argument for further support in delivering structured long-term rehabilitation 
for patients recovering from critical illness (354). 
Finally, these findings should prompt thinking about the use of a proxy in critical 
illness to provide information on the medical history for a patient. The use of a 
proxy is widely practiced in medicine with limited evidence of its utility or 
reliability. These results provide some reassurance that this is a valid method to 
be used for the collection of an alcohol history for a critically ill patient, 
although further research would be beneficial. 
8.5 Future directions 
This thesis has explored the complexity surrounding the decision to admit a 
patient with advanced chronic liver disease to critical care and reports the 
outcome of those who are admitted to critical care. However, the number and 
characteristics of those individuals with critical illness who are not admitted to 
critical care remain unknown. It would be useful to identify this cohort of 
patients and determine the reasons for non-admittance to critical care together 
with their outcomes. 
There is also limited research that investigates the patient journey prior to 
admission. It remains unanswered as to whether critical illness is predictable in 
those with chronic disease and a study plotting the trajectory of disease severity 
in those with chronic liver disease would be beneficial. Likewise monitoring the 
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recovery of critically ill cirrhotics could help determine whether individuals 
return to baseline liver function and physiological reserve. Any future research 
in chronic liver disease would need to determine whether patients were 
admitted to critical care with ACLF or a chronic decompensation. 
With a movement towards publishing outcomes from large datasets and the 
increased use of electronic patient records it is likely that long-term survival 
following critical care admission will be reported on a national level in Scotland. 
However, reporting at a population level would support the call for increased 
critical care resources and help inform health policy.    
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Appendix 1 
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Appendix 2 
Survey 2 of criteria used by gastroenterologists and intensivists used to refer or 
admit patients to ICU, distributed using www.surveymonkey.com 
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Appendix 3 
WHO Alcohol Use Disorders Identification test Questionnaire
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Appendix 4 
4AT Questionnaire 
 
  
 4AT 
 
 
 
Assessment test 
for delirium &  
cognitive impairment 
 
                             (label) 
Patient name:   
 
Date of birth: 
 
Patient number: 
 
_________________________________________________________ 
 
 
Date:             Time: 
 
 
Tester:   
 
 
            
                              CIRCLE 
[1] ALERTNESS      
This includes patients who may be markedly drowsy (eg. difficult to rouse and/or obviously sleepy  
during assessment) or agitated/hyperactive. Observe the patient. If asleep, attempt to wake with  
speech or gentle touch on shoulder. Ask the patient to state their name and address to assist rating.   
 
     Normal (fully alert, but not agitated, throughout assessment)   0 
Mild sleepiness for <10 seconds after waking, then normal  0 
Clearly abnormal      4 
 
 
[2] AMT4 
Age, date of birth, place (name of the hospital or building), current year.    
 
No mistakes      0 
     1 mistake       1 
     2 or more mistakes/untestable     2 
 
 
[3] ATTENTION 
Ask the patient: “Please tell me the months of the year in backwards order, starting at December.”  
To assist initial understanding one prompt of “what is the month before December?” is permitted. 
 
Months of the year backwards     Achieves 7 months or more correctly    0 
     Starts but scores <7 months / refuses to start   1
     Untestable (cannot start because unwell, drowsy, inattentive) 2 
 
 
[4] ACUTE CHANGE OR FLUCTUATING COURSE 
Evidence of significant change or fluctuation in: alertness, cognition, other mental function  
(eg. paranoia, hallucinations) arising over the last 2 weeks and still evident in last 24hrs  
        
      No      0 
      Yes      4 
 
 
4 or above: possible delirium +/- cognitive impairment 
1-3: possible cognitive impairment  
0: delirium or severe cognitive impairment unlikely (but 
delirium still possible if [4] information incomplete) 
 
                
                       4AT SCORE
 
 
GUIDANCE NOTES                          Version 1.2. Information and download: www.the4AT.com 
The 4AT is a screening instrument designed for rapid initial assessment of delirium and cognitive impairment. A score of 4 or more 
suggests delirium but is not diagnostic: more detailed assessment of mental status may be required to reach a diagnosis. A score of 1-3 
suggests cognitive impairment and more detailed cognitive testing and informant history-taking are required. A score of 0 does not 
definitively exclude delirium or cognitive impairment: more detailed testing may be required depending on the clinical context. Items 1-3 
are rated solely on observation of the patient at the time of assessment. Item 4 requires information from one or more source(s), eg. your 
own knowledge of the patient, other staff who know the patient (eg. ward nurses), GP letter, case notes, carers. The tester should take 
account of communication difficulties (hearing impairment, dysphasia, lack of common language) when carrying out the test and 
interpreting the score.  
 
Alertness: Altered level of alertness is very likely to be delirium in general hospital settings. If the patient shows significant altered 
alertness during the bedside assessment, score 4 for this item. AMT4 (Abbreviated Mental Test - 4): This score can be extracted from 
items in the AMT10 if the latter is done immediately before. Acute Change or Fluctuating Course: Fluctuation can occur without delirium 
in some cases of dementia, but marked fluctuation usually indicates delirium. To help elicit any hallucinations and/or paranoid thoughts 
ask the patient questions such as, “Are you concerned about anything going on here?”; “Do you feel frightened by anything or anyone?”; 
“Have you been seeing or hearing anything unusual?”  
© 2011-2014 MacLullich, Ryan, Cash  
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Appendix 5 
Ethical approval for study investigating use of a proxy to measure alcohol history 
for patients in intensive care  
 
 
   
            WoSRES 
West of Scotland Research Ethics Service   
  
 West of Scotland REC 3 
Ground  Floor – The Tennent Institute 
Western Infirmary 
38 Church Street 
Glasgow G11  6NT 
www.nhsggc.org.uk 
 
Dr Tara Quasim 
Room 2.71 New Lister Building  
Glasgow Royal Infirmary 
10-16 Alexandra Parade 
Glasgow 
G4 0SF 
 
Date 19th February 2015 
Your Ref  
Our Ref  
Direct line 0141 211 2123 
Fax 0141 211 1847 
E-mail WOSREC3@ggc.scot.nhs.uk 
 
Dear Dr Quasim  
 
Study title: Investigation into the use of a proxy for alcohol history 
for patients in intensive care using the Adult Use 
Disorders Identification Test (AUDIT).   
REC reference: 15/WS/0014 
IRAS project ID: 162929 
 
Thank you for your letter 12th February 2015 responding to the Committee’s request for further 
information on the above research and submitting revised documentation.   
 
The further information was considered in correspondence by a Sub-Committee of the REC.  A 
list of the Sub-Committee members is attached.   
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the date 
of this favourable opinion letter.  The expectation is that this information will be published for all 
studies that receive an ethical opinion but should you wish to provide a substitute contact point, 
wish to make a request to defer, or require further information, please contact the REC 
Manager, Mrs Liz Jamieson, wosrec3@ggc.scot.nhs.uk. Under very limited circumstances (e.g. 
for student research which has received an unfavourable opinion), it may be possible to grant 
an exemption to the publication of the study.  
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below. 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the 
study. 
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Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk.   
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of approvals from host organisations 
  
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
"Conditions of the favourable opinion" below).  
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
 
Document   Version   Date   
Covering letter on headed paper [Cover Letter for Amendments]  1  12 February 2015  
IRAS Checklist XML [Checklist_14012015]    14 January 2015  
Other [CV J McPeake]  1  14 January 2015  
Other [CV Professor John Kinsella]  1  14 January 2015  
Other [4AT Validated Questionnaire]  1  14 January 2015  
Other [Participant Consent Form]  2  12 February 2015  
Other [GP Letter]  2  12 February 2015  
Other [Proxy Consent Form]  2  12 February 2015  
Other [Proxy Frequency and Nature of Relationship]  2  12 February 2015  
Other [Proxy Information Sheet]  2  12 February 2015  
Other [Participant Information Sheet]  3  12 February 2015  
Other [Study Protocol]  3  12 February 2015  
REC Application Form [REC_Form_14012015]    14 January 2015  
Summary CV for Chief Investigator (CI)  1  14 January 2015  
Summary CV for student  2  14 January 2015  
Validated questionnaire [WHO AUDIT Screening Tool]  1  14 January 2015  
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Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
• Notifying substantial amendments 
• Adding new sites and investigators 
• Notification of serious breaches of the protocol 
• Progress and safety reports 
• Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
User Feedback 
 
The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received and 
the application procedure. If you wish to make your views known please use the feedback form 
available on the HRA website: 
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/    
 
HRA Training 
 
We are pleased to welcome researchers and R&D staff at our training days – see details at 
http://www.hra.nhs.uk/hra-training/   
 
15/WS/0014                          Please quote this number on all correspondence 
 
With the Committee’s best wishes for the success of this project. 
 
Yours sincerely 
 
Liz Jamieson 
REC Manager 
On behalf of Dr Adam Burnel, Chair 
 
Enclosures: List of names and professions of members who were present at the 
meeting and those who submitted written comments  
   “After ethical review – guidance for researchers”  
 
Copy to:  Joanne McGarry 
 Elaine O'Neil, NHS Greater Glasgow and Clyde R&D 
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            WoSRES 
West of Scotland Research Ethics Service   
  
 West of Scotland REC 3 
West of Scotland Research Ethics Service 
West Glasgow Ambulatory Care Hospital 
(former Royal Hospital for Sick Children Yorkhill) 
Dalnair Street  
Glasgow G3 8SW 
www.nhsggc.org.uk 
Dr Tara Quasim 
Room 2.71 New Lister Building  
Glasgow Royal Infirmary 
10-16 Alexandra Parade  
Glasgow 
G4 0SF 
 
Date 8th March 2016 
Your Ref  
Our Ref  
Direct line 0141 232 1805 
E-mail WOSREC3@ggc.scot.nhs.uk 
  
 
Dear Dr Quasim 
 
Study title: Investigation into the use of a proxy for alcohol history for 
patients in intensive care using the Adult Use Disorders 
Identification Test (AUDIT).   
REC reference: 15/WS/0014 
Amendment number: AM01 
Amendment date: 18 February 2016 
IRAS project ID: 162929 
 
Thank you for your email of 18 February 2016, notifying the Committee of the above 
amendment. 
 
The amendment covered an extension to the study for a further 12 months. 
 
The Committee does not consider this to be a “substantial amendment“as defined in the 
Standard Operating Procedures for Research Ethics Committees.  The amendment does 
not therefore require an ethical opinion from the Committee and may be implemented 
immediately, provided that it does not affect the approval for the research given by the R&D 
office for the relevant NHS care organisation. 
 
Documents received 
 
The documents received were as follows: 
 
Document   Version   Date   
Notice of Minor Amendment [Email re Extension to Study]  AM01  18 February 2016  
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 
15/WS/0014:    Please quote this number on all correspondence 
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Yours sincerely 
 
Liz Jamieson 
REC Manager 
 
  
 
Copy to: Ms Joanne McGarry, NHS R&D Greater Glasgow & Clyde  
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Appendix 6 
Participant consent form and information leaflet for the study investigating use 
of a proxy to measure alcohol history for patients in intensive care 
University Department of Anaesthesia 
Level 2, New Lister Building  
Glasgow Royal Infirmary 
Glasgow 
G4 0SF 
 
Subject number: 
 
Use of a proxy for alcohol history for patients in intensive care using the Alcohol Use 
Disorders Identification Test (AUDIT) 
 
Consent Form  
Please initial the BOX 
 
I confirm that I have read and understand the information sheet dated 06/02/2015  
(version 3) for the above study and have had the opportunity to ask questions 
 
I understand that my participation is voluntary and that I am free to withdraw  
at any time, without giving any reason, without my medical care or legal rights 
being affected.  
 
I understand that sections of my medical notes may be looked at by the research 
team where it is relevant to my taking part in the research. I give my permission 
for the research team to have access to my records. 
 
I confirm that my General Practitioner will be informed of my involvement in the 
above study 
 
 
I agree to take part in the above study 
 
 
---------------------------------------               -----------------         ---------------------------------- 
Name of Participant           Date      Signature 
 
---------------------------------------               -----------------          --------------------------------- 
Name of Researcher           Date       Signature 
 
1 copy to the patient, 1 copy to the researcher, 1 Original for the patients’ notes 
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University Department of Anaesthesia,  
Level 2, New Lister Building  
Glasgow Royal Infirmary 
Glasgow 
G4 0SF 
 
Use of a proxy for alcohol history for patients in intensive care using the Alcohol Use 
Disorders Identification Test (AUDIT) 
 
 
Participant Information Sheet 
 
We would like to invite you to take part in a research study. Before you decide you need to 
understand why the research is being done and what it will involve for you. Please take 
time to read the following information carefully. Talk to others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like more information.  
 
Who is conducting the research? 
The research is being carried out by Dr Charlotte Soulsby, Joanne McPeake, Dr Tara Quasim, Dr 
Malcolm Sim and Professor John Kinsella from the Department of Anaesthesia, Pain and Critical 
Care Medicine in Glasgow Royal Infirmary and the University of Glasgow. 
 
What is the purpose of the study? 
The purpose of the study is to assess whether a family member or friend can be used to provide 
reliable source of information about alcohol intake for patients who are unable to give the 
information themselves whilst they are inpatients in intensive care. At present, there is no proven 
method for assessing alcohol intake in intensive care patients, with many units recording units of 
alcohol consumed. Accurately reporting volume of alcohol is difficult and patient participation is 
difficult when they are sedated or ventilated. 
 
Why have I been invited? 
You have been invited to take part in this study as you have been a patient in the Intensive Care 
Unit in the Queen Elizabeth University Hospital, Glasgow.  
 
Do I have to take part? 
No. It is up to you to decide. We will describe the study and go through this information sheet, 
which we will then be given to you. You will be asked to sign a consent form to show you have 
agreed to take part. You are free to withdraw at any time, without giving a reason. This would not 
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affect the standard of care you receive or your future treatment. If you do decide to take part, your 
General Practitioner (GP) will be informed of your involvement. 
 
What does taking part involve? 
Many patients who have been discharged from intensive care are confused. You will be asked to 
complete a short questionnaire consisting of six questions to assess if you are confused prior to you 
completing the second questionnaire consisting of ten questions on alcohol habits and drinking 
patterns. During your stay in Intensive Care your next of kin was asked to complete the same 
questionnaire on alcohol intake, answering on your behalf. If you do not wish to take part the 
information that they have provided will be destroyed. 
 
What happens to the information? 
Your identity and personal information will not be recorded and the results of the questionnaire 
will be kept anonymous. In order to link the answers from both alcohol questionnaires it will be 
necessary to give each pair of questionnaires completed by a patient and their respective relative or 
friend the same unique identifying number which will not correspond to any identifiable 
information. Participation in this study will not be recorded in your medical notes. 
 
What are the possible benefits of taking part? 
It is hoped that by taking part in this research you will be providing a way for medical staff to 
assess alcohol intake in individuals who are not able to provide this information themselves. This 
enables them to consider the problems associated with excess alcohol intake and withdrawal. 
 
Are there any risks? 
There should be no risks associated with completion of the questionnaires. It may lead you to 
consider your own drinking behaviours and patterns. If your responses suggest that you have 
hazardous or harmful levels of alcohol consumption or alcohol dependence you will be given the 
contact details for your local Addaction Alcohol Behaviour Change (ABC) or community addiction 
team (CAT). It will be your decision if you wish to contact either organisation for advice and 
support on how to reduce your alcohol consumption.  
 
Who has reviewed the study? 
This study has been reviewed by the West of Scotland Research Ethics Committee.  
 
If you have any further questions? 
We will give you a copy of the information sheet and signed consent form to keep.  
 
Contacts: 
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Dr Charlotte Soulsby, Clinical Research Fellow, University of Glasgow. Telephone (0141) 
2018631 
 
If you have a complaint about any aspect of the study? 
If you are unhappy about any aspect of the study and wish to make a complaint, please contact: 
Professor John Kinsella 
University Department of Anaesthesia 
New Lister Building 
Glasgow Royal Infirmary 
Glasgow 
(0141) 2018630 
 
 
Thank you for your time and cooperation 
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Appendix 7 
EQ-5D-3L Questionnaire and Registration 
By placing a tick in one box in each group below, please indicate which statements 
best describe your own health state today. 
  
Mobility  
I have no problems in walking about q 
I have some problems in walking about q 
I am confined to bed q 
  
Self-Care  
I have no problems with self-care q 
I have some problems washing or dressing myself q 
I am unable to wash or dress myself q 
  
Usual Activities (e.g. work, study, housework, family or leisure 
activities)  
I have no problems with performing my usual activities q 
I have some problems with performing my usual activities q 
I am unable to perform my usual activities q 
  
Pain / Discomfort  
I have no pain or discomfort q 
I have moderate pain or discomfort q 
I have extreme pain or discomfort q 
  
Anxiety / Depression  
I am not anxious or depressed q 
I am moderately anxious or depressed q 
I am extremely anxious or depressed q 
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9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100 
0 
 
 
 
 
To help people say how good or bad a health state is, 
we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked 100 and 
the worst state you can imagine is marked 0. 
 
We would like you to indicate on this scale how good or 
bad your own health is today, in your opinion. Please do 
this by drawing a line from the box below to whichever 
point on the scale indicates how good or bad your health 
state is today. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Best imaginable 
health state 
Worst 
imaginable 
health state 
Your own health 
state today 
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Appendix 8 
Adapted Insomnia Severity Index Questionnaire  
Please respond to these questions in relation to your sleep OVER THE LAST 
MONTH, even if you do not have a sleep problem currently 
1. Please rate the severity of any problem(s) sleeping 
None Mild Moderate Severe Very 
Severe 
a) Difficulty falling asleep  0 1 2  3  4 
b) Difficulty staying asleep 0 1 2  3  4 
c) Problem waking up too early 0 1 2  3  4 
2. How many nights per week were you bothered by problems sleeping? 
None  1 2 3 4 5 6 7 
3. How satisfied/dissatisfied are you with your current sleep pattern? 
Very satisfied Satisfied Neutral Dissatisfied Very dissatisfied 
0   1  2  3  4 
 
 
4. To what extent do you consider your sleep problem, if you have one, to 
interfere with your daily functioning (e.g. daytime fatigue, ability to function at 
work/daily chores, concentration, memory, mood etc.) 
Not at all   A little Somewhat  Much  Very much 
interfering          interfering  
0   1  2   3  4 
 
5. If you are having problems with your sleep, how noticeable to others do you 
think your sleep problem is in terms of impairing the quality of your life? 
Not at all   A little Somewhat  Much  Very much 
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noticeable          noticeable 
0   1  2   3  4 
 
6. How worried/distressed are you about your current sleep pattern? 
Not at all   A little Somewhat  Much  Very much 
worried          worried  
0   1  2   3  4 
 
7. How many nights a week are you using prescribed medication for your sleep? 
None  1 2 3 4 5 6 7 
 
8. How many nights a week are you using over-the-counter medication for your 
sleep? 
None  1 2 3 4 5 6 7 
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Appendix 9 
Ethical approval for study to explore quality of life in survivors of ICU 
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East of Scotland Research Ethics Service (EoSRES)   
 
                                                                                                                           
 
  
 
 
 
 
 
 
Miss  Joanne McPeake 
University of Glasgow 
Level Two, New Lister Building, Room 2.73 
10-16 Alexandra Parade 
Glasgow G31 2ER 
 
Date:   22 May 2015 
Your Ref:  
Our Ref: DL/15/ES/0084 
Enquiries to: Mrs Diane Leonard 
Direct Line: 01382 383871 
Email: diane.leonard@nhs.net 
Dear Miss McPeake 
 
Study title: A study to explore quality of life in survivors of ICU 
REC reference: 15/ES/0084 
IRAS project ID: 172758 
 
Thank you for your letter of 18 May 2015, responding to the Proportionate Review  
Sub-Committee’s request for changes to the documentation for the above study. 
 
The revised documentation has been reviewed and approved by the sub-committee. 
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the 
date of this favourable opinion letter.  The expectation is that this information will be 
published for all studies that receive an ethical opinion but should you wish to provide a 
substitute contact point, wish to make a request to defer, or require further information, 
please contact the Assistant Co-ordinator Mrs Diane Leonard, eosres.tayside@nhs.net. 
Under very limited circumstances (e.g. for student research which has received an 
unfavourable opinion), it may be possible to grant an exemption to the publication of the 
study. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting 
documentation as revised. 
 
Conditions of the favourable opinion 
 
Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management permission (“R&D approval”) should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
 
 
TAyside medical Science Centre  
Residency Block Level 3 
George Pirie Way 
Ninewells Hospital and Medical School 
Dundee DD1 9SY 
 
  Research Ethics Service 
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Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk.  
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of approvals from host organisations.  
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered 
on a publically accessible database. This should be before the first participant is recruited but 
no later than 6 weeks after recruitment of the first participant. 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment.  We will audit the registration details as part 
of the annual progress reporting process. 
  
To ensure transparency in research, we strongly recommend that all research is registered but 
for non-clinical trials this is not currently mandatory. 
  
If a sponsor wishes to request a deferral for study registration within the required timeframe, 
they should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials will 
be registered, however, in exceptional circumstances non registration may be permissible with 
prior agreement from NRES. Guidance on where to register is provided on the HRA website. 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of the 
study (see “Conditions of the favourable opinion” above). 
 
Approved documents 
 
The documents reviewed and approved by the Committee are: 
 
Document   Version   Date   
IRAS Checklist XML [Checklist_05052015]    05 May 2015  
Other  1  18 May 2015  
Other [Reminder Letter]  3  22 May 2015  
Participant consent form [Consent Form]  2.0  20 April 2015  
Participant information sheet (PIS)  3  18 May 2015  
REC Application Form [REC_Form_05052015]    28 April 2015  
Research protocol or project proposal [Study Protocol]  2.0  20 April 2015  
Summary CV for Chief Investigator (CI) [CV Joanne McPeake 
(1.0 20/4/15)]  
1.0  21 July 2014  
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Document   Version   Date   
Summary CV for student [CV Dr Soulsby]  1.0  20 April 2015  
Summary CV for supervisor (student research) [CV Tara 
Quasim]  
1.0  20 April 2015  
Validated questionnaire [Validated Questionnaire]  1.0  20 April 2015  
Validated questionnaire [EQ-5 questionnaire]      
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
  Notifying substantial amendments 
  Adding new sites and investigators 
  Notification of serious breaches of the protocol 
  Progress and safety reports 
  Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
Feedback 
 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views 
known please use the feedback form available on the HRA website: 
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance  
 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ 
training days – see details at http://www.hra.nhs.uk/hra-training/  
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15/ES/0084   Please quote this number on all correspondence 
 
Yours sincerely 
 
for Dr Carol Macmillan 
Chair 
 
E-mail: eosres.tayside@nhs.net 
 
 
Enclosures:    “After ethical review – guidance for researchers”  
 
Copy to: Ms Emma- Jane Gault, University of Glasgow 
Dr Charlotte Soulsby 
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Appendix 10 
Participant consent form and information leaflet for the study exploring quality 
of life in survivors of ICU 
 
VERSION 2 
(20/04/2015)  
 
STUDY TITLE: A study to explore the quality of life in survivors of ICU 
 
CONSENT FORM 
 I confirm that I have read and understand the information sheet dated    
18/05/2015 (VERSION 3) for the above study and have had the  
opportunity to ask questions 
 
I understand that my participation is voluntary and that I am free to withdraw  
at any time, without giving any reason and without my medical care or  
legal rights being affected.  
 
Where it is relevant to the research project, I understand that sections of my  
ICU medical notes may be looked at. I give my permission for the research  
team to have access to my records. I understand that all the information  
extracted will be anonymised. 
 
 I agree to take part in the above study. 
 
----------------------------  ---------------   --------------------------- 
Name of Participant   Date    Signature 
 
----------------------------  ---------------   --------------------------- 
Name of Witness   Date    Signature 
 
1 copy to the patient, 1 copy to the researcher, 1 original for the patients’ notes 
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STUDY TITLE: A study to explore the quality of life in survivors of ICU 
Information Sheet 
We would like to invite you to take part in a research study. Before you decide you need to 
understand why the research is being done and what it would involve for you. Please take time to 
read the following information carefully. Talk to others about the study if you wish. Ask us if there 
is anything that is not clear or if you would like more information.  
Who is conducting the research? 
The research is being carried out by doctors and nurses from the intensive care unit at Glasgow 
Royal Infirmary.  This project is also contributing to an education qualification for Dr Charlotte 
Soulsby, an intensive care doctor.  The degree is a MD (a postgraduate research qualification).  The 
educational supervisor is Dr Tara Quasim.   
What is the purpose of the study? 
 
We are aware that people can find it a struggle to get back to their previous quality of life after an 
illness that requires admission to an Intensive Care Unit. We want to find out if there are any gaps 
in the service we provide from Intensive Care.  
 
This letter contains 2 questionnaires. The first is called the EQ5D which provides us with a 
measure of your current quality of life. The second questionnaire, called the Insomnia Severity 
Index, seeks to understand information about your sleeping patterns.  The data will be stored 
anonymously so it cannot be traced back to an individual. This research is important as we would 
ideally like to continue to provide a rehabilitation package after a stay in the Intensive Care Unit 
but we need to know what you felt were the important issues.  
Why have I been invited? 
You have been invited to take part in this study as you have previously been a patient in the 
Intensive Care Unit at Glasgow Royal Infirmary. 
Do I have to take part? 
It is up to you to decide. We will describe the study in this information sheet and if you have any 
further queries or would prefer a telephone, or face-to-face interview, please contact Miss Evelyn 
Selfridge (0141 2018502) and she will direct your call or query to me. You will be asked to sign a 
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consent form to show you have agreed to take part. You are free to withdraw at any time, without 
giving reason. This would not affect the standard of care you receive or your future treatment.  
 
What does taking part involve? 
It involves you filling out these 2 questionnaires and returning them in the stamped addressed 
envelope provided. It will take approximately 5 minutes to complete.  As stated earlier, if preferred 
we can conduct a telephone or face to face interview. The researchers will also look at your 
medical notes while you were in the ICU.   
What happens to the information? 
Your identity and personal information will be completely confidential.  The information obtained 
will remain confidential and stored within an encrypted USB stick and on a central, secure IT back 
up.  All paper information will be kept in a locked filling cabinet. Once you have completed the 
questionnaires, or declined to participate in the study, all personal information will be erased and 
therefore you will not be able to be identifiable. The data are held in accordance with the Data 
Protection Act, which means that we keep it safely and cannot reveal it to other people, without 
your permission.  
What are the possible benefits of taking part? 
There are no direct benefits for you but it is hoped that by taking part in this research, you will 
provide valuable information regarding quality of life after Intensive Care and allow us to 
determine what, if any, issues we can provide more help with for future patients. If completing 
these questionnaires causes any feelings of upset or distress, please contact the details below (Miss 
Joanne McPeake). We can then refer you to our ICU follow up service to deal with these issues 
directly.   
Who has reviewed the study? 
The East of Scotland Research Ethics Service REC1, which has responsibility for scrutinising all 
proposals for medical research on humans in Tayside, has examined the proposal and has raised no 
objections from the point of view of medical ethics.  It is a requirement that your records in this 
research, together with any relevant medical records be made available for scrutiny by monitors 
from NHS Greater Glasgow and Clyde, whose role is to check that research is properly conducted 
in the interests of those taking part are adequately protected.   
If you have any further questions? 
We will give you a copy of the information sheet and signed consent form to keep. If you would 
like more information about the study and wish to speak to someone not closely linked to the study, 
please contact Professor J Kinsella  
Contacts: 
Professor J Kinsella 
Level 2, Room 2.70 
New Lister Building 
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Glasgow Royal Infirmary 
10-16 Alexandra Parade 
G31 2ER 
0141 2018630 
 
Supervisors 
Miss Joanne McPeake  
Level 2, Room 2.73 
New Lister Building 
Glasgow Royal Infirmary 
10-16 Alexandra Parade 
G31 2ER 
0141 2018634 
 
Dr Tara Quasim  
Level 2, Room 2.71 
New Lister Building 
Glasgow Royal Infirmary 
10-16 Alexandra Parade 
G31 2ER 
0141 2018505 
 
Student 
Dr Charlotte Soulsby 
Level 2, Room 2.73 
New Lister Building 
Glasgow Royal Infirmary 
10-16 Alexandra Parade 
G31 2ER 
0141 2018634 
 
If you have a complaint about any aspect of the study? 
If you are unhappy about any aspect of the study and wish to make a complaint, please contact the 
researcher in the first instance but the normal NHS complaint mechanism is also available to you. 
Thank-you for your time  
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Appendix 11 
Rstudio version 1.0.136: Screen shots
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